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Abstract
Since its discovery in 1983, HIV-1 has spread rapidly resulting in a global
pandemic. Currently an estimated 40 million people are infected with the
virus. Infection leads eventually to the acquired immunodeficiency syndrome
(AIDS) and death. The symptoms of the syndrome are largely due to the
devastating effect HIV has on the immune system. HIV has been the focus of
an unprecedented amount of research however there are still many aspects
of HIV pathogenesis which remain incompletely characterized. One area
which continues to attract attention is HIV tropism. HIV requires two
receptors- CD4 and a co-receptor- for infection. In vivo, HIV variants mainly
use either CCR5 or CXCR4 as co-receptors and thus variants can be
classified as either R5 (CCR5 using), X4 (CXCR4 using) or (R5X4) (dual
tropic). However these classifications do not fully explain the differing abilities
of variants to infect particular cell types. It is thought that other factors, such
as receptor density or alternative receptors, may underlie observed
differences in tropism. In addition to studying viral variants to investigate
determinants of tropism, it is also possible to investigate post-mortem
material from HIV infected individuals to characterize nature and cellular
location of HIV variants. HIV can infect cells in the brain and this leads in
some cases to HIV associated dementia (HAD). The presence of HIV in the
brain poses a challenge to attempts to eradicate the virus as many drugs
have poor CNS penetration. There have been concerns that sub-optimal
levels of drugs in the CNS may support the evolution of drug resistant
variants. Alternatively, low levels of drugs may allow growth of drug sensitive
variants which could reseed the periphery if the drug regime was halted.
Characterisation of the provirus present in post mortem brain material could
lead to a better understanding of this issue. The virus in the brain appears to
mainly infect microglia and macrophages however it is not clear to what
extent other brain cells might be infected. Conflicting reports have emerged
regarding the infection of astrocytes and neurons. Thus a method for
separating the various brain cells which allows them to be tested for HIV
could be valuable.
VIII
In the first part of this project, methods to characterise the cellular tropism of
HIV were investigated. A problem with many previous methods is that
manipulation or amplification of the HIV genome has resulted in artefactual
changes in the sequence. Thus any results obtained regarding the cellular
tropism of variants may not accurately reflect the in vivo situation. A vector
was produced which could be used to produce recombinant HIV expressing
study subject derived env. The vector incorporated the EGFP to allow easy
identification of infected cells. Three methods for production of virus without
the need to amplify the genome in E. coli were designed. All methods were
capable of producing infectious virus expressing various env genes.
The second part of the project sought to investigate the distribution of drug
resistance variants in vivo. DNA was extracted from post mortem brain and
lymphoid tissues from HIV infected study subjects. Limiting dilution PCR was
used to obtain PCR products each derived from a single template molecule.
No differences were found in the distribution of drug-resistance mutations
between the two compartments for three out of four study subjects. In one
study subject there were considerably more drug resistance mutations in the
lymphoid derived sequences than in those amplified from brain tissue. This is
probably due to low levels of anti-HIV drugs in the CNS of this subject.
In the final part of the project, a method for the bulk isolation of microglia and
astrocytes from post-mortem HIV-infected brains was optimised. Cellular
debris was first removed using a density gradient. The cells were then fixed
using a gentle ethanol fixation technique. This inactivated the HIV, fixed and
permeabilised the cells while maintaining DNA integrity. FACS sorting was
carried out using CD68 and GFAP as markers of microglia and astrocytes
respectively. Separation of cells was carried out using two HIV-infected
brains. No provirus was detected in the separated cells however the brain
material used was from asymptomatic study subjects and had extremely low
proviral loads. It is hoped that in the future the technique could be used to
separate brain material which has a higher proviral load. This would allow
quantification of the level of HIV infection of these two cell types.
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The syndrome now known as the acquired immunodeficiency syndrome
(AIDS) was first noticed by physicians in the United States in the late
seventies and early eighties. A report in Morbidity and Mortality in 1981
described five previously healthy young Californian men who had recently
developed lymphadenopathy, lowered CD4 T cell counts along with diseases
consistent with a lowered immune response (CDC, 1981). These included
infections such as Pneumocystis carinii pneumonia, Toxoplasma gondii
encephalitis, cytomegalovirus-associated retinitis and cryptococcal meningitis
as well as unusual cancers such as non-Hodgkins lymphoma and Kaposi's
sarcoma. This publication prompted a number of other physicians who had
observed similar clinical pictures to come forward (Masur et al., 1981; Siegal
et al., 1981; Gottlieb et al., 1981). With increasing reports from each centre, it
was noted that the syndrome mainly affected certain groups of people; men
who have sex with men, intravenous drug users, haemophiliacs, blood-
transfusion recipients, recent Haitian immigrants and the sexual partners of
any of the above. This epidemiological pattern strongly suggested that the
syndrome was caused by a pathogen which could be transmitted in infected
blood or by sexual intercourse with an infected person.
The etiological agent of AIDS was first identified by Barre-Sinoussi and
colleagues in 1983 (Barre Sinoussi et al., 1983). These researchers were
able to culture a virus from a lymph node biopsy obtained from an individual
with AIDS. Reverse transcriptase was identified in the culture supernatant
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confirming that a retrovirus was present. Subsequent studies by two groups
in the USA provided further evidence that a new retrovirus was the causative
agent of AIDS (Gallo et al., 1984; Levy et al., 1984). Initially each group
assigned the virus a different name: lymphadonopathy-associated virus
(LAV), human T-cell lymphotropic virus III (HTLV-III) and AIDS-associated
retrovirus (ARV) respectively. However it became clear that these viruses
shared many common features and in 1986, the International Committee for
the Taxonomy of Viruses named the virus the human immunodeficiency virus
(HIV) and later HIV type 1 (HIV-1) (Coffin et al., 1986). Also in 1986 a second
human immunodeficiency virus was isolated from individuals in western
Africa. This virus was genetically distinct from and less pathogenic than HIV-
1 and was termed HIV type 2 (HIV-2)(Clavel et al., 1986b; Clavel et al.,
1986a).
1.1.2 Origin of HIV
Both HIV-1 and HIV-2 are thought to have arisen by the transfer of distinct
Simian Immunodeficiency Viruses (SIVs) into the human population
(reviewed in McGrath et al 2001). It is thought that cross-species infection
probably first occurred into persons butchering monkey meat.
The source of HIV-2 was identified as the sooty mangabey monkey found in
West Africa (Gao et al., 1992; Hirsch et al., 1989). Up to 30% of wild-caught
sooty mangabeys harbour SIVsm (Sharp and Li, 1988). Phylogenetic
analysis indicates that SIVSm and HIV-2 are interspersed. This suggests that
multiple cross-species transmissions have occurred. The source of HIV-1 is
the chimpanzee species Pan troglodytes troglodytes (P.t.t) (Gao et al., 1999).
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A number of strains of SIVcpz have been isolated from P.t.t. and these show
significant similarity to HIV-1. There are three genetically distinct groups of
HIV-1 viruses: group M (main) is the group responsible for the current global
pandemic. Groups O (outlier) and N (non-M, non-O) have only resulted in a
small number of infections. It is assumed that HIV-1 groups M, N and O were
initiated by three separate cross-species transmissions. Group M viruses are
further divided into various subtypes (figure 1.1).
The timing of the crossover to human recipients of the ancestor of HIV-1
group M has been estimated using computational phylogenetic analysis
(Korber et al., 2000). According to this analysis, the most recent common
ancestor of HIV group M occurred around 1931. The earliest known sample
of HIV dates from 1959 (Zhu et al., 1998). The computational method used
by Korber et al was validated by correctly estimating the date of this, and
another historical sequence.
1.1.3 Transmission
HIV can be transmitted in a variety of ways but the vast majority of infections
are acquired through sexual contact (reviewed in Cohen and Fauci, 2001).
While the epidemic was first noticed in men who have sex with men, the
majority of infections worldwide occur through heterosexual contact. The per
contact risk of becoming infected as a result of sex with an infected partner is
low; most estimates are less than 1% (Hansasuta and Rowland-Jones, 2001).
The precise risk varies considerably depending on a number of factors
including type of sexual contact, genetic factors, presence of genital ulcers or




GROUP O M N
SUBTYPE ABCDEFGHIJ A8CDEFG
Figure 1.1: Classification of the human immunodeficiency viruses. Circulating
recombinant forms are not shown on this figure.
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Tragically, HIV can be transmitted to babies during birth or via breast feeding.
In some poorer countries, as many as 42% of children born to infected
mothers become infected (Datta et al., 1994).
HIV can be transmitted in infected blood products or by shared use of
contaminated needles. A large number of haemophiliacs were infected due to
HIV infected blood transfusions in the 1980s (reviewed in Levine, 1985).
Epidemics have also occurred in populations of intra-venous drug users
where needle-sharing is common. In a worldwide context, needle-sharing is a
relatively minor mode of transmission however, in some areas, including
Edinburgh, this is the main source of new HIV infections (Abdala et al., 2003;
Bell et al., 2002).
1.1.4 Clinical features
There are three phases of HIV infection each with quite different clinical
pictures (reviewed in Cohen and Fauci, 2001). During acute infection, up to
90% of individuals experience a flu-like illness. Symptoms may include fever,
fatigue, headache, vomiting, diarrhoea, myalgia and a cutaneous rash. Due
to the non-specific nature of these symptoms, HIV infection is not usually
recognised at this point. In one study only 25% of people presenting to a
clinic with acute infection were diagnosed with HIV infection at the time
(Schacker et al., 1996). After this acute episode, individuals enter an
extended period (approximately 10 years) of clinical latency. In this period the
immune system is able to function fairly well although there may be some
signs of mild immunosupression especially as the CD4 T cell count falls
below 500 cells/pl. Symptoms may include fatigue, lymphadonopathy,
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prolonged and atypical infections and mild neuropathy. The diagnosis of
AIDS is made in an HIV infected individual when the CD4 T cell count falls
below 200 cells/pl or if the person displays a clinical picture consistent with
severe immunodeficiency. This state is characterised by so called
"opportunistic infections". These are caused by organisms which are non¬
pathogenic to healthy individuals but are able to cause severe disease in
immuno-compromised individuals. In addition a number of malignancies can
arise in AIDS. These may also be initiated by infectious organisms.
1.2 Pathogenesis
The immunodeficiency seen in AIDS is due to a decrease in T cell numbers
and probably also aberrant T-cell function. Figure 1.2 shows how T cell
numbers and viral concentration vary over the course of HIV infection.
1.2.1 Mechanisms of cell death
Most T cells which die during HIV infection do so by apoptosis (reviewed in
Alimonti et al., 2003 and Gougeon, 2003). There are three main pathways
which lead to cell apoptosis in HIV infected individuals: apoptosis of HIV
infected cells; activation induced apoptosis and HIV protein induced
apoptosis. The latter two occur mainly in non-HIV infected cells. The relative
contribution of each pathway to overall pathogenesis remains controversial
and it is likely to vary in different stages of disease. In particular, apoptosis of
infected cells is thought to play a minor role in T cell depletion during chronic
HIV infection while it may be a major factor in acute infection.
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Figure 1.2: T cell and viral dynamics over course of HIV infection (Janeway
2001).
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HIV has a number of methods of promoting apoptosis in infected cells. The
host cell membrane can be disrupted by continual viral budding (Fauci, 1988)
or by the permeabilising effect of Vpu (Gonzalez and Carrasco, 2001). Build
up of unintegrated proviral DNA can be toxic (Shaw et al., 1984). HIV
proteins are also able to upregulate expression of pro-apoptotic genes or
down-regulate anti-apoptotic genes in infected host cell (Alimonti et al, 2003).
Surprisingly, other HIV proteins act to inhibit apoptosis of infected cells. Nef
and Tat mediated down-regulation of MHC I prevents CTL-mediated killing
(Alimonti et al, 2003). Vpr appears to have a role in upregulating an anti-
apoptotic and decreasing a pro-apoptotic protein (Conti et al., 1998). It is
thought that the combination of these effects may be to prolong cell survival
long enough to produce new infectious virus while maintaining a reduced
half-life compared with uninfected cells.
Activation-induced cell death is a normal physiological phenomenon by which
the immune system prevents excess proliferation of T cells. Activation itself,
up-regulates factors such as Fas and Fas ligand, which later induce
apoptosis of the cell (Lenardo et al., 1999). HIV indirectly causes massive
amounts of cell death simply by activating T cells which then undergo
apoptosis.
A number of HIV proteins when released into the extra-cellular environment
can induce apoptosis in uninfected cells. Released gp120 can cause
apoptosis of nearby cells via interaction with CD4 and co-receptor molecules
(Arthos et al., 2002). In addition, infected cells displaying gp120 on their
surface can induce apoptosis of neighbouring cells (Blanco et al., 2003).
9
Extracellular Tat can be endocytosed by cells. Once in the cell, Tat has a
number of effects which act to promote apoptosis (Li et al., 1995). It is also
thought that Tat in infected monocytes acts to upregulate TNF-related
apoptosis-inducing ligand which through interaction with nearby cells
promotes bystander apoptosis (Zhang et al., 2001). Finally, Nef and Vpu are
able to cause membrane disruption of both CD4+ and CD4- cells (Azad,
2000).
1.2.2 Initiating and propagating infection
It has been impossible to study the events immediately post HIV infection in
humans. There have, however, been numerous studies of mucosal infection
of rhesus macaques with SIVMac251 (reviewed in Weber, 2001; Douek et al.,
2003) or studies of HIV infection of tissue culture cells. It is assumed that
early events in HIV infected humans may mirror those observed in these
models. After mucosal infection it appears that the major site of viral
replication is the population of CD4 T cells resident in the lamina propria of
mucosal tissues (Veazey et al., 1998; Stahlhennig et al., 1999).
Another cell type which may play an important role in early infection are
dendritic cells (DC) (reviewed in Steinman et al., 2003). Blood monocytes
which have been induced to differentiate into immature DCs ex vivo can be
productively infected with HIV as can skin-derived Langherhan's cells.
However, infection levels in both of these in vitro experiments have been low
(less than 10%). There are conflicting reports regarding productive infection
of DCs in vivo (Tenner-Racz et al., 1994; Mcllroy et al., 1995). Current
consensus appears to be that infection of DCs can occur but is extremely
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rare.
Perhaps a more significant role for DCs in HIV pathogenesis is their ability to
promote T cell infection. When DCs are exposed to HIV and then co-cultured
with T cells, substantial productive infection of the T cells occurs (Cameron et
al., 1992). It is thought that this in vitro phenomenon may mirror the situation
in mucosal membranes; DCs could encounter HIV at the mucosal surface,
migrate to lymph nodes and then mediate T cell infection. The presence of
the C-type lectin DC-SIGN appears to be crucial to DC's ability to transmit
infection to T cells (Geijtenbeek et al., 2000). This molecule has an affinity for
HIV even higher than that of the CD4molecule (Curtis et al., 1992). It is
thought that after binding, DC-SIGN internalises the virus thus protecting it
during the journey to the lymph node. In the lymph node the DC can mediate
prolific infection of T cells. The mechanism by which DC-SIGN promotes
efficient T cell infection is unclear. One theory is that binding to DC-SIGN
causes a conformational change in gp120 which increases its affinity for
either CD4 or its coreceptor (Geijtenbeek and van Kooyk, 2003). Some DC
subsets, such as Langherhan's cells, do not express DC-SIGN and in these
some other receptor may mediate HIV uptake and enhance T cell infection.
Surprisingly, the presence of a suitable co-receptor on both DCs and T cells
is also necessary for efficient transmission of infection (Granelli-Piperno et al.,
1998). This suggests that infection of the DCs may play some role in this
process.
Other cell types may also play a role in transporting and trapping HIV in vivo.
Erythrocytes can bind complement fragments in HIV-containing immune
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complexes via their complement receptor 1 (CR1) and transmit the infectious
virus to susceptible cells (Montefiori et al., 1994; Moir et al., 2000). A
significant portion of the viral population can be found in association with
erythrocytes (Hess et al., 2002). Follicular dendritic cells can also trap HIV in
immune complexes bound to complement receptors (Joling et al., 1993).
These cells can maintain HIV in an infectious form for many months and thus
may be an important sanctuary site for virus (Smith et al., 2001).
In addition to their role in attachment of HIV, complement components may
also enhance HIV infection of some cells (Reisinger et al., 1990; Boyer et al.,
1991). Cell lines infected with C3b-opsonised virus showed a significant
increase in viral production compared to those infected with non-opsonised
virus. This phenomenon has been observed with both CD4 positive and CD4
negative cell lines . The significance of these findings to the in vivo
pathogenesis of HIV infection remains unresolved.
In macaque model systems, over the first few weeks of infection, there is
explosive replication of SIV in CD4 cells in lymphoid tissues including the
lymph nodes, spleen, thymus and mucosal tracts (reviewed in Granelli-
Piperno et al, 1998; Douek et al, 2003). Limited studies of lymph node
biopsies from humans recently infected with HIV have also found that CD4 T
cells are the major location of virus (Zhang et al., 1999; Schacker et al.,
2001). In particular, CCR5+ CD4+ memory cells are targeted by the virus.
The magnitude of this initial burst of replication may be underestimated in
studies which only measure CD4 cell loss in the periphery as the majority of
T cells are located at mucosal sites. The gastrointestinal tract alone is
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thought to harbour around 60% of T cells. Unlike the situation in the blood,
lymph nodes and spleen, most T cells found at mucosal sites are of a CCR5+
CD4+ memory phenotype- the main target of acute viral infection. In rhesus
macaques Douek et al (2003), reported a modest drop of peripheral CD4 T
cells counts following SIV infection while in contrast, CD4 cells at a mucosal
site (measured by pulmonary lavage) were almost completely eliminated. In
fact, when levels of memory cells, as opposed to total T cell number, were
measured in the periphery, a profound depletion was observed. Studies in
humans have also revealed a profound loss in intestinal T cell numbers
following acute infection which persists throughout the infection (Lim et al.,
1993). This dramatic decline is despite a homeostatic increase in proliferation
of memory T cells.
It is presumed that the killing of T cells during the acute response is due to
direct cytopathic effects of the virus, unopposed as yet by the immune
response. Within a few weeks a cell mediated response to the virus has
developed. It is thought that this cell mediated response (Koup et al., 1994;
Borrow et al., 1994), along with HIV-specific antibodies (Cheingsong Popov
et al., 1991), brings to an end the high viraemia seen in acute infection.
Another contributing factor may be that the HIV simply runs out of target cells
in the mucosa (Phillips, 1996).
1.2.3 T cell dynamics in chronic infection
In order to understand the T cell dynamics of chronic HIV infection it is helpful
to study T cell maturation and renewal in healthy individuals (reviewed in
Douek et al, 2003; Clark et al., 1999). Both CD4 and CD8 T cells can be
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divided into three phenotypically distinct populations. Confusingly, a number
of different terms have been used to describe these populations. Here, they
will be referred to as naive, memory and active. These types can be
identified experimentally by differential expression of surface markers. Once
a naive cell has been activated by recognising its antigen in the context of
MHC and receiving necessary co-stimulation, it can remain active or "fall
back" to a memory (resting) phenotype. The precise dynamics of these
processes differ between CD4 and CD8 cells. Renewal of the naive CD4
population is dependent on the thymus while CD8 cells can be produced in
both thymus-dependent and thymus-independent manners. Renewal of naive
CD4 cells is slow and it is thought that it occurs at close to maximum capacity
even in immuno-competent adults. Once activated the vast majority of T cells
die. The portion which does survive and re-enter the memory pool, is far
greater for CD8 cells than for CD4s.
Numerous studies have found an increased turnover of both CD4 and CD8 T
cells during chronic HIV infection (reviewed in Douek et al, 2003; Clark et al,
1999). It appears that this increase in turnover is mainly in the memory and
active populations. These populations are stimulated to proliferate by HIV-
induced activation and the natural consequence of activation is subsequent
death of most cells.
This process alone does not account for the on-going T cell depletion
observed in HIV infected individuals. HIV causes proliferation of activated
cells which then die but these cells are programmed to die anyway so this
does not drastically affect overall T cell numbers. It is thought that CD4
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depletion is rather caused by a more subtle "chipping away" of the immune
system's renewal mechanisms. There is chronic activation and differentiation
of both the naive and memory populations (Grossman et al., 2002). The
population of memory cells has already been severely depleted during the
acute phase of infection and cytopathic effects of the virus may continue to
play a role in killing CD4 cells. In addition the capacity of the bone marrow
and thymus to renew these populations is severely impaired by HIV infection
(Mir et al., 1989; Gaulton et al., 1997). Over time the combination of these
effects causes a gradual decline in CD4 T cell numbers eventually leading to
outright immuno-suppression. The ability of the CD8 cell population to remain




HIV is a member of the lentivirus genus made up of retroviruses with
complex genomes and a cone-shaped nucleocapsid. HIV particles are
spheres of approximately 100nm diameter (figure 1.3) (reviewed in Freed
and Martin, 2001; Turner and Summers, 1999). The outermost layer of all
lentiviruses is a lipid membrane derived from the host cell during viral
budding. Embedded in the membrane are various host membrane proteins
including major histocompatibility antigens, actin and ubiquitin (Arthur et al.,
1992). In addition the HIV envelope (Env) protein is found protruding from the
membrane. Attached to the inner surface of this membrane via interactions





Figure 1.3: Schematic representation of HIV virion structure showing location
of various components. See text for more details. MA: Matrix; CA: Capsid;
NC: Nucleocapsid; LM: Lipid Membrane; MyA: Myristic acid moity; RT:
Reverse Transcriptase (Adapted from Hunt 1999).
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(MA) protein. Likewise, around 2000 copies of the capsid (CA) protein make
up the cone-shaped inner capsid. Within this compartment are the two copies
of the viral RNA genome stabilised by an interaction with around 2000 copies
of the nucleocapsid (NC) protein. Also within the capsid are the viral
enzymes (integrase (IN), reverse transcriptase (RT) and protease (PR)), viral
protein R (Vpr) and the p6 protein. Host cell-derived cyclophilin A is
incorporated via its interaction with CA. Viral proteins Nef and Vif are also
incorporated although the significance of this is unclear.
The genomes of all retroviruses possess three genes known as gag, pol and
env (reviewed in Freed and Martin, 2001). When the HIV genome was first
investigated it caused surprise because, unlike the simple retroviruses
previously identified, it contained a number of additional overlapping genes
(figure 1.4). The open reading frames for some of these are split by DNA
segments and thus RNA splicing is necessary for their expression.
1.3.2 Genetic diversity and distribution
HIV-1 group M viruses have been subdivided into subtypes according to
phylogenetic analysis of gag and env sequences. So far nine subtypes and
ten circulating intersubtype recombinant forms (CRFs) have been identified
(Tatt et al., 2001). The various subtypes and CRFs have heterogeneous
distributions and disease impacts (figure 1.5) (reviewed in Tatt et al, 2001
and Essex, 1999). Over halt of infections are caused by subtype C which is
the main strain in Southern Africa, India and China. Subtypes A and D are
the main strains in more northern areas of sub-Saharan Africa. In South-East
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Europe the impact of the virus has been far less than in many other areas
and most infections have been with subtype B.
Some developing countries initially had a limited subtype B epidemic before
another subtype emerged to cause higher levels of infection (Weniger et al.,
1994; Subbarao et al., 1998; Janssens et al., 1997). In addition, mode of
transmission is strongly correlated with subtype. For example subtype C is
usually transmitted by heterosexual sex while subtype B is associated with
intravenous drug use and homosexual sex (Essex, 1999). These phenomena
have led some to suggest that certain subtypes may differ biologically. A
disproportionate amount of research has focused on subtype B due to its
prevalence in the richer countries of Europe and the Americas and it is now
important to establish if the findings can be applied to all subtypes.
1.4 Life Cycle
The retroviruses have a unique and fascinating life cycle which enables them
to insert their genome into the host cell genome. Thus the host cell
machinery becomes subverted to produce viral proteins. The main stages of
the life cycle are outlined in figure 1.6 and further described below. A more
detailed description of the specific roles played by each of the viral proteins is
given in sections 1.5-1.7.
1.4.1 Adsorption and fusion
The first stage in the life cycle is adsorption and fusion (figure 1.7). HIV
attaches to the cell by an interaction between the gp120 portion of Env and
host cell CD4. It appears that gp120 must interact with three different CD4
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Figure: 1.6: Diagramatic representation of HIV life cycle. The virion fuses with
the host membrane and releases its contents into the cell. RNA is reverse
transcribed into single stranded DNA. Double strand synthesis takes place.
The double stranded DNA genome inserts into the host genome. RNA is
transcribed and translated. Newly synthesised viral peptides along with newly
transcribed genomic RNA accumulate at the host membrane and bud out
forming new virions (Alberts et al., 1998).
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Figure 1.7: Attachment and membrane fusion of HIV with host cell
1: gp120 interacts with CD4 causing a conformational change in gp120; 2:
gp120 binds to co-receptor causing a conformational change in gp41 which
allows it to insert into the host membrane; 3: fusion of viral and host
membranes and 4: release of viral contents into cell (Adapted from Hunt
1999).
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interaction causes a conformational change in gp120 revealing a site which
binds to a co-receptor. In vivo the co-receptor is usually either CCR5 or
CXCR4 (see section 1.11). Co-receptor binding causes a further
conformational change which enables the gp41 portion of Env to insert into
and fuse with the host cell membrane releasing the contents of the virion into
the cell.
1.4.2 Uncoating
After the contents of the virion have entered the cell, components which do
not form part of the pre-integration complex (PIC) must be shed. This
process is known as uncoating (reviewed in Dvorin and Malim, 2003). Three
virion components have been shown to play a role in uncoating. These are
Nef, Vif and the host derived protein, cyclophilin A. Defects in, or lack of
these molecules has been shown to reduce the efficiency of a step after viral
entry and before completion of reverse transcription (Piguet and Trono, 1999;
Vonschwedler et al., 1993; Braaten et al., 1996). The mechanism by which
any of these molecules enhance viral uncoating remains unclear.
1.4.3 Reverse Transcription
Reverse transcription of the viral RNA genome into double stranded DNA is
an early step of the life cycle (reviewed in Goff, 2001) (figure 1.8). The
reaction occurs in a complex known as the pre-integration complex (PIC)
containing MA, NC, Vpr, RT, IN, viral RNA and a tRNA molecule incorporated
from the host cell from which the virion budded.
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Figure 1.8: Reverse transcription of HIV genome. Thick tines represent DNA
and thin lines represent RNA. The tRNA molecule binds to the primer binding
site (pbs) near the 5' end of the RNA genome. DNA synthesis, catalysed by RT,
occurs in a 5' to 3' direction forming the so called minus-strand strong-stop
DNA. This short piece of single stranded DNA jumps to the 3' end of the RNA
genome. In order to do this, the portion of RNA which has already been copied
must by degraded. This is achieved by the RNase H activity of RT. The strong-
stop DNA is now able to move to the 3' end where it re-aneals to the repeat
region (r). RT continues to catalyse DNA synthesis in a 5' direction with the
copied RNA being deleted by RNase H as the synthesis machinery moves
along. Two portions of the RNA template known as the ppts are resistant to
RNase H degradation and remain annealed to the DNA. These can then act as
primers for plus-strand DNA synthesis which continues past the end of the
genome to include the first 19 bases of the tRNA. This piece of DNA is refered
to as the plus-strand strong-stop DNA. The tRNA molecule is degraded by
RNase H leaving the plus-strand strong-stop DNA with an unpaired PBS. This
pairs with the 3* end of the minus strand DNA creating a circular form. DNA
synthesis occurs from the 3' end of both strands. The already formed U3, R and
U5 regions of the strands peel away and act as templates and thus a linear
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1.4.4 Nuclear Import
The ability of HIV to infect non-dividing cells relies on the PIC being able to
travel to the nuclear membrane and enter the nucleus (reviewed in Strebel
and Bour, 1999; Dvorin and Malim, 2003). The mechanism by which the PIC
travels to the nuclear membrane is unclear. A number of other viruses,
including herpes simplex virus 1 and adenovirus, travel along components of
the host cell cytoskeleton in order to reach the nucleus (Sodeik et al., 1997;
Leopold et al., 2000). The cytoskeleton forms the interior framework of cells
and consists of intermediate filaments, actin and microtubules (reviewed in
Dvorin and Malim, 2003). Molecules can be transported in either direction
along the latter two components by association with motor proteins. Along
actin filaments these are the myosin family for plus end transport and myosin
VI for minus end transport. Along microtubules, the kinesin family mediates
plus end transport while the dynein family, move in a minus end direction.
There has been some evidence that interactions between the PIC and actin
filaments are important in an early stage of PIC transport (Bukrinskaya et al.,
1998; Iyengar et al., 1998). However, recent studies have implicated
microtubules as the main mediator of PIC transport to the nucleus. Using
fluorescent labelling, PICs were visualized moving along microtubules
(Dvorin and Malim, 2003). Further research is required to fully characterize
the mechanism of PIC transport.
Once at the nuclear membrane, the PIC uses the host's nuclear import
machinery to enter the nucleus. The intact PIC is estimated to have a
diameter of around 56nm. This is too large for normal signal mediated import
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through the nuclear pore suggesting that either a conformational change or
shedding of some components must occur before entry (Miller et al., 1997;
Pante and Kann, 2002). MA and INT possess putative nuclear localization
signals (NLS) which may bind to the dimer of importin a and importin p
(Gallay et al., 1997; Gallay et al., 1996). Vpr also localizes to the nucleus and
is able to bind both importin a and the nuclear pore itself (Popov et al., 1998;
Fouchier et al., 1998). It has been suggested that Vpr plays a role in
stabilizing the interaction of MA and INT with the importin proteins (Popov et
al, 1998). Despite these findings, nuclear import can occur in the absence of
both MA and Vpr and a transferable NLS has not been identified on INT
(Dvorin and Malim, 2003). Controversially, some have suggested that import
of the DNA provirus can occur in the absence of any viral proteins via
interactions with host cell DNA-binding nuclear import proteins (Dvorin et al.,
2002).
1.4.5 Integration
Once in the nucleus the provirus must be integrated into the host genome
before the cell will efficiently produce progeny virus (Sakai et al., 1993).
Integration is catalysed by viral INT (reviewed in Goff, 2001; Engelman, 2003)
(figure 1.9).
Purified PICs are unable to mediate integration alone however the addition of
cellular extracts restores this activity (Farnet and Bushman, 1997). This
suggests that host factors are required for efficient integration. Two host DNA
binding proteins, BAF and HMAGA1, which form stable nucleoprotein






Figure 1.9: Integration of provirus into host genome. The first step, known as
3'-end processing, involves the removal of two nucleotides from the 3' end of
each DNA strand. This results in a "sticky" ended piece of linear DNA with
recessed 3'-ends and protruding 5'-ends. In the second step, known as
strand transfer, the 3'-end of the viral provirus attacks the phosphodiester
bond of the target DNA at the site where integration will occur. INT catalyses
the binding of the 3'end to the host DNA. (Goff 2001)
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complexes is thought to inhibit intramolecular integration; i.e. integration of
the end of the provirus into another part of the proviral sequence. It is thought
that BAF may have the additional function of binding host cell DNA to allow
intermolecular integration.
The repair of the nicked DNA and binding of the 5'end to the host DNA is
thought to be mediated by both viral and host enzymes (Engelman, 2003).
The steps involved are thought to be DNA synthesis to fill in single strand
gap, cleavage to remove viral 5' dinucleotide overhang and ligation of
cleaved 5' end to newly synthesised DNA.
1.4.6 Transcription and Translation of Viral Genome
Transcription of HIV genes is catalysed by the host polymerase RNA II
(reviewed in Freed and Martin, 2001). The loading of this enzyme onto the
viral genome relies on promoter elements located in the viral LTR and host
cell transcription factors (TF). The HIV core promoter, which is necessary for
basal levels of RNA synthesis, consists of the TATA element and three Sp1
binding sites. TFIID first binds to the TATA region located upstream of the
transcription start site. TFIID binds TFIIB which mediates Pol II recruitment to
promoter area. Pol II must be phosphorylated in order to produce full length
transcripts. A number of cellular kinases are able to achieve this. Tat plays a
role in recruiting one such kinase and thus promoting transcription (see
section 1.6). Sp1 is a constitutively expressed host transcription factor.
Binding of Sp1 to at least one of its viral binding sites markedly increases
levels of transcription.
The two NFkB binding sites upstream of the core promoter provide cellular
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activation dependent enhancement of viral transcription. In quiescent T cells
NFkB is found only in the cytoplasm. Upon activation, NFkB rapidly
accumulates in the nucleus. Its physiological role is to increase transcription
of various cellular genes following activation but in HIV infected cells can also
increase transcription of HIV (Alcami et al., 1995).
RNA splicing is a vital feature of HIV gene expression (reviewed in Goff,
2001; Alonso and Peterlin, 1999). When HIV is first transcribed, all the RNA
transcripts are multiply spliced before export to the cytoplasm so that only the
regulatory proteins Tat and Rev are expressed. As the concentration of these
proteins build up they facilitate increased transcription and export of
unspliced and partially spliced RNA transcripts (see section 1.6). These act
as templates for production of other viral proteins.
Unspliced RNA acts as a template for Gag and Pol production. In most cases
translation results in production of Gag only as Pol lies in a different reading
frame. However, approximately 10% of the time, the ribosome "jumps back" a
nucleotide due to a RNA slippy sequence. This puts the ribosome in the
correct frame for pol translation and thus a Gag/Pol fusion protein is formed.
Singly spliced RNA, in which most of the gag and pol sequences have been
removed, is used for the translation of env while other viral genes are
translated from multiply spliced transcripts (reviewed in Freed and Martin,
2001). Most viral genes are translated by cytoplasmic ribosomes however
env is translated in endoplasmic reticulum (ER) associated ribosomes (see
section 1.5.3).
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1.4.7 Assembly and Budding
The final step in HIV's life cycle is for all the newly formed viral components
to assemble at the host membrane and bud out as a immature virus particle
(reviewed in Greene and Peterlin, 2002; Gottlinger, 2001). The assembly of
viral proteins at the host cell membrane is mainly mediated by the Gag
polyprotein. In fact Gag can direct the formation of virus like particles even in
the absence of other viral genes. Approximately 2000 Gag proteins are
thought to be required to make just one HIV virion (Wilk et al., 2001). The
precise roles of the various domains of Gag are discussed in more detail in
section 1.5.1. Once the necessary components are assembled at the
membrane the virion is able to "bud" out coating itself in the host membrane.
It is thought that the virus achieves this by subverting the host cell's
endocytotic mechanism for production of multi-vesicular bodies.
1.5 Structural Proteins
1.5.1 Gag
The Gag proteins play an important role in directing the assembly of HIV
particles (reviewed in Gottlinger, 2001). Gag is initially translated as a
polyprotein and in this form it mediates the formation of immature viral
particles. To become infectious, the virion must undergo a maturation step in
which the Gag polyprotein is cleaved by viral protease into its constituent
parts.
1.5.1.1 Matrix
The matrix (MA) domain consists of a N-terminal globular "head" formed by
four alpha-helixes and a C-terminal alpha-helical "tail" (reviewed in Turner
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and Summers, 1999). MA is involved in targeting the Gag polyprotein to the
plasma membrane (reviewed in Gottlinger, 2001). Essential to this function is
a myristic acid moiety which covalently attaches to an N-terminal glycine in
MA (Gottlinger et al., 1989). The globular head is also thought to be
important in the affinity of MA for membranes. This part of the domain forms
trimers which have conserved basic residues on their outer surface. These
may interact with the acidic phospholipids heads found in membranes.
Indeed mutations to these basic domains disrupts virus assembly (Zhou et al.,
1994).
It is thought that binding of the myristic acid to membranes is initially
prevented by the conformation of MA and a conformational change is
required in order to reveal the acid moiety (Spearman et al., 1997). This
mechanism, known as a "myristic switch", would explain the finding that
mutations to (Paillart and Gottlinger, 1999) or even complete deletions of
(Reil et al., 1998) the globular head of MA can lead to dramatic increases in
virus particle production; these disruptions may expose the myristic acid and
thus increase affinity for membranes. MA also plays a role in the
incorporation of Env into budding virions (Dorfman et al., 1994).
1.5.1.2 Capsid
Capsid (CA) consists of two largely alpha-helical domains separated by a
flexible linker sequence (reviewed in Turner and Summers, 1999).
The N-terminal domain of CA binds the enzyme cyclophilin A (a peptidyl-
prolyl cistrans isomerase) and mediates its incorporation into HIV virions
(Luban et al., 1993). The presence of this enzyme in virions increases
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infectivity; however the precise mechanism by which it achieves this remains
unclear (Gamble et al., 1996).
The first 20 amino acids of the C-terminal domain of CA constitute the Major
Homology Region (MHR) which is conserved in all retroviruses (Gamble et
al., 1997). The remainder of the domain along with a portion of the adjacent
p2 "spacer" peptide mediate Gag dimerisation in vitro and are thought to play
a role in correct virion assembly in vivo. Cleavage between the C-terminal
domain of CA and p2 during virus maturation is thought to lead to the
formation of the characteristic cone shaped capsid (Accola et al., 1998).
1.5.1.3 Nucleocapsid
The major function of the nucleocapsid (NC) domain is the specific
encapsulation of genomic HIV RNA into developing virions (Berkowitz et al.,
1993). Crucial to this function are two zinc finger domains joined by a highly
basic linker domain (Bess, Jr. et al., 1992; Summers et al., 1992). The basic
linker domain results in non-specific binding to RNA while the zinc-fingers
bind specifically to the M^-site.
A second function is the packaging of Gag into virions. The non-specific,
RNA binding activity of the basic linker sequence is crucial to this. Binding of
multiple NCs to RNA is thought to promote dimer formation (Zhang et al.,
1998). This appears to be an important first step in virion assembly.
Interactions between NC and cytoskeletal components may facilitate Gag
transport (Rey et al., 1996).
NC also plays a role in thermodynamic folding of the RNA genome, RNA
dimerisation, tRNA binding and strand transfer (Rein et al., 1998).
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1.5.1.4 p6
p6 protein plays a role in virion release following assembly at the host
membrane (Gottlinger et al., 1991). It appears that p6 acts together with PR
and host cell ubiquitin to mediate virion release (Schubert et al., 2000). The




HIV protease (PR) exists as dimers and a cleft between the two monomers
functions as the enzyme's active site (reviewed in Turner and Summers,
1999). PR functions to cleave a number of viral polypeptides (reviewed in
Freed and Martin, 2001). The precise amino acid signal which triggers the
enzyme to cleave a target is unclear; however a number of sites are known
to be cleaved with various efficiencies. The first cleavage event releases PR
itself. It is unknown if this step is self-catalytic or if another molecule of PR
performs this function. PR goes on to liberate the various domains of Gag
and Pol. Nef is also cleaved although the reason for this is not known
(Bukovsky et al., 1997). PR becomes most active as the virions are budding
from the membrane (Kaplan et al., 1994). The release of the various Gag
domains at this time results in the dramatic alteration in morphology known
as virion maturation.
1.5.2.2 Integrase
HIV Integrase (INT) has three catalytic activities: 3'-end processing, cleavage
of host DNA and ligating the 3'-end viral strands to 5'-end host strands
(strand transfer). These activities allow INT to catalyse the integration of the
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DNA provirus into the host cell genome as outlined in section 1.4.5
INT has three structural and functional domains (reviewed in Turner and
Summers, 1999). The N-terminal zinc-finger containing domain contributes to
enzyme stability via multimer formation. The core region has a secondary
structure analogous to other polynucleotidyl transferases and is the main
catalytic part of the enzyme. It is able to bind DNA only in the presence of a
divalent metal ion. The C-terminal domain is required, along with the core for
3'-end processing and integration. It shows non-specific DNA binding which
may be important in maintaining INT's association with nucleic acid during
reverse transcription.
1.5.2.3 Reverse Transcriptase
HIV Reverse Transcriptase (RT) has three enzymatic activities (reviewed in
Goff, 2001): RNA-templated DNA synthesis, RNaseH activity for degradation
of tRNA and RNA base-paired with DNA and DNA-templated DNA synthesis.
Together these actions allow HIV to convert its RNA genome into double
stranded DNA which can integrate into the host genome (section 1.4.3).
RT is a heterodimer of p66 and p55 peptides (reviewed in Turner and
Summers, 1999). The p55 peptide is produced by PR cleavage of p66 to
release the RNAseH domain. Surprisingly, the secondary folding of the two
monomers differs dramatically. The structure of p66 has been compared to a
partially open hand with the active site lying in the palm between the thumb
and finger domains. This active site contains three aspartic acid residues
which are essential for the enzyme's function. In p55 these residues are
buried within the peptide suggesting that it does not have an enzymatic role.
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The high mutation rate of RT is critical in influencing viral evolution and this is
discussed further in section 1.9.
1.5.3 Env
The 160kD Env precursor protein is synthesised in ER associated ribosomes.
A number of modifications to the protein occur in the ER. It becomes heavily
glycosylated such that half of its mass consists of oligosaccharide chains
which are further modified during Env's journey to the cytoplasmic membrane
(Leonard et al., 1990). These are thought to play a role in inhibiting antibody
binding to the mature protein (Profy et al., 1990). Trimerisation, disulphide
bond formation and association with a host chaperone molecule also occur
within the ER. Env is then transported to the Golgi body. Within this
compartment cleavage by cellular furin occurs separating the surface gp120
from the transmembrane gp41. From the Golgi body Env is transported to the
cytoplasmic membrane. The two subunits remain attached to each other by
weak non-covalent interactions which allow a large amount of gp120 to be
shed from the cell surface (Freed and Martin, 2001).
1.5.3 gp41
The structure of various portions of HIV gp41 has been solved (Chan et al.,
1997; Tan et al., 1997; Weissenhorn et al., 1997). In addition the structure of
the almost intact gp41 of SIV has been elucidated (Caffrey et al., 1998) and it
is assumed that the HIV gp41 structure closely mirrors this. Each monomer
of gp41 has a rod-like structure formed by two anti-parallel a-helices.
Protruding from one end of the rod is an extended loop which is able to bind
gp120. From the other end emerges both the C-terminal end of the protein,
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which passes through the viral membrane and interacts with MA, and the N-
terminal end which contains the fusogenic peptides (Caffrey et al., 1998).
The mechanism for viral/host fusion is thought to be a "spring-loaded" action
(reviewed in Turner and Summers, 1999). In this model there would be a
conformational change in gp41, triggered by binding of a co-receptor to
gp120. This would result in the two a-helical portions, which are normally
folded back on each other, become extended to form one long helical rod
with the fusogenic peptide exposed at the end. Following insertion of the
fusion peptide, gp41 would fold back into the original conformation thus
bringing the viral host membranes into close proximity (Melikyan et al., 2000).
It has been suggested that the energy released upon refolding to the more
stable structure may aid membrane fusion. This mechanism mirrors that
found in the envelope protein, haemagglutinin (HA), of the influenza virus
(Carr and Kim, 1993). Indeed there are structural similarities between HIV
gp41 and HA in both primary and secondary structural levels.
1.5.3.2 gp120
The details of the secondary structure of gp120 are complex, involving
numerous overlapping and intersecting (3-sheets and a-helices. Essentially it
forms two globular masses separated by a [3-sheet (reviewed in Turner and
Summers, 1999). There are 5 conserved (C1-C5) and 5 variable (V1-V5)
regions (Starcich et al., 1986). Four of the variable regions (V1-V4) form
loops extending from the surface with disulphide bonds at their base.
CD4 binds in the oligosaccharide-free cleft between the two globular parts.
This interaction forms a hydrophobic pocket formed by the deep cleft and
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covered by CD4. Surprisingly, many of the residues lining this cavity are
highly conserved although they do not interact directly with CD4 (Kwong et
al., 1998). A larger cavity is also formed around CD4. In this case the non-
interacting residues are not conserved however they are surrounded by
conserved CD4 binding sites. This highly unusual structure is thought to
contribute to the difficulty in raising antibodies to the CD4 binding site
(reviewed in Poignard et al., 2001). Binding of CD4 induces a conformational
change which exposes the chemokine receptor binding site. It is unclear if
this conformational change involves just a change of position of the variable
loops or if a much more fundamental conformational change occurs after
CD4 binding (Kwong et al, 1998).
1.6 Regulatory Proteins
The first viral proteins to be produced are the transactivator of transcription
(tat) and regulator of viral expression (rev). These proteins regulate and
amplify the production of other viral products (reviewed in Freed and Martin,
2001; Alonso and Peterlin, 1999).
1.6.1 Tat
Tat is encoded by two exons. These encode the three domains which
contribute to Tat's transactivation activity: the activation and basic domains
(see later) and the C-terminal domain which may have a minor auxiliary role
in transactivation (Sadaie et al., 1988).
The function of the activation domain is to recruit host factors which in turn
act to enhance transcription. The critical host factors for this function are the
heterodimer of CDK9 and cyclin T1. CDK9 is a kinase which is able to
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hyperphosphorylate the CTD of Pol II (Marshall et al., 1996). This alters the
enzymatic activity of Pol II from initiation of transcription to transcriptional
elongator. The cyclin T1 portion of the heterodimer binds Tat and also
enhances the Tat/TAR interaction (Wei et al., 1998).
The basic domain of Tat contains an arginine rich motif which has two
functions. Firstly, it allows Tat to bind to its RNA target, the transactivation
response region, or TAR (Dingwall et al., 1989). TAR is found at the five
prime end of both spliced and unspliced HIV viral transcripts. It consists of a
base paired stem, containing a trinucleotide unpaired "bulge", with a
hexanucleotide Guanine (G) rich loop at the end (Feng and Holland, 1988).
Tat interacts mainly with the bulge region while cyclin T interacts mainly with
the loop region. In addition this domain acts as a nuclear localization signal
(Hauber et al., 1989).
1.6.2 Rev
HIV uses the host cell machinery for post translational modifications of RNA
such as capping, 3'-end cleavage, polyadenalation and splicing (reviewed in
Freed and Martin, 2001). The default pathway for transcripts involves the
complete splicing out of all introns prior to nuclear export. This mechanism
produces the multiply spliced mRNAs which encode Tat, Rev and Nef. Other
transcripts are not exported by this pathway due to the presence of cis-acting
AU-rich regions which cause nuclear retention. In order to produce other viral
proteins, unspliced or partially spliced transcripts must be exported by an
alternative means and this is achieved by Rev (Regulator of Viral Expression).
Like Tat, Rev is encoded by two exons however in the case of Rev both
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exons are required for its primary function. Rev has two functional domains:
an arginine-rich domain which includes a nuclear localization signal (NLS)
and a hydrophobic region containing a nuclear export signal (NES) (reviewed
in Strebel and Bour, 1999).
Rev exports transcripts via a pathway involving interactions with numerous
cellular factors. Critical to the process is the GTPase, Ran. This exists mainly
as Ran-GTP in the nucleus while in the cytoplasm it is mainly in the form of
Ran-GDP (Izaurralde et al., 1997). Another essential host factor is the
nuclear pore complex (NPC). This is a multimer of up to one hundred
different proteins known as nucleoporins (Fabre and Hurt, 1997).
Rev is produced in the cytoplasm from the early mRNA transcripts. It then
binds directly via its NLS to Importin-P which directs its import through the
NPC. The binding of Ran-GTP to Rev allows it to dissociate from lmportin-3
and bind to the cis-acting Rev Responsive Element (RRE). The RRE is a
highly folded cis-acting region found in unspliced and partially spliced HIV
transcripts. Multimerisation of Rev occurs around the RRE masking the NLS
while exposing the NES. To facilitate export, Rev then binds via its NES
element to the exportin peptide CRM1. Ran-GTP is required to stabilize this
interaction. CRM1 is able to interact with nucleoporins to mediate the export
to the cytoplasm of the entire complex of Rev, RNA transcript, Ran-GTP and
CRM1. In the cytoplasm, Ran-GTP is hydrolysed to Ran-GDP and this allows
the dissociation of the exported components (Strebel and Bour, 1999).
1.7 Accessory Proteins
HIV possesses four accessory proteins which have various roles in viral
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pathogenesis (reviewed in Steffens and Hope, 2001; Strebel and Bour, 1999).
1.7.1 Net
The 27 kDa Nef protein is the first viral protein to accumulate following HIV
infection of a cell. It is thought to play at least three distinct roles in HIV
pathogenesis (reviewed in Strebel and Bour, 1999).
Nef contributes to the cellular activation of T-cells. The gene expression
profiles after either Nef mediated or normal T-cell receptor mediated
activation are remarkably similar and certain T-cell receptor components are
required for Nef activation (Simmons et al., 2001). These findings suggest
that Nef may activate cells by mimicking T-cell receptor signalling. A Nef
associated cellular kinase, p21-associated kinase 2 (PAK2), has been
identified as a potential mediator of Nef-induced cellular activation (Arora et
al., 2000).
Nef expression can also result in down-regulation of certain host cell surface
molecules by either clatherin-mediated or non-clatherin dependent
endocytotic pathways (Swigut et al., 2001; Luo et al., 2001). Packaging of
Nef into virions increases viral infectivity by an unknown mechanism (Miller et
al., 1994).
1.7.2 Vpr
Vpr is incorporated into viral particles via an interaction with p6 at a rate of
between 100-200 copies per virion (Muller et al., 2000). Like Nef, it appears
to have numerous activities which are to some degree genetically distinct
(reviewed in Steffens and Hope, 2001; Zhu et al., 2001).
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Vpr causes infected cells to arrest in the G2 phase of the cell cycle by
inhibition of the cyclinB/p34cdc2 complex which is crucial in initiation of
mitosis (Re et al., 1995; He et al., 1995). Along with MA and INT, Vpr plays a
role in facilitating nuclear import of the pre-integration complex. MA and INT
associate with the lmportin-a/lmportin-p heterodimer via their NLS
sequences. It appears that Vpr may stabilize this interaction allowing the
entire complex to be imported (Popov et al, 1998).
1.7.3 Vpu
Vpu forms multimers which lodge in the membranes of infected cells. It has
two known functions (reviewed in Steffens and Hope, 2001; Strebel and Bour,
1999). Firstly it binds CD4 and facilitates its degradation. It achieves this by
binding the host protein h-TrCP which activates Skp1 which in turn degrades
CD4 (Margottin et al., 1998). Additionally Vpu plays a role in virion release
although the mechanism of this remains unclear (Marassi et al., 1999).
1.7.4 Vif
The vif gene encodes a 23 kDa basic protein which is crucial for viral
infectivity (Fisher et al., 1987). Its cellular target has recently been identified
as the apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G
(APOBEC3G) (Sheehy et al., 2002). In the absence of Vif, this cellular
protein is incorporated into virions and converts cytosine residues to uracil
residues in newly synthesised viral DNA (Zhang et al., 2003). It is thought
that this action may destabilise the DNA and thus lead to its degradation by
host cell enzymes. Vif blocks the incorporation of APOBEC3G into virions




The interplay between HIV and the host immune system is highly
complicated. As outlined previously (section 1.2), HIV can have a devastating
effect on many aspects of host immunity. Indeed certain arms of the immune
system, such as some complement responses, appear to actively promote
HIV pathogenesis. On the other hand, some host responses are useful in
combating HIV. The study of long term non-progressors (LTNP), HIV-infected
individuals who remain disease free for ten years or more, has been
particularly useful in identifying responses which prevent or slow down
pathogenesis. In addition, the immune responses found in multiply exposed
non-infected (MENI) individuals have been studied in the hope of identifying
responses which could protect against initial infection.
1.8.1.1 Innate responses
The innate immune response consists of a plethora of interacting cellular and
soluble factors. The interactions between innate responses and HIV have
recently attracted increased attention and a number of factors which appear
to correlate with protection against disease have been identified.
Mannose binding lectin (MBL), a circulatory protein, is able to bind and thus
opsonise HIV virions or target them for destruction by complements
components (Ezekowitz et al., 1989; Saifuddin et al., 2000). Low levels of
MBL or polymorphisms in the MBL receptor are associated with increased
risk of HIV infection, faster progression to disease and shorter survival
periods post-AIDS diagnosis (Pastinen et al., 1998; Boniotto et al., 2000).
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The ability to produce type 1 interferon (IFN) in the face of pathogen
challenge is associated with long term survival of HIV infected individuals
(Lopez et al., 1983). The major cellular producers of IFN are a small
population of peripheral leukocytes known as plasmacytoid dendritic cells
(PDCs) (Siegal et al., 1999). These cells have a formidable ability to secrete
IFN following exposure to HIV-infected T cells or, to a lesser extent, free
virions (Levy et al., 2003). It appears that high numbers of PDCs may be able
to delay disease onset even in the face of low CD4 T cell numbers (Soumelis
et al., 2001).
CD8 T cells are also capable of generating protective innate responses to
HIV. These cells are better known for their adaptive cytotoxic function
however, they are also able to secrete a CD8 anti-HIV factor (CAF) which
inhibits a wide variety of HIV-1, HIV-2 and SIV variants (Levy et al., 1996).
This factor remains to be fully characterised but appears to involve a
protease activity (Mackewicz et al., 2003). The ability of CD8 cells to mount
this response is associated with long term survival of HIV infected individuals
(Barker et al., 1998).
Natural killer (NK) cell function may be correlated with reduced susceptibility
to HIV infection and slower disease progression (Nagachinta, et al., 1997;
Ratcliffe, et al., 1994). Ex vivo studies have shown that NK cells can exert a
suppressive effect on HIV infected CD4 T cells both by release of soluble
CC-chemokines and by cell to cell contact (Kottilil, et al., 2003). Both these




The emergence of cytotoxic CD8 T lymphocytes (CTLs) is thought to be the
major factor in the dramatic reduction of viral loads seen following primary
infection (Koup et al, 1994) and throughout infection levels of CTLs are
inversely correlated with plasma viral loads (Ogg et al., 1998). If this
response is not sustained, patients progress rapidly to AIDS (Hay et al.,
1999). Despite this, CTLs do not seem able to completely clear HIV and thus
the virus persists and eventually causes AIDS. LTNP and MENI individuals
have been extensively studied in an attempt to characterise particularly
effective CTL responses. It appears that CTL responses with broader
specificities may be related to longer survival (Harrer et al., 1996). It is
unclear whether the breadth of the response, or the presence within this
response of CTLs specific for certain antigens underlies the slow disease
progression. One theory is that the emergence of CTL responses to early
HIV proteins such as Tat and Rev is responsible for protection (Vanbaalen et
al., 1997).
1.8.2 Vaccination
Despite a huge amount of research there is still no effective vaccine against
HIV. A major difficulty in developing a vaccine which protects against HIV
infection is that it is not clear what immune responses such a vaccine would
need to stimulate. It is hoped that the study of MEDI individuals might lead to
better characterisation of protective responses. Perhaps a more achievable
aim would be the production of a vaccine which delayed or even prevented
the progression to AIDS in HIV infected individuals. There has been
extensive research of LTNP in an attempt to define responses which delay
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disease. Alternatively, immune responses which are not normally seen in the
course of HIV infection might prove protective against infection or disease if
stimulated artificially.
Initial research into anti-HIV vaccines attempted to elicit an antibody
response to HIV Env. The results of these trials were largely disappointing as
the antibody produced was not capable of neutralising heterologous HIV
strains (Moore et al., 1995). However, more recently a number of antibodies
have been identified which appear to have broad specificity for a range of
HIV variants (Moore et al., 2001). Passive immunisation with these
neutralising antibodies (nAbs) is protective in monkeys against a challenge
with SIV/HIV (SHIV) chimeric virus (Mascola et al., 2000). Researchers are
now investigating potential vaccine strategies which would stimulate the
production of these nAbs in vivo.
Following disappointing early results with antibody-stimulating vaccines, most
recent research into potential anti-HIV vaccines has concentrated on eliciting
CTL responses. Although these would not be able to prevent initial infection
they may be able to delay the onset of disease. In order to stimulate CTL
responses, HIV antigens must be presented by host dendritic cells (DCs).
Vaccine trials in animal models have been carried out using a variety of
constructs designed to deliver antigenic peptides to DCs. These have
included naked plasmid DNA encoding HIV peptides (Amara et al., 2001);
recombinant viruses encoding HIV/SIV peptides (Zhong et al., 2000;
Engelmayer et al., 2001); liposomes containing HIV peptides (Zheng et al.,
1999) or HIV peptides linked to a lipid tail (Andrieu et al., 2000). The results
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of these trials have been promising however there are still many obstacles to
overcome. The magnitude of CTL response generated needs to be increased;
perhaps by using adjuvants or novel prime/boost combinations. In addition,
strategies to maintain T cell responses over time need to be further
investigated.
1.8.3 Drug treatment
The first antiretroviral agent to be licensed was the RT inhibitor zidovudine in
1987. Initial trials of on individuals with AIDS or ARC had shown that there
was a significant decrease in mortality when zidovudine was taken compared
to the placebo control (Fischl et al., 1987). Unfortunately the clinical benefits
of taking zidovudine alone decrease dramatically over time mainly due to the
rapid emergence of resistant variants (Volberding et al., 1994). Since the
discovery of zidovudine numerous other antiretroviral agents have been
identified and licensed. These have all been inhibitors of either RT or PR.
Taking a combination of drugs with distinct targets results in a significant
delay in the emergence of drug resistant variants. In particular, since the
emergence of PR inhibitors in the mid-nineties, HIV infected individuals can
be treated with a combinations of drugs known as highly active anti-retroviral
treatment (HAART). Such regimes are able to suppress viral replication
below the level of detection for many years although they do not eradicate
the virus from cells (Menendez-Arias, 2002; Weller, 1999).
Anti-retroviral agents produce a number of adverse side effects of varying
severity (Weller, 1999). Zidovudine can cause haematological disturbances
such as anaemia and neutropenia. Neuropathies can occur with didanosine
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or zalcitabine treatment. Both nevirapine and efavirenz can cause skin
rashes. Most of the inhibitors of RT can also cause gastrointestinal
disturbances in some patients. Perhaps the most unacceptable side effect for
patients, however, are the disturbances of lipid metabolism associated with
PR inhibitor use. These can lead to abnormal fat distribution: sub-cutaneous
fat is lost from the face, limbs and upper body while increased fat deposits
accumulate around the abdomen, breasts and upper back.
1.9 Viral Evolution
HIV has a remarkably high rate of evolution. A number of viral and host
factors have an influence on this.
1.9.1 Viral factors
The HIV genome is copied many times during the HIV life cycle: RNA
templated minus strand DNA synthesis catalysed by viral RT; DNA-templated
plus-strand DNA synthesis catalysed by viral RT; DNA-templated DNA
replication catalysed by cellular DNA polymerases and DNA templated
genomic RNA synthesis catalysed by cellular RNA polymerase II. The in vivo
point mutation rate of HIV has been estimated as 3.4 x 10"5 (Mansky and
Temin, 1995). This rate is relatively high compared with cellular genes
suggesting that one or both of the polymerases unique to HIV replication (i.e.
viral RT and RNA polymerase II) have a higher mutation rate than host
polymerases. An additional mechanism of viral diversity is recombination.
1.9.1.1 Reverse Transcription
RT contributes to viral evolution due to its relatively low fidelity (reviewed in
McGrath et al., 2001; Preston and Dougherty, 1996). Unlike cellular
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polymerases, RT lacks a 3' to 5' exonuclease which could correct any mis-
incorporations. The in vivo rate of RT is around 20 times lower than the
estimated mutation rate of purified HIV RT suggesting that in vivo factors act
to modulate RT fidelity. One such factor could be the presence of Vpr. It
binds the host DNA repair enzyme, uracil DNA glycosylase and facilitates its
incorporation into virions (Mansky et al., 2000).
1.9.1.2 RNA polymerase II
Once integrated, the DNA provirus is copied into RNA by host cell RNA
polymerase II. In the host cell, this enzyme does not contribute to genomic
mutation rates as the RNA is used only as a template for protein synthesis.
For this reason, there is not a strong selection pressure on this enzyme to
maintain a high fidelity. Thus, in common with HIV RT, this enzyme lacks a
proof-reading mechanism. In the case of HIV however, the RNA produced by
this enzyme is used both to translate proteins from and as genomic RNA.
Thus the mutation rate of this enzyme can contribute to HIV mutation rates.
The precise mutation rate of human RNA polymerase II has not been
established but it is thought that it is probably similar to the mutation rate of
the prokaryotic version of the enzyme. This has been calculated as
approximately one error every 104-105 nucleotides synthesised (Blank et al.,
1986; Libby and Gallant, 1991). If human RNA polymerase II does have a
mutation rate of this order it may play a role in mutation rates of HIV as
significant as viral RT.
1.9.1.3 Recombination
Every retroviral virion contains two homologous copies of the RNA genome.
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This allows for high rates of recombination; around 2% per kilobase per
replication (Hu and Temin, 1990). Recombination is thought to occur mainly
during minus-strand DNA synthesis (Zhang et al., 2000). In this model, when
the RT encounters breaks in the RNA while synthesising the first strand
(minus-strand) of DNA, it can switch to use the other RNA molecule as
template. Recombination has been directly observed in a rhesus monkey
infected with two strains of SIV each containing distinct mutations which
significantly lowered viral replication (Wooley et al., 1997). Within two weeks
recombinant virus lacking both mutations predominated. Indirect evidence for
recombination also exists in the form of mosaic genomes. A number of CRFs
have caused major epidemics (see section 1.3.2). These presumably arose
when one cell was infected with two different subtypes of virus. Virus
released from this cell could contain a genome from each subtype which
could recombine upon proviral synthesis. Discordance of phylogenies
between gag and env sequences from brain and lymph of individual persons
suggest that recombination occurs frequently even between anatomically
distinct sites (Morris et al., 1999).
1.9.2 Host factors
1.9.2.1 Immune Response
The most important immune factor driving viral evolution seems to be the
emergence of CD8+ cytotoxic T lymphocytes (CTL). Unfortunately, within 22-
30 days of the emergence of a CTL response, CTL escape mutants can
appear and when they do, they rapidly become the dominant variants
(Borrow et al., 1997; Price et al., 1997). This provides strong evidence that
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host CTL responses are an important driver of evolution. It is thought that the
ability of CTLs to control viral load and the emergence of escape mutants are
important determinants of the length of the chronic stage of HIV infection.
Antibody responses impose a milder selective pressure on viral evolution
than CTL responses. Antibody responses to infection can arise between 5
weeks and a year after initial infection (Arendrup et al., 1992; Pilgrim et al.,
1997). Escape mutants to neutralising antibody do appear. In fact, antibody is
commonly capable of neutralising virus from earlier time points but not the
current viral strains (reviewed in Da Silva 2003). This indicates that there is
some advantage to the virus in evolving away from antibody responses.
However, the presence of antibody escape mutants in long term non-
progressors suggests that their role in disease progression is minimal
(Bradney et al., 1999).
1.9.2.2 HLA type
Another factor influencing viral evolution is the human leukocyte antigen
(HLA) genotype of the infected person. There are two types of HLA. HLA
class I presents intra-cellular antigen to CD8 cells thus generating a CTL
response. HLA class II present endocytosed extra-cellular antigen to CD4
cells and thus play a role in cytokine production and T call help. Each class of
HLA has three loci each of which can be either homo- or hetero-zygous.
Studies investigating specific HLA allelic associations with disease
progression have been difficult due to the highly polymorphic nature of the
HLA loci. However, some convincing data regarding such associations are
emerging. Unsurprisingly, most associations between disease progression
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and HLA allele have involved HLA class I as this is involved with generation
of CTL responses.
Perhaps the most striking finding in studies of HLA and AIDS is that the
degree of homozygosity at class I loci is significantly associated with more
rapid disease progression (Carrington et al., 1999; Tang et al., 1999). It is
thought that this is because higher diversity of HLA molecules provides a
bigger challenge to HIV's attempts to "out-evolve" the immune system.
Another factor may be that selective pressure of prevalent HLA alleles has
driven HIV variants in the population at large to be resistant to presentation
by these (Goulder et al., 1997a; McMichael and Klenerman, 2002). Thus
people with a second different allele may be better able to combat the virus.
In addition to this heterozygote advantage, a number of specific HLA alleles
with significant associations with disease progression have been identified.
Two class I alleles found to be protective against disease progression are
HLA-B*57 (Migueles et al., 2000; Klein et al., 1998) and HLA-B*27 (Goulder
et al., 1997b). CTL responses to peptides bound to these molecules are
strongly protective and emergence of escape mutations is restricted. This is
probably because mutations necessary to escape presentation by these HLA
alleles negatively affect viral fitness. Conversely the presence of HLA-B*35 is
strongly associated with disease progression (Gao et al., 2001). This is partly
because this allele is a poor generator of CTL responses but there appears
to be a further, as yet uncharacterised, negative effect of this allele
(Carrington and O'Brien, 2003).
1.9.2.3 Anti-retrovirals
Anti-retroviral treatment (although not strictly a host factor) can also exert a
strong selection pressure on viral evolution as demonstrated by the rapid
emergence of escape mutants following the advent of monotherapy (figure
1.10). The emergence of drug resistant mutants is discussed in more detail in
chapter 4.
1.9.3 Models of evolution
For the past fifty years or so there has been much controversy surrounding
the predominant mechanism for evolutionary change in general (reviewed in
Page and Holmes, 1998). The argument has centred on the relative roles of
chance and natural selection on fixing mutations within populations. Two
opposing models have been proposed; the neutralist and the selectionist
models. Both models are in agreement that the majority of mutations to occur
at the molecular level will be deleterious to the organism and will therefore be
lost.
The neutralist model states that most other mutations will be neutral (Kimura,
1968; Jukes and Cantor, 1969). The majority of these will also be lost but a
small number of these will become fixed. The mutations which become fixed
will be a random selection of all possible neutral mutations. This model does
accept that some advantageous mutations will occur but these will be so
infrequent as to be irrelevant to the overall pattern of evolution. Thus over
time the genetic code will change randomly- so called "genetic drift".
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Figure 1.10: Emergence of drug resistance during mono-therapy with a
protease inhibitor. Within days of beginning treatment there is a dramatic fall
in viral RNA (first graph) and increase in CD4 T cell numbers (second graph).
However drug resistant mutants arise quickly leading to a rebound in viral
numbers and decline in CD4 T cell numbers. By 4 weeks resistant mutants
are the dominant viral variant (third graph) (Wei et al., 1995).
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The selectionist model was proposed by some as the obvious extension of
Darwinism and gives more weight to positive selection as a factor in evolution.
While selectionists also believe that most mutations will be deleterious, they
believe that most other mutations will confer at least a slight advantage to the
organism. In this model, the mutations which become fixed are those which
most improve the fitness of the organism.
Which model best explains evolution in a given circumstance, is determined
by a number of factors most important of which seem to be presence of
selective pressure and effective population size. If there is substantial
selective pressure acting on a gene it may exhibit deterministic evolution
characteristic of the selectionist model. This is the case for HIV which is
constantly facing changing host pressures. Each time the selection pressure
alters, a new opportunity arises for mutations to improve upon viral fitness.
When there is a large effective population, survival is much more likely to be
determined by fitness whereas in small effective populations random events
may be more important in controlling viral evolution. Conflicting reports exist
about the effective population size in a HIV infected individual. On the one
hand there are a large number of productively infected cells, estimated to be
between 107 and 108 (Haase et al., 1996), and an even larger number of
virions generated per day, thought to be at least 1010 (Perelson et al., 1996;
Rouzine and Coffin, 1999a). However, some studies have suggested that the
population of infected cells which produce virus which goes on to infect other
cells, is much lower than the total number of infected cells (Leigh-Brown,
1997). This could either be due to frequent bottleneck effects or because
54
virus produced from most infected cells is actually non-infectious. It has been
suggested that the effective population size and therefore relative importance
of neutralist or selectionist behaviour, may vary throughout HIV infection
depending on external factors (Rouzine and Coffin, 1999b). For example,
the genetic bottleneck seen with the advent of anti-retroviral treatment is
suggestive of a selectionist model whereas neutralist behaviour may be
relatively more important during steady state chronic infection.
1.10 AIDS Dementia Complex
In the absence of effective treatment, there are a variety of neurologic
manifestations of HIV infection. A number of brain disorders are caused by
opportunistic infections during AIDS such as cryptococcal meningitis,
toxoplasma encephalitis, cytomegalovirus encephalitis, neurosyphilis and
primary CNS lymphoma. In addition to these, HIV itself can cause
neurological dysfunction. The mildest form of HIV-associated CNS disease is
termed minor cognitive motor disorder. A more severe disorder, known as
AIDS dementia complex (ADC) is associated with significant encephalopathy.
The prevalence of this disorder in the absence of effective treatment is
controversial; estimates of incidence in persons with AIDS range from 5% to
60% (reviewed in Clifford, 2002; Tardieu and Boutet, 2002). One reason for
these disparate results is that it can be difficult to rule out opportunistic
infections as the etiological agent for observed clinical deficits. A post¬
mortem study found that HIV encephalopathy was apparent in 25% of brains
from persons with AIDS (Masliah et al., 2000).
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1.10.1 Clinical presentation
The clinical presentation of ADC has led to it being classed as a sub cortical
dementia. This distinguishes it from so called cortical dementias, such as
Alzheimer's disease in which the initial observations include deficits of higher
functions including reasoning and memory. In addition to ADC, other
diseases including Parkinson's disease- associated dementia and
Huntington's chorea are classed as sub cortical dementias. In these illnesses
the initial pathological damage tends to be in regions lying below the cerebral
cortex although more generalised cerebral pathology may occur with time.
Characteristic symptoms include deficits in attention, motivation and
emotionality (reviewed in www.memorylossonline.com).
The main features of ADC are sub acute cognitive decline and slowing of
motor function (reviewed in Clifford, 2002). Many people with ADC are aware
of their own clinical decline. They often report a reduction in concentration
span which leads to an impaired ability to perform tasks, read or enjoy
hobbies. Loss of motor function is almost ubiquitous in ADC. In fact this
symptom alone has been used as a reliable indication of the severity of
disease. Motor loss is typically symmetrical and mainly involves the arms and
legs. This can result in a reduction of functionality and independence of the
affected individual.
1.10.2 Pathological features
The defining features of HIV encephalitis (HIVE), the pathological disorder
underlying ADC, are giant cells and or detection of HIV p24 positive
microglia/macrophages/giant cells in brain tissue (Budka et al., 1991).
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Histological findings may also include astrocytosis, myelin pallor, monocyte
infiltration and neuronal loss (reviewed in Bell, 1998; Kaul et al., 2001;
Rhodes and Ward, 1991). As suggested above, the earliest pathological
changes occur in sub cortical regions. Pathological changes are also present
in sub cortical white matter where multinucleated giant cells and abnormal
staining are observed (Clifford, 2002). Positron emission tomography scans
have revealed hypermetabolism in deep grey structures (Rottenberg et al.,
1987). This is followed by marked atrophy of the basal ganglia which has
been observed by MRI scans (Aylward et al., 1993).
In later stage ADC, cortical pathology is also apparent. There is a noticeable
loss of thickness of the cortical mantle. The reason for this loss may vary by
brain region. In the hippocampus, atrophy of neurons without cell loss was
observed (Sa et al., 2000). However, quantitative neuronal loss is apparent in
the frontal and temporal lobes (Everall et al., 1991). The mechanism for this
cell loss is thought to be apoptosis mediated by a number of mechanisms
outlined below. In addition, other more subtle pathological changes such as
synaptic changes, vacuolisation and (3-amyloid accumulation can occur
(Giometto et al., 1997; Masliah et al., 1997).
Surprisingly, neither the viral titre in the brain, nor most of the pathological
changes outlined above, correlate well with the clinical severity of ADC. In
fact the best pathological indicator of degree of impairment is the amount of
macrophage activation (Glass et al., 1995; Adle-Biassette et al., 1999).
1.10.3 Pathogenesis
The only brain cells known to be productively infected by HIV are microglia
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however the current model of neuropathogenesis involves interactions
between HIV, microglia, astrocytes and neurons. This model is summarised
in figure 1.11 and the role of the different cell types is outlined below.
Endothelial Cells
In order to enter the brain HIV must get past the endothelial cells which line
the blood brain barrier (BBB). Some studies have suggested that HIV
achieves this by first infecting endothelial cells; however subsequent studies
have disputed this (Nottet et al., 1996). An alternative hypothesis is that HIV
or HIV proteins are toxic to endothelial cells and thus increase the
permeability of the BBB. Toxicity of gp120 and gp160 proteins has been
demonstrated for both rat and human brain endothelial cells (Kanmogne et
al., 2002). Supporting this theory is the observation of apoptotic endothelial
cells in post mortem brain sections from individuals with AIDS (Shi et al.,
1996).
Microglia and macrophages
Infiltration of infected macrophages is thought to be the primary route of HIV
entry into the brain (reviewed in Gartner, 2000) and macrophages are also
the principal site of viral replication within the brain. A number of types of
macrophage can exist in the brain and these may vary in their ability to
support HIV infection. As mentioned above, blood monocytes can enter the
brain and within the brain there exist microglia. In addition, brain
macrophages reside in the meninges and choroid plexus. It is thought that
each of these cell types must be activated before they are permissive to HIV
infection (reviewed in Tardieu and Boutet, 2002). Soluble gp120 alone
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Figure 1.11: Model of pathways leading to neural damage in HAD. A cascade
of damaging effects is initiated either by infection of macrophages/ microglia
or by the effects of shed HIV proteins. Substances released from
macrophages and microglia can have a direct toxic effect on neurons.
Additionally, some substances can cause astrocytes to release neurotoxic
substances (Kaul et al., 2001).
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can also bind and stimulate macrophages or microglia.
Once activated/ infected the cells release various damaging substances
which have effects on other cells. In fact infected and/or activated
macrophages/microglia are necessary for HIV or gp120 induced neuronal
damage (Giulian et al., 1990; Giulian et al., 1993). Neuronal damage can be
mediated by the release of excitotoxic substances such as glutamate,
inflammatory-cytokines such as IL1-P and TNF-a, cytokine-induced L-
cysteine, arachidonic acid, chemokines, free radicals such as superoxide
anion and HIV-proteins (Lipton and Gendelman, 1995; Giulian et al, 1990;
Pulliam et al., 1991).
Astrocytes
Astrocytes may be non-productively infected with HIV (reviewed in Brack-
Werner, 1999; Tornatore et al., 1994; Ranki et al., 1995). As astrocytes play
a role in inactivating neurotoxins (Fine et al., 1996), buffering glutamate and
maintaining the blood-brain barrier (Brack-Werner, 1999); this could have an
influence on neuropathogenesis. One study has reported that a high level of
HIV DNA-positive astrocytes is associated with higher levels of astrocyte
apoptosis and a more rapid disease progression (Thompson et al., 2001).
Microglial released substances such as TNF-a and arachidonate can act on
astrocytes both to induce glutamate release and to inhibit glutamate reuptake
(Fine et al, 1996; Genis et al., 1992). In addition cytokines and viral proteins
can act on inducible nitric oxide synthase (iNOS) in astrocytes. The resultant
nitric oxide is a modest neurotoxin however it can also react with microglial
released superoxide anion to produce the potent oxidant peroxynitrite
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(Beckman and Koppenol, 1996).
Neurons
While there is no evidence of productive infection of neurones with HIV, there
is conflicting data on the frequency and significance in the aetiology of HIV-
related brain disease of latent infection in this cell type (Nuovo et al., 1994;
Bagasra et al., 1996; An et al., 1999).
Various in vitro studies have found evidence for direct neurotoxic effects of
HIV-proteins (Meucci et al., 1998; Hesselgesser et al., 1997). However the
significance of these findings in vivo is unclear. The concentrations of viral
proteins used experimentally often far exceed those found in HIV-infected
brains and experiments using mixed neural cell cultures have shown that
indirect effects of microglial and astrocytic released substances may play a
more significant role in neural damage (Lipton and Gendelman, 1995; Kaul
and Lipton, 1999).
Excitotoxic substances such as glutamate released from microglia and
astrocytes can over-activate glutamate receptors, particularly the N-methyl-
D-aspartate (NMDAR) subtype. Severe over-activation can cause the cell to
become necrotic while a lower degree of activation can initiate the cellular
pathways which result in apoptosis (Bonfoco et al., 1995).
TNF-a and IL-p released from microglia stimulate production of L-cysteine
which can also stimulate NMDARs and lead to neuronal apoptosis (Yeh et al.,
2000). It is thought that TNF-a may act synergistically with HIV/Tat to induce
neuronal death (Shi et al., 1998).
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Finally free radicals are thought to play a part in neuronal damage. In
particular, peroxynitrite is able to disrupt neurofilament assembly (Beckman
and Koppenol, 1996; Coyle and Puttfarcken, 1993).
1.11 Tropism
The cells known to be infected by HIV in vivo are T cells, macrophages,
microglia and dendritic cells. The infection of a number of other cells such as
astrocytes and endothelial cells remains controversial (Brack-Werner, 1999;
Bagasra et al, 1996; An et al, 1999). This relatively narrow tropism reflects
HIV's requirement for both CD4 and a co-receptor in order to infect cells
(Deng et al., 1996; Feng et al., 1996) (section 1.4.1). A number of viral and
cellular factors contribute to the differential tropism of various viral strains for
different cell types.
1.11.1 Co-receptors
The discovery that HIV uses seven transmembrane chemokine receptors as
co-receptors led many to believe that the issue of HIV tropism would be
solved. However, while around 15 chemokine receptors have been found to
support HIV infection in vitro, it appears that only 2 are used significantly in
vivo (reviewed in Clapham and McKnight, 2001). CCR5 is the main receptor
used during transmission and asymptomatic infection (Benkirane et al., 1997;
Wilkinson et al., 1998; Scarlatti et al., 1997). With the onset of AIDS, there is
a switch to CXCR4 usage in some people- around 50% of those infected with
subtype B (Scarlatti et al, 1997). In some study subjects dual tropic (X4R5)
viruses are found. CCR5 using (R5) viruses are able to infect memory T cells
and macrophages while CXCR4 using (X4) viruses are able to infect both
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naive and memory T cells and some populations of macrophages (reviewed
in Clapham and McKnight, 2001). More subtle differences in tropism than
merely co-receptor usage exist. For example although macrophage tropism
has been used interchangeably with "R5" this may be misleading. In one
study both non-macrophage tropic R5 viruses and macrophage tropic X4
viruses were identified (Gorry et al., 2001). Another paper reported that
CCR5 deficient macrophages allowed CXCR4 dependent entry by a dual
tropic virus but not by an X4 virus (Collman and Yi, 1999). These results
suggest that macrophage tropism is not solely determined by co-receptor
usage.
1.11.2 Receptor expression levels
In some cases the relative levels of receptor expression may influence
tropism. The inability of primary X4 viruses to replicate in T cell lines was
overcome by overexpression of CD4 (Piatt et al., 2000) while over-
expression of CXCR4 on primary macrophages dramatically increased the
efficiency of infection by X4 laboratory isolates (Tokunaga et al., 2001).
However, receptor expression levels cannot fully explain differences in
tropism. Altering the expression levels of either CD4 or CCR5 did not explain
the differences in tropism between a macrophage tropic and a non-
macrophage tropic R5 isolates (Gorry et al, 2001).
1.11.3 Other receptors
While CD4 and a co-receptor are required for viral fusion, it is possible that
other receptors may cause initial cell adhesion and thereby influence tropism.
When HIV buds from a cell it selectively incorporates certain host cell derived
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membrane molecules (Tremblay et al., 1998; Henriksson and Bosch, 1998).
The nature and quantity of adhesion molecules acquired may influence the
cell type adhered to and subsequently infected by the virion. Virus grown in
cells overexpressing intercellular adhesion molecule 1 (ICAM-1), had a 10
fold increased infectivity for LFA-1 cells (Fortin et al., 1997).
A number of other cell-surface molecules may contribute to attachment.
Heparan sulfate proteoglycan (HSPG) expression can greatly affect the
infection of cells by laboratory X4 viruses (Mondor et al., 1998; Roderiquez et
al., 1995; Patel et al., 1993) although its significance in vivo is unclear. Other
molecules which could potentially play a role include mannose receptors and
galactosyl ceramide (Ugolini et al., 1999).
1.11.4 Viral Factors
The envelope protein of HIV consists of a three transmembrane gp41
peptides, non-covalently linked to three extra-cellular gp120 peptides. Gp120
consists of 5 conserved and 5 variable regions (figure 1.12). Particularly
important to determining tropism is the V3 loop (Kwong et al, 1998). although
V1 and V2 also have some influence (Cho et al., 1998). The V3 loop itself
has two functional domains: the V3 crown and the V3 loop. Both the crown
and loop region appear to play a role in the binding of soluble R5 gp120 to
CCR5 however only the crown region is required for CCR5 binding by virion
associated gp120 (Cormier and Dragic, 2002). The genetic factors which
determine co-receptor usage are variable and strain specific. An association
between the presence of basic residues in V3 and T-cell tropism has been
noted (Fouchier et al., 1992; Basmaciogullari et al., 2002). Substitutions at a
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C5
Figure 1.12: Schematic representation of the variable (V1-V5) and conserved
(C1-C5) regions of gp120 (Hoffman and Doms, 1999).
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number of amino acid sites in gp120 are correlated with a switch from
CXCR4 to CCR5 usage in vivo (Rizzuto et al., 1998).
1.12 Neurotropism
1.12.1 Compartmentalisation
Within an infected individual, the env gene from brain or lymphoid tissue
derived virus can differ significantly. This mirrors similar differences observed
between lymph derived virus and that found in semen, faeces or lungs. One
study found that virus from the colons and brains of patients grouped
together phylogenetically and were distinct from blood-derived virus (Wang et
al., 2001). This suggests that rather than there being many separate tissue
compartments, a population of virus arises which is able to infect tissue
macrophages in many different organs.
There are two possible explanations for the differences observed in viral
sequences derived from the blood/lymphoid tissue and those from the brain.
It could be that these populations are physically separated from each other
and thus viral evolution occurs independently in each. Alternatively, the
differences could reflect an adaptive process whereby the virus evolves to be
better able to infect the target cells in the tissue in which it is located.
Accumulating evidence suggests that there is no physical barrier between the
blood and the brain viral compartments. One study showed that the
segregation of viral populations between the intestinal and blood
compartments is not complete (Vanderhoek et al., 1998). Rather, while the
proportion of two variants differed in the two compartments, both variants
could be found to some degree in both compartments. This shows that there
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is no physical impediment to variants mixing between these two
compartments. Further evidence that differences in viral populations between
blood and brain are due to adaptive processes was provided by a study
which examined recombination between variants in these two locations
(Morris et al, 1999). The presence of discordant phylogenies for different HIV
genes when sequences for the two populations were compared led to the
conclusion that the viral subspecies infecting brain and lymphoid cells
recombine frequently. This suggests that there is no barrier to recombination
between compartments allowing some genes (especially env) to evolve to
adapt to the new environment, while others can retain similarity to those
found elsewhere in the body via recombination.
1.12.2 Neurotropic versus macrophage tropic
Specifically neurovirulent SIVmac strains have been isolated (Anderson et al.,
1993) but whether such variants exist for HIV is controversial. One study
found that brain-derived virus showed a preferential tropism for microglia
compared to blood monocytes-derived macrophages (Strizki et al., 1996).
However others have found that microglia and macrophage tropism of brain-
derived virus is similar (Ghorpade et al., 1998; Hibbitts et al., 1999).
1.12.3 Co-receptors in the brain
When considering infection of cells in the brain it is important to determine
the cellular distribution of receptors able to mediate HIV infection (reviewed in
Martin-Garcia et al., 2002). The principle resident brain cells infected are
microglia. These express CCR5 as well as low levels of both CD4 and
CXCR4 (Dick et al., 1997; He et al., 1997; Albright et al., 1999). In addition a
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number of other potential coreceptors such as CCR3 are found on this cell
type. CCR5 seems to be the main coreceptor used for infection of these cells
as anti-CCR5 antibodies are able to inhibit infection in vitro (Albright et al,
1999).
The other brain cell type for which convincing evidence of infection exists are
astrocytes. A number of studies have found evidence of HIV infection of
astrocytes in vivo (reviewed in Brack-Werner, 1999) although there have
been questions about the validity of some techniques used. Certainly primary
human foetal astrocytes can be non-productively infected in vitro (Sabri et al.,
1999). The cellular receptors which mediate infection of this cell type remain
something of a mystery. These cells do not appear to express CD4 at all and
express CCR5 and CXCR4 only at very low levels. Moreover, neither
antibodies to the CD4 binding site of HIV or to chemokine receptors, nor a
variety of chemokines, inhibited infection of primary human foetal astrocytes
(Sabri et al, 1999). If these results reflect the in vivo situation, it would mean
that astrocytes are the first identified CD4 negative cell type to be infected in
vivo. This surprising possibility is probably the reason that the scientific
community has been slow to accept that astrocytes are infected at all. The
receptor (s) which does mediate astrocyte infection in vitro or in vivo remains
uncharacterised. There has been some evidence that the glycosphingolipid
galactosylceramide (GalCer) could mediate infection of this cell type
(Harouse et al., 1991; Bhat et al., 1991) however this is still controversial.
Aims
The aim of this project was to investigate the distribution of HIV within its host.
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Each results chapter focuses on a different aspect of this topic. The first
chapter aims to produce a system which would allow the investigation of the
determinants of cellular tropism. The second chapter seeks to characterise
the distribution of drug-resistance mutations in different anatomical locations.
The final chapter attempts to identify the cellular location of HIV within the
central nervous system. Thus the project attempts to further the
understanding of where HIV is found, determinants of cellular tropism and
how the virus differs phenotypically in different locations.
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Chapter 2: Materials and methods
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2.1 Analysis and manipulation of DNA
2.1.1 Minimising contamination in PCR
Nested polymerase chain reaction (PCR) is a highly sensitive technique
which can be used to amplify DNA sequences from only one template
molecule. This sensitivity makes nested PCR an extremely valuable tool in
many aspects of molecular biology research however is also means that
there is a high risk of contamination which could lead to false positive results.
A number of steps were taken to reduce the risk of DNA contamination. All
PCR buffers were mixed in a dedicated room which was never used for
nucleic acid manipulations. Primary and secondary PCRs were set up in
separate rooms with dedicated equipment (e.g. pipettes) and lab coats.
Equipment was never transferred from the secondary lab to the primary lab.
Likewise, once a primary PCR had been carried out, the PCR tubes were
never opened in the primary lab. Throughout procedures latex gloves were
used. These were always removed before leaving a lab. DNA contamination
was minimised within all labs by regularly cleaning lab benches and pipettes
with a solution of 1% (v/v) bleach.
Known negative control DNA samples were included along with every PCR
run to check for any DNA contamination.
2.1.2 Primer sequences
A number of considerations were taken into account when designing PCR
primers. The portion of DNA sequence to be used as a template for primer
design was carefully chosen to yield optimal primers. A region was chosen
which had a G + C content of 40-60%, did not contain runs of any one base
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and did not contain "palindromic" sequences which could lead to secondary
structure formation of the primers. Primers were generally designed to be
between 20 and 30 bases long and had a high degree of sequence similarity
with the template DNA of interest. In particular, mismatched bases were
avoided at the 3' end of primers as this can substantially reduce primer
binding. Complementary sequences between primers were avoided in order
to reduce primer dimmer formation. Oligonucleotide primers were
synthesised by VH Bio or Oswell. Primer sequences used are outlined below
in table 2.1.















M13S TTGTAAAACGACGGCCAGTG Fragment for
OE
M13AS GGAAACAGCTATGACCATGA Fragment for
OE
332 TACAATGTACACATGGAATT V3 OS
306 TGGCAGTCTAGCAGAAGAAG V3 IS
307 CTGGGTCCCCTCCTGAGG V3 IAS
308 ATTACAGTAGAAAAATTCCCC V3 OAS
531 GCGAGAGCGTCAGTATTAAGCGG p17 OS
532 GGGAAAAAATTCGGTTAAGGCC p17 IS
533 CTTCTACTACTTTTACCCATGC p17 IAS
534 TCTGATAATGCTGAAAACATGGG p17 OAS
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291 N/K p-actin OS
293 N/K p-actin IS
294 N/K p-actin IAS
292 N/K p-actin OAS
Env A GGCTTAGGCATCTCCTATGGCAGGAAGAA Env OS
Env B AGAAAGAGCAGAAGACAGTGGCAATGA Env IS
Env M TAGCCCTTCCAGTCCCCCCTTTTCTTTTA Env IAS
Env N CTGCCAATCAGGGAAGTAGCCTTGTGT Env OAS
P510S TTAGTAGGACCTACACCTGTC RT OS
P51 OAS CCCCACTAACTTCTGTATGTC RT OAS
PA IS GGAATGGATGGCCCAAAAGTT RT (A) IS
PA IAS CTGATATCTAATCCCTGGTGTCTC RT (A) IAS
PB IS CTGGATGTGGGTGATGCATAT RT (B) IS
PB IAS CACTATAGGCTGTACTGTCCA RT (B) IAS
PROF ACCAGAAGAGAGCTTCAGG PROS
PRIF AACTCCCYCTCAGAAGCAGG PR IS
PRIR TGGTACAGTTTCAATAGGAC PR IAS
PROR TTGGGCCATCCATTCCTGGC PROAS
Table 2.1: Oligonucleotide primer sequences and function. OS: Outer sense;
IS: Inner sense; IAS: Inner anti-sense OAS: Outer anti-sense; N/K: Primer
sequence not known as primers obtained from colleague with no record of
sequence.
2.1.3 Basic PCR reactions
PCRs were carried out using a Genius PCR machine (Techne). PCRs were
carried out in reaction volumes of 20 pi unless specified. Reaction mix
consisted of 2 pi template DNA (0.5 pi if template was cloned plasmid DNA),
10% (v/v) 10 x Promega PCR reaction buffer (100 mM Tris-HCI (pH 9.0), 500
mM KCI, 15 mM MgCI2 and 1% (v/v) Triton X-100), 30 pM of each dNTP
(dGTP, dATP, dTTP and dCTP) (Promega), 2 units of Taq polymerase
(Promega), 0.25 pM of each primer and nuclease free water (Promega) to
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the final reaction volume.
The thermocycling conditions used were as follows:
For V3, PR, p17 and p-actin (both primary and secondary):
[94°C for 18 seconds, 55°C for 21 seconds and 72°C for 1.5 minutes] for 30
cycles followed by 72°C for 10 minutes
For RT primary:
[94°C for 18 seconds, 60°C for 21 seconds and 72°C for 1.5 minutes] for 40
cycles followed by 72°C for 10 minutes
For RT secondary:
[94°C for 18 seconds, 60°C for 21 seconds and 72°C for 1.5 minutes] for 25
cycles followed by 72°C for 10 minutes
When nested PCR was required, 2 pi of the primary PCR reaction mix was
transferred to a clean tube and acted as template for the secondary reaction.
The basic recipe used for the reaction mix was the same for both primary and
secondary reactions.
2.1.4 Long range PCR
PCRs were carried out using a Genius PCR machine (Techne). Long range
PCRs were carried out in reaction volumes of 50 pi. Reaction mix consisted
of 2 pi template DNA (0.5 pi if template was cloned plasmid DNA), 10% (v/v)
10 x Roche Expand High Fidelity PCR reaction buffer with MgCh, 60 pM of
each dNTP (dGTP, dATP, dTTP and dCTP) (Promega), 2 units of Expand
74
High Fidelity polymerase (Roche), 0.5 pM of each primer and nuclease free
water (Promega) to the final reaction volume. The thermocycling conditions
used were:
[94°C for 45 seconds, 50°C for 45 seconds and 72°C for 4 minute] for 20
cycles followed by [94°C for 45 seconds, 50°C for 45 seconds and 72°C for 4
minutes 15 seconds] for 15 cycles followed by 72°C for 10 minutes.
When nested PCR was required, 2 pi of the primary PCR reaction mix was
transferred to a clean tube and acted as template for the secondary reaction.
The basic recipe used for the reaction mix and the thermocycling conditions
were the same for both primary and secondary reactions.
2.1.5 Limiting dilution PCR
Serial ten fold dilutions of the extracted DNA ranging from 10"1 to 10~5, were
prepared using nuclease free water (Promega). Nested PCRs were carried
out using 2pl of each dilution as template. 20 replicate nested PCRs were
carried out using DNA at a dilution of 1/3 of the last positive dilution. If eight
or fewer of these PCRs were positive then the products were assumed to be
derived from a single template molecule. If more than eight reactions were
positive then a further 20 reactions were carried out at a new dilution which
would be expected to yield eight or fewer positives out of 20.
The average number of template molecules (T) present per tube was




The total DNA concentration of samples was also assessed using a
spectrophotometer and thus the number of proviral copies per million cells
was calculated on the basis that a human diploid cell contains 6.6 pg of DNA.
2.1.6 Generation of fragments by overlap extension
Amplification of fragments was carried out in a 50 pi reaction volume using
either 5 pi of ligation mix or 1 pi of NL4.3envEGFP plasmid. The primers
used for amplification were M13S and 307 for one fragment and 306 and
M13AS for the second fragment. Fragments were generated by
thermocycling using the following conditions:
[94°C for 45 seconds, 50°C for 45 seconds and 72°C for 6 minutes] for 35
cycles followed by 72°C for 10 minutes
Products were visualised on an ethidium bromide stained agarose gel to
ensure fragments of the predicted size were present. 10 pi of each fragment
were mixed. Primers were removed from this mix either by spin purifying or
by adding 4 pi exonuclease I (Amersham) and incubating at 37°C for 20
minutes. If the sample was treated with exonuclease heat inactivation of the
enzyme at 80°C for 15 minutes was carried out. To the mixture was added
the follow:
10% (v/v) of total final volume 10 x Taq reaction buffer (n.b. exonucleased
samples will contain buffer from PCR step and only the excess amount
required was added), 1 pi Taq, 1 pi dNTPs (Promega), 0.5 pi primer M13S
and 0.5 pi primer M13AS
Thermocycling was carried out as follows:
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[94°C for 45 seconds, 72°C for 7 minutes] for the number of cycles indicated
2.1.7 Automated sequencing
Automated sequencing reactions were carried out using ABI Prism BigDye
Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems) and
analysed using an ABI Prism 3100 genetic analyser (Perkin Elmer ABI
biosystems). This system uses the chain termination method (Sanger et al.,
1977) of cycle sequencing (Murray, 1989). The reaction mix includes the
thermostable polymerase AmpliTaq DNA polymerase, reaction buffer, dNTPs
and terminating nucleotide analogues. These nucleotide analogues are
labelled with fluorescent dyes. Each of the four types of nucleotide analogue
is labelled with a unique colour of fluorescent dye. Thermocycling the
reaction mix with a DNA fragment results in the production of single strands
of DNA of various lengths labelled with the colour of the terminating
nucleotide. These can be analysed using the genetic analyser to obtain the
sequence of the fragment.
For each fragment to be analysed two sequencing reactions were carried out:
one using a sense primer located at the 5' end of the fragment and one using
an anti-sense primer located at the 3' end of the fragment. To sequence the
RT region two overlapping fragments were obtained and sequenced for each
product. The primers used for sequencing different fragments are shown in
table 2.2.
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DNA fragment Sense primer Anti-sense primer
V3 306 307
RT (frag A) PA IS PA IAS
RT (frag B) PB IS PB IAS
PR PRIF PRIR
Table 2.2: Primers used for sequencing reactions
3 pi of BigDye reaction mix was added to approximately 50 ng of DNA and
the mix made up to 10 pi with nuclease free water (Promega). The mixture
was overlaid with a drop of mineral oil. Thermocycling conditions were as
follows:
[96°C for 30 seconds, 50°C for 15 seconds and 60°C for 4 minutes] for 25
cycles
After thermocycling, reaction was held at 4°C until it was transferred to a 1.5
ml eppendorf tube and sent for automated sequencing.
2.1.8 Sequence analysis
All manipulations and alignment of sequences was carried out using the
Bioedit sequence alignment editor computer package (Hall, 1999).
Sequences were converted from ABI to FASTA format for analysis.
Sequences obtained using reverse primers were converted to their reverse
complement form. The "forward" and "reverse" sequences obtained for a
given region were compared. Ambiguous loci or loci at which discordant
bases appeared in the two sequences were identified. The fluorescence
trace file was examined and the base which appeared most probable chosen.
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In this way, a single sequence was obtained for each PCR product.
Sequences were aligned manually. Attempts were made to minimise the
number of insertion/deletions required to fully align sequences. Where an
insertion or deletion was necessary, it was located in such a way as to
minimise disruption to the amino acid sequence. Where significant
differences from the rest of the alignment were noted, the trace file was re¬
examined to ensure that the sequence was not due to an artefact.
Phylogenetic trees were created from the aligned sequences using the
Molecular Evolutionary Genetic Analysis (MEGA) software package (version
2.1). The programme was used to generate a distance matrix for the
sequences and then to convert them into a neighbour-joining tree. The
observed number of nucleotide differences between two sequences under-
represents the "true" genetic divergence as it does not take into account
multiple substitutions at the same site; this bias becomes more pronounced
as sequences diverge further. There are a number of different distance
correction methods which estimate "true" genetic divergence from observed
genetic difference. Multiple HIV sequences obtained from a single individual
will differ at relatively few bases and thus the simple one parameter Jukes-
Cantor distance correction method was used to generate a distance matrix.
In this model, the likelihood of any nucleotide being substituted by any other
nucleotide is assumed to be equal. The estimated number of nucleotide
substitutions (K) is calculated from the observed number of nucleotide
differences (A) using the equation below:
K = -3/4log(1- 4/3 A)
79
The distance matrix was used to produce a tree using the neighbour-joining
method. This method uses a complex algorithm to produce an estimate of the
minimum evolution tree (i.e. the tree which fits the data with the shortest total
branch length). An outgroup of epidemiologically unlinked sequences was
included to allow the tree to be rooted.
To test the robustness of the phylogenetic relationships revealed by the tree,
bootstrap re-sampling was employed. In this method, "pseudoreplicate"
sequences are produced by sampling (with replacement) basepairs from the
sequence data used for construction of the tree. The alignment of
pseudoreplicate sequences is used to create a new tree and any splits which
are common to this and the original tree noted. This process is repeated
many hundreds of times. The bootstrap value of a given split in the original
tree is the percentage of the generated trees which contained the same split.
Bootstrap values of greater than 70% were displayed on the trees.
2.1.9 DNA quantification using spectrophotometer
The concentration and approximate purity of DNA samples were assessed by
taking spectrophotometric absorbance readings at wavelengths of 260 nm
and 280 nm. The spectrophotometer used was a GeneQuant II (Pharmacia
Biotech). The concentration of DNA in jug/pil was calculated by multiplying the
optical density at 260 nm by 0.05. The ratio of optical density at 260 nm to
optical density at 280 nm was used as an indication of purity. Pure DNA has
a 260:280 ratio of approximately 1.8.
2.1.10 Visualisation of DNA on agarose gel
10 x TAE buffer was prepared by dissolving 242 g Tris base (AnalaR), 57.1
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ml Glacial Acetic acid (Molecular Biology certified; Kodak) and 100 ml 0.5 M
EDTA (Molecular Biology certified; Kodak) in distilled water to a final volume
of 1 litre. pH was adjusted with dilute HCI to 8.5. 1% (w/v) agarose gels were
made by adding 3 g of agarose (Sigma) to 300 ml of 1 x TAE buffer and
dissolving by heating to boiling point in a microwave. Mixture was allowed to
cool to approximately 50°C before the addition of 20 pi of 10 mg/ml ethidium
bromide (Sigma). Gel was poured into flat bed mould into which combs had
been inserted. Gel was allowed to set for at least 1 hour before use.
DNA samples were mixed in a ratio of 5:1 with 6 x loading buffer (50% (v/v)
glycerol, 7.5% (w/v) Ficoll 400, 0.015% (v/v) bromophenol blue, 0.015% (v/v)
xylene cyanol, 0.2% (v/v) orange G, 5 mM Tris-HCI (pH 7.5) and 50 mM
EDTA. Gells were submerged in 1 x TAE and DNA/loading buffer mix
pipetted into the wells. A voltage of 150 V was applied across the gel for
between 30 minutes and 2 hours depending on the expected size of the DNA
fragments. Bands of DNA were visualised by the fluorescence of bound
ethidium bromide under a shortwave (254 nm) ultra violet light. 100 bp or 1
kb DNA step ladder (Promega) were run along side samples to allow
assessment of DNA fragment size.
2.1.11DNA purification using QIAquick PCR purification kit
(Qiagen)
DNA cleanup was routinely carried out using QIAquick PCR purification kit.
This kit makes use of the fact that DNA will bind to a silica membrane in the
presence of a high salt concentration but will be eluted in low salt conditions.
All centrifugation steps were carried out at 12000 x g for 1 minute at room
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temperature. 5 volumes of buffer PB were mixed with 1 volume of DNA
sample and the mixture added to a QIAquick spin column. The column was
centrifuged. The high salt concentration of the buffer allows the DNA to bind
to the silica membrane while impurities and liquid pass through. 0.75 ml of
buffer PE, a high salt concentration wash buffer containing ethanol was
added to the column and the tube centrifuged. The flow through was
discarded and the tube re-centrifuged to remove residual buffer. The column
was placed in a clean tube and 30 pi nuclease free water (Promega) added
to the membrane. The column was incubated at room temperature for 1
minute before centrifuging it to collect eluted DNA.
2.1.12 DNA extraction from agarose gel using QIAquick Gel
Extraction Kit (Qiagen)
DNA was extracted form agarose gels using the QIAquick Gel extraction kit.
The columns used in this kit are identical to those used for DNA cleanup. The
band of DNA of interest was excised from the gel and placed in a clean
eppendorf. The fragment of gel was dissolved at 50°C for 10 minutes in a
volume in mis three times the weight in grams of the gel fragment of buffer
QE. This mixture was added to the column and the column centrifuged. From
this point, the DNA was washed and eluted as described above for DNA
cleanup.
2.1.13 Enzymatic manipulations of DNA
Restriction digests
Restriction digests were carried out in total volumes between 20 and 100 pi.
The reaction mix consisted of DNA to be digested, 10% (v/v) of the
appropriate New England Biolabs or Promega 10 x buffer, 0.1 pl/ml bovine
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serum albumin (BSA) (Promega), approximately 1 unit of restriction enzyme
per pg DNA and nuclease free water (Promega) to the final volume. Where
double digests were performed, a buffer which allowed both enzymes to
digest adequately was selected. Digests were allowed to proceed for at least
1 hour at 37°C.
Shrimp alkaline phosphatase
Shrimp alkaline phosphatase (SAP) (Amersham) was used to remove
phosphate groups from the 5' strand of digested plasmid. This prevents the
plasmid from self-ligating. Following digestion, restriction enzymes were heat
inactivated as specified for individual enzymes by manufacturer (usually 80°C
for 15 minutes). Reaction was cooled to room temperature before addition of
1 pi of SAP per 50 pi of reaction mix. Reaction was incubated at 37°C for 15
minutes and then heat inactivated at 80°C for 15 minutes.
Ligations
Relative concentrations of vector and insert were estimated by visualisation
of DNA on an agarose gel. Vector was mixed with insert at a molar ratio of
approximately 1:2 to a total volume of 8 pi. 1 pi of 10 x ligation buffer and 1 pi
of T4 DNA ligase (NEB) were added and the liquid mixed by pipetting.
Reaction was allowed to proceed at room temperature overnight.
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2.2 Recombinant DNA technology
2.2.1 Reagents
SOC media: 2% (w/v) tryptone (Difco), 0.5% (w/v) yeast extract (Gibco),
0.005% (w/v) NaCI, 2.5 mM KCI, 10 mM MgCI2 and 10 mM glucose in
distilled water
Luria-Bertani (LB) Broth: 1% (w/v) tryptone, 0.5% (w/v) yeast extract and 1%
(w/v) NaCI in distilled water
LB agar plates: 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% NaCI (w/v)
and 1% (w/v) agar in distilled water
Competent cells: For all transformations Select 96™ Competent Cells
(Promega) were used.
2.2.2 Transformation
Competent cells were stored at -70°C. A vial containing 50 pi competent cells
was thawed on ice (approximately 5 minutes). 5 pi of ligation reaction was
added and the cells mixed gently by flicking the tube. Cells were incubated
on ice for 30 minutes, heat shocked at 42°C for 30 seconds and then placed
back on ice for 2 minutes. 250 pi SOC media was added and the vial was
transferred to a 37°C incubator with orbital shaking (225 rpm) for 1 hour. LB
agar plates containing 50 pl/mi ampicillin were pre-warmed in a 37°C
incubator. Aliquots of 50 pi and 200 pi of cells were spread evenly over
separate plates using a sterile glass spreader. Plates were left at room
temperature for 30 minutes before being inverted and placed in a 37°C
incubated overnight.
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2.2.3 Minipreps ofplasmid DNA
3 ml of LB broth containing 1 ju.g/jj.1 ampicillin (Sigma) was poured into a
sterile 15 ml tube and inoculated with a single colony of bacteria. The culture
was incubated at 37°C or 30°C as indicated for 16 hours with orbital shaking
(225 rpm). Bacterial cells were pelleted by centrifugation at 6000 x g for 3
minutes. Plasmid DNA was extracted using the QIAprep Miniprep kit
(Qiagen). The procedure involves alkaline lysis of the bacterial cells followed
by adsorption of plasmid DNA to a silica membrane in the presence of a high
salt concentration. The DNA can be eluted from the membrane by a low salt
buffer.
Bacterial cell pellet was resuspended in 250 pi of Buffer P1 and transferred
to a 1.5 ml eppendorf tube. 250 pi of buffer P2 was added and the tube
gently inverted 6 times. 350 pi of buffer N3 was added and the tube mixed by
inverting gently 6 times. The tube was centrifuged for 10 minutes at 12000 x
g to pellet the white precipitate (containing cellular matter and genomic DNA).
The supernatant was transferred to a QIAprep column placed in a 2 ml
collection tube. The tube was centrifuged at 6000 x g for 1 minute and the
flowthrough discarded. 500 ml of buffer PB were added. The tube was
centrifuged at 6000 x g for 1 minute and the flowthrough discarded. This step
efficiently removes endonucleases. 750 pi of buffer PE were added. The tube
was centrifuged at 6000 x g for 1 minute and the flowthrough discarded. This
step removes salts. The tube was centrifuged at 6000 x g for an additional 1
minute to thoroughly dry the membrane.
The column was transferred to a clean 1.5 ml eppendorf tube. 50 pi of
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nuclease free water (Promega) was added to the centre of the membrane.
The tube was allowed to sit at room temperature for 1 minute. The tube was
then centrifuged at 6000 x g for 1 minute to elute the DNA in the water.
2.2.4 Midipreps ofplasmid DNA
3 ml of LB broth containing 1 pg/pl of ampicillin was poured into a sterile 15
ml tube. The broth was inoculated with a single bacterial colony and
incubated at 30°C or 37°C, as indicated in text, for approximately 8 hours.
200 pi of this started culture was added to a sterile flask containing 100 ml
LB broth containing 1 pg/pl ampicillin. This culture was incubated at 30°C or
37°C, as indicated in text, for approximately 16 hours with vigorous rotational
shaking. The bacterial cells were harvested by centrifugation at 6000 x g for
15 minutes at 4°C. Plasmid DNA was extracted using the QIAfilter Plasmid
Midi kit (Qiagen). The procedure involves alkaline lysis of the bacterial cells
followed by binding of plasmid DNA to an anion-exchange membrane in the
presence of low salt and pH conditions. RNA, proteins and metabolites are
removed by a medium salt wash and then the plasmid DNA can be eluted
with a high salt buffer. Isopropanol precipitation is used to concentrate and
desalt the eluted DNA.
The bacterial pellet was resuspended in 4 ml of buffer P1. 4 ml of buffer P2
was added and the contents of the tube mixed thoroughly by gently inverting
6 times. This lysis reaction was allowed to proceed at room temperature for 5
minutes. 4 ml of chilled buffer P3 was added to the cell lysate and the tube
inverted 6 times to precipitate genomic DNA, protein, cell debris and SDS.
This mixture was poured into a QIAfilter cartridge. The cartridge was
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incubated at room temperature for 10 minutes during which time the
precipitated material formed a layer floating on top of the solution. A
QIAGEN-tip 100 was equilibrated by adding 4 ml of buffer QBT and allowing
it to flow through by gravity flow. The cap was removed from the nozzle of the
QIAfilter and the plunger gently inserted into the cartridge. The cell lysate
was filtered into the QIAGEN-tip leaving the genomic DNA, protein, cellular
debris and SDS in the cartridge which was discarded. The filtered lysate was
allowed to pass through the resin of the QIAGEN-tip by gravity flow. The
QIAGEN-tip was washed twice with 10 ml of buffer QC before the DNA was
eluted with 5 ml of buffer QF. DNA was precipitated by the addition of 3.5 ml
of room temperature isopropanol. The contents of the tube were mixed by
inversion before being centrifuged at 15000 x g for 30 minutes at 4°C to
pellet the DNA. The supernatant was discarded. The pellet was washed with
2 ml of room temperature 70% (v/v) ethanol before centrifugation at 15000 x
g for 10 minutes. The ethanol was discarded and the pellet air-dried. The
pellet was dissolved in 500 pi of nuclease free water (Promega).
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2.3 Eukaryotic cell culture
2.3.1 General tissue culture technique
All tissue culture work was carried out in a class 2 hood. The interior of the
hood was decontaminated using 5% (v/v) Decon (Fisher) prior to use. All
boxes of pipettes or tips were sterilised by autoclaving. The surface of any
pieces of equipment (e.g. pipettes or tip boxes) required in the hood, were
decontaminated with 70% (v/v) ethanol before being placed in the hood.
Latex gloves, sterilised with 70% (v/v) ethanol, were worn for any work within
the hood.
Culturing HIV in vitro can lead to concentrations of virus far higher than those
found in an infected individual. Thus such work could pose additional
infection risks. Any work involving culturing of HIV was carried out in class 2
hood in a category 3 containment lab. While working in this lab, two pairs of
latex gloves, plastic sleeve protectors, a plastic apron and a lab coat were
always worn. Any waste from this lab was initially decontaminated using 1%
(w/v) virkon (Antec), then autoclaved at 121°C for 30 minutes and finally
incinerated.
2.3.2 Reagents
Cell lines were grown in either Dulbecco's Modified Eagle's Medium (DMEM)
(Invitrogen) or RPMI media (Invitrogen) supplemented with 10% (v/v) foetal
calf serum (FCS) (Sigma) and 2 mM L-glutamine (Sigma). Media were
supplemented with Geneticin (G418), Hygromycin or Puromycin (Life

















































































































































Table 2.3: Cell lines used for HIV production and growth
2.3.4 Freezing cells
Cells were pelleted by centrifugation at 500 x g for 5 minutes. Cells were
resuspended at a concentration of 106 to 107 cells per ml in FCS containing
10% (w/v) dimethyl sulphoxide (Merck). 1ml aliquots of cell suspension were
transferred to cryovials (Nunc). These tubes were placed in a freezing box
containing isopropanol which was then placed in a freezer at -70°C. This
allows the cells to cool at a rate of approximately 1°C per minute. After at
least 24 hours, the vials were transferred to the liquid nitrogen storage facility.
2.3.5 Thawing cells
An aliquot of frozen cells was removed from the liquid nitrogen storage facility
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and thawed rapidly in a water bath at 37°C. 10 ml of media (pre-warmed to
37°C) was added drop wise to the cells in a universal container. The cells
were pelleted by centrifugation at 500 x g for 5 minutes. The supernatant was
discarded and the cells resuspended in 10 ml fresh media. The cell
suspension was transferred to a 25 cm3 tissue culture flask and incubated at
37°C.
2.3.6 Culturing adherent cell lines
Cells were cultured in 25 cm3 flasks at 37°C in an atmosphere containing 7%
CO2. Cells were monitored and split when approximately 80% confluence
was achieved (every two or three days). To split cells, the media was first
discarded. The monolayer was washed with 5 ml sterile phosphate buffered
saline (PBS: 7.02 mM Na2HP04, 1.47 mM KH2P04, 0.137 M NaCI, and 2.68
mM KCI). 1ml 0.05 % (w/v) Trypsin was added and the cells incubated at
37°C until cells detached from the plastic. Cells were resuspended in 10 ml
fresh media and 2 mis transferred to a fresh flask. A further 8 ml of fresh
media was added and the cells mixed by pipetting.
2.3.7 Culturing cells in suspension
Cells were cultured at in 25 cm3 flasks at 37°C in an atmosphere containing
5% C02. Cells were split every two to three days. The cell suspension was
first centrifuged at 500 x g for 5 minutes to pellet the cells. The supernatant
was discarded and the cells resuspended in 10 ml fresh media. Cells were
counted using a haemocytometer. A portion of the cell suspension was
diluted with fresh media to give 10 ml of cell suspension at an approximate
concentration of 3 x 105 cells/ml. This was transferred to a fresh flask.
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2.3.8 Transfection by electroporation
293T cells were suspended in serum free media at a concentration of 106
cells/ml. 800pl of cell suspension was mixed with the DNA for transfection.
This mixture was transferred to a sterile 0.4 cm electrode gap Gene Pulser
Cuvette (Biorad). The cuvette was placed in an electroporator (Biorad, Gene
Pulser) and the cell/DNA mixture was subjected to a single pulse of 250 V
and 960 pFD capacitance. The cuvette was removed and the cells
immediately transferred to a universal tube containing 5 ml of pre-warmed
media (containing 10% (v/v) foetal calf serum). Cells were cultured in a small
tissue culture flask for 2 days before being analysed.
2.3.9 Liposome transfection
Liposomes are lipid bilayers which form colloidal particles in aqueous
medium. The lipid reagent used for transfection was Transfast™ Transfection
Reagent (Promega). This reagent consists of a synthetic cationic lipid along
with a neutral lipid which has been demonstrated to enhance DNA uptake by
cells. The reagent binds DNA and enhances its uptake by cells. The precise
mechanism of DNA uptake is unclear but may involve endocytosis or
membrane fusion.
The day before a transfection was to be carried out, the vial of transfast
reagent was warmed to room temperature and suspended in 400 pi of
nuclease free water (Promega). The reagent was then frozen for at least 24
hours before use. Immediately prior to use, the reagent was thawed and
mixed by vortexing.
293T cells for transfection were plated the day prior to a transfection being
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carried out. Cells were split as described in section 2.3.6 and the number of
cells indicated in table 2.4 placed in the appropriate culture container with











24 well plate 2 5 x 104 0.2
12 well plate 4 1 x 105 0.4
6 well plate 10 2.5 x 10b 1
P25 tissue
culture flask
30 7.5 x 10b 3
Table 2.4: Areas of culture plates for cell growth
The concentration of the DNA to be used for transfection was assessed using
a spectrophotometer (section 2.1.9). In a sterile tube, the DNA was mixed
with 15 pi of Transfast reagent per pg of DNA and serum free media to a final
volume as indicated in table 2.4. The contents of the tube were mixed
thoroughly by vortexing and then incubated at room temperature for 15
minutes. The cells to be transfected were removed from the incubator and
the media was removed by pipetting. The DNA/Transfast reagent/media
mixture was mixed again by vortexing before it was carefully pipetted onto
the cell monolayer. The cells were returned to the incubator for 1 hour. The
cells were then overlaid with pre-warmed media containing 10% (v/v) foetal
calf serum before being returned to the incubator. Cells were cultured for at
least 24 hours before being analysed.
2.3.10 Fluorescent microscopy
An inverted fluorescent microscope was used to observe transfected or
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infected cells for expression of the EGFP gene. EGFP was excited at a
wavelength of 488 nm and emitted light at 507 nm. A Hamamatsu digital
camera was used to take pictures of cells. Pictures were edited using the
Openlab computer package.
2.3.11 Harvesting and storing virus
A single cell suspension was formed by pipetting cells. Cells were transferred
to a universal container and pelleted by centrifugation at 500 x g for 5
minutes. The supernatant was filtered through a 0.8 pm filter to remove
remaining cells and cell debris.
To freeze, 1 ml aliquots of the filtered supernatant were transferred into 2 ml
cryovials (Nunc). Vials were carefully labelled before being transferred for
storage at -70°C.
When virus was required the vial was removed from the freezer and thawed
quickly in water pre-warmed to 37°C.
2.3.12 Infecting PMI ceils
Transfected 293T cells were monitored by visualisation using a fluorescent
microscope. When a transfection had been successful, green cells were
usually visible after two days. In these cases, approximately half of the media
was removed from the container and replaced with an equal volume of PM1
cells in suspension in RPMI media at a concentration of approximately 2.5 x
105 cells/ml. Cells were co-cultured for up to a week and the non-adherent
PM1 cells monitored for signs of infection. In cases where infectious virus
was not present there was very little fluorescence visible at this point. Once
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the PM1 cells appeared to be infected, approximately half the volume of
media was removed from the container and transferred to a fresh container
containing an equal volume of PM1 cells at a concentration of approximately
2.5 x 105 cells/ml. Cells were monitored daily for infection and additional
media added as required.
2.3.13 Infecting indicator cell lines
Virus was harvested from PM1 cells and filtered as described above. 1 ml of
virus was added to a well containing 50% confluent cells. The cells were
cultured at 37°C and monitored daily for infection.
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2.4 Analysis of human and animal tissue
2.4.1 Biological safety when working with infectious material
HIV is classified as a biological pathogen of hazard group 3. Many of the HIV
positive samples used are also infected with Hepatitis C. Hepatitis C is also
classed as a biological pathogen of hazard group 3. Both these are blood
borne viruses and thus the main risk of infection is via a cut with a
contaminated sharp implement such as a scalpel, scissors or needle. In
addition there is a risk of infection from splashes of infectious material onto
the skin or face where virus could enter via a mucus membrane or an
existing cut. To minimise such risks all work with infectious material was
carried out in a class 2 microbiological safety hood. Two pairs of latex gloves
were worn at all times. The use of sharp objects was avoided wherever
possible. Laboratory surfaces were regularly cleaned with a solution of 5%
(v/v) Decon (Fisher). Any equipment used in the hood was decontaminated
with 70% (v/v) ethanol prior to removal. All waste material generated was first
decontaminated chemically using 1% (w/v) virkon (Antec) and then
autoclaved.
2.4.2 Preparation of fresh brain tissue
Mice were killed by C02 inhalation. The aorta was cut to prevent excess
blood contamination. The fur on the head was soaked in 70% (v/v) ethanol
prior to removal of the brain. The intact brain was rolled on a piece of filter
paper to remove meninges. A dissecting microscope was used to visualise
the brain and larger blood vessels adherent to the brain surface removed
using forceps.
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Human brain tissue was supplied in pieces of approximately 1cm3 suspended
in PBS. Between 15 and 20 of such pieces were supplied for each autopsy.
Material included both grey and white matter. The tissue was washed with
PBS to remove any excess blood and any visible blood vessels were
dissected out.
2.4.3 Collagenase and papain digestion
This method was based on a previously published protocol (Wright et al.,
1997). A portion of brain tissue was diced finely using a razor (mice) or
forced through a sterile metal sieve (human). Material was suspended in
approximately 3 ml Hanks balanced salt solution (HBSS) (Sigma) per 1 ml
pulverised brain matter. Crude collagenase (Sigma) was added to a final
concentration of 0.1% (w/v) and papain (Sigma) was added to a final
concentration of 6 units/ml. Cells were incubated at 37°C for 2 hours with
gentle agitation every 20 minutes. Cells were triturated using a Pasteur
pipette until no lumps of tissue were visible.
2.4.4 Controlled trypsin digestion
This method was based on a previously published method which was
designed to obtain a single cell suspension of brain cells with preserved
cellular morphology (Chatterjee and Sarkar, 1984). Brain tissue was cut into
a limited number of pieces (each piece was approximately 1 g). Pieces of
tissue were added to a volume of digestion medium (3% (w/v) glucose, 3%
(w/v) fructose, 0.6% (w/v) albumin, 6mM KH2PC>4:NaOH and 40% (v/v)
trypsin; pH6) at least 4 times the volume of tissue. Brain tissue was
incubated at 37°C for 10 minutes with agitation every minute. Buffered foetal
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calf serum (FCS) was added (1 ml FCS per ml digestion media used). All
further steps were carried out on ice. Tissue was passed through a pipette
with a 3 mm opening 20 times and then allowed to settle. The supernatant
was removed and stored on ice. Further media (5% (w/v) glucose, 5% (w/v)
fructose, 16% (w/v) albumin, 6mM KH2PC>4:NaOH; pH6) was added (1ml per
ml digestion buffer used). Tissue was passed through a pipette with a 2.5
mm opening 20 times and then allowed to settle. The supernatant was
removed and pooled with the supernatant previously obtained. Trituration
through pipettes of decreasing bore size was continued in this manner until
all pieces of tissue had disintegrated.
2.4.5 Standard trypsin digestion
Trypsin was added to a final concentration of 10% (v/v) and the mixture
shaken vigorously. Digestion was allowed to proceed for 15-30 minutes at
37°C. 10% (v/v) FCS was added to quench the trypsin activity. Material was
triturated through pipettes of decreasing bore diameter until no lumps of
tissue were visible. If necessary, extra PBS was added to aid this process.
2.4.6 Liberase and DNAse digestion
This method was based on a previously published method which was used
prior to FACS analysis of murine cells (Ford et al., 1995). However, in an
attempt to optimise cell yield, crude collagenase was replaced with a purified
blend of collagenase and neutral proteases, Liberase blendzyme 3 (Roche).
This blend contains less endotoxin than standard preparations of collagenase
and has been shown to improve yields of cells obtained from tissues
(Linetsky et al., 1997).
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A portion of brain tissue was diced finely using a razor (mice) or forced
through a sterile metal sieve (human). Tissue was re-suspended in a volume
of PBS approximately 4 times that of the volume of tissue. 0.15 units of
Liberase 3 (Roche) and 2000 units of DNase (Sigma) were added per ml of
PBS. Tissue was incubated at 37°C for 1 hour. During this period, tissue was
re-suspended in media using a cut-off 200-1000 pi pipette every 15 minutes.
Tissue was triturated through pipettes of decreasing bore size to
disaggregate cells.
2.4.7 Obtaining single cell suspension
Suspension was filtered first through a 500 pm filter and then a 200 pm filter
(BD Biosciences) to remove any remaining clumps of cells or portions of
blood vessels. Suspension was centrifuged at 500 x g for 10 minutes to pellet
brain material. Cells were then washed with media (PBS, DMEM or HBBS) to
remove any traces of enzymes.
2.4.8 Enrichment of neuron and astrocytes using Ficoll
Pelleted cells were suspended in 50 ml of Ficoll media (9% (w/v) Ficoll
(Amersham Biosciences), 8% (w/v) glucose, 5% (w/v) fructose and 10 mM
KH2P04:NaOH). The cell suspension was centrifuged at 170 x g for 10
minutes to obtain a neuron enriched pellet. The supernatant was re-
centrifuged at 430 x g for 10 minutes. The pellet was discarded. The
supernatant was re-centrifuged at 670 x g for 15 minutes to produce an
astrocyte enriched pellet.
2.4.9 Separation of cells using a continuous Percoll gradient
Percoll (Amersham Biosciences) was diluted to the desired concentration
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using a volume of 10 x PBS equal to 10% (v/v) of the final volume and
distilled water. 50 mis of diluted percoll was placed in a tube. A continuous
gradient was formed by centrifuging the tube at 30000 x g for 15 minutes.
The cells to be separated were suspended in 5 ml of PBS and carefully layed
on top of the gradient. The tube was centrifuged at 800 x g for 15 minutes.
2.4.10 Separation of cells using a discontinuous Percoll
gradient
Dilutions of Percoll were prepared as above using 10 x PBS and distilled
water. Layers of decreasing density were carefully added to a tube in such a
way that the interfaces between layers remained distinct. Cells were
resuspended in PBS and layered on top. Material was spun at 1250 x g for
25 minutes to separate myelin fragments from cells. After centrifugation a
thick cream coloured band of myelin was visible near the top of the percoll
while a faint band of cells was visible towards the bottom. The myelin layer
was discarded and the cells aspirated. Cells were washed in PBS.
2.4.11 Immunomagnetic separation of cells using the MACS
system
All components of the MACS system were obtained from Miltenyi Biotech.
Pelleted cells were resuspended in automacs buffer (AMB; PBS
supplemented with 0.5% (w/v) bovine serum albumin, 2 mM EDTA- pH7.2) at
a concentration of 107 cells/80 pi. 20 pi (2 pg) of primary antibody was added
per 107 cells and the cells incubated at 4°C for 20 minutes. Cells were re¬
suspended in 20 ml AMB and then centrifuged at 500 x g for 10 minutes.
Pelleted cells were re-suspended at a concentration of 107 cells/80 pi in AMB.
20 pi Goat anti-mouse IgG MACS beads suspension was added and the
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cells incubated at 4°C for 20 minutes. Cells were re-suspended in 20 ml AMB
and then centrifuged at 500 x g for 10 minutes. Cells were resuspended in 1
ml AMB. Cells were passed through the AutoMacs machine using the
positive selection programme.
2.4.12 Paraformaldehyde Fixation
Paraformaldehyde was dissolved in PBS to the desired concentration (1-4%
w/v) in a fume cupboard at a temperature of 50°C. Pelleted cells were re-
suspended in paraformaldehyde solution and incubated at 4°C for at least 15
minutes. Cells were stored in paraformaldehyde solution for up to one week.
Paraformaldehyde solution was used within three days of preparation.
2.4.13 Triton permeabilisation
Cells were first fixed in paraformaldehyde as described. Cells were pelleted
by centrifugation at 500 x g for 10 minutes. The pellet was re-suspended in
Triton X-100 (Union Carbide) permeabilisation buffer (0.1% (v/v) Triton X-100,
150 mM NaCI, 1 mM HEPES, 4% (v/v) FCS in PBS). Cells were incubated at
4°C for 15 minutes. Cells were washed twice using PBS.
2.4.14 Gentle Ethanol Fixation
Cells were resuspended in a solution of 50% (v/v) FCS in PBS. The volume
used varied between 300pl and 2ml depending on quantity of cells. A volume
of 70% (v/v) ethanol four times the volume of 50% (v/v) FCS used was pre-
chilled to -20°C. The cells were pipetted up and down vigorously while the
chilled 70% (v/v) ethanol was added drop by drop. This prevented clumping
of cells. Cells were incubated for at least 2 hours at 4°C. Cells were washed
twice with PBS.
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2.4.15 Flow cytometric analysis
Antibodies









igGi Mouse 0.4 10 None Chemicon























CD11 b To stain
microglia
igGi Mouse 0.2 10 FITC Sigma
CD68 To stain
microglia







IgGi Mouse 0.1 20 FITC Serotec
Table 2.5: Antibodies used for FACS staining
Cell staining
Before staining cells were washed with PBS to remove fixative if pre-fixed.
Cells were suspended in 10% (v/v) normal mouse serum (NMS) (Dako) in
PBS and incubated at 4°C for 30 minutes. Cells were pelleted and
supernatant mostly removed. Cells were resuspended in drop of supernatant
of approximately the same volume as the cell pellet. Primary antibody was
added (the volume used is indicated in table 2.5) and the cells mixed by
flicking tube. Cells were incubated at 4°C for 1 hour. If primary antibody was
conjugated to a flourochrome the tube was wrapped in tin foil during this
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incubation. If a secondary antibody was required cells were washed with PBS,
pelleted and incubated with antibody as previously. Cells were washed twice
with PBS. Cells were either fixed or, if previously fixed, resuspended in PBS.
2.4.16 Preparing cytospins
All cytospin products were obtained from Thermo Shandon. A wash slide and
filter card were assembled in the cytoclip which was secured in the cytospin
machine. Initially 50 pi of PBS buffer was added to the well and the slides
spun at 150 rpm for 3 minutes. These slides were discarded and replaced
with clean labelled slides. 50 pi of cell suspension (at a concentration of 1-5 x
105 cells/ml) was added to the well. Slides were spun at 150 rpm for 3
minutes. Slides were removed and air-dried.
2.4.17 GFAP Immunocytochemistry
Slides were fixed in acetone/methanol for 20 minutes. Cells were blocked in
100 ml methanol + 25 ml H2O2 and then washed with H20. Slides were
inserted into Sequenza Immunostaining center (Thermo Shandon) for all
further steps. Slides were washed twice with PBS before being incubated in
20% (v/v) normal swine serum for 10 minutes. 100 pi of primary polyclonal
anti-GFAP antibody (Dako) (diluted 1:1500) was added and slides incubated
for 30 minutes. Slides were washed twice in PBS before 100 pi of
biotinylated swine anti-rabbit IgG antibody (Dako) (diluted 1:200) was added
and the slides incubated for 30 minutes. Stained cells were visualised using
the StrepABC kit and DAB solution (DAKO) according to the manufacturer's
instructions. Slides were washed with H20 before counterstaining with
haematoxylin. Slides were dehydrated, cleared and mounted.
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2.4.18 Phenol/Chloroform extraction
500 |jl lysis buffer (0.11 M NaCh, 55 mM Tris pH 8.0, 1.1 mM
ethylenediamine tetraacetic acid (EDTA) pH 8.0, 0.55% (w/v) sodium dodecyl
sulphate (SDS), 1 mg/ml Proteinase K, 40 pg/ml poly A) was added to a
block of tissue of approximately 1cm3 or a cell pellet of FACS sorted cells in a
1.5 ml eppendorf tube. Tube was mixed by vortexing and incubated at 65°C
for two hours or until tissue was completely dissolved. 450 pi of H20
saturated phenol (Sigma) was added and the tube vortexed for 5 minutes.
The mixture was centrifuged at 12000 x g for 10 minutes at room
temperature. The aqueous layer was transferred to a new eppendorf tube
containing 450 pi chloroform/isoamylalcohol (Rathburn) 50:1 and mixed by
vortexing for two minutes. The mixture was again centrifuged at 12000 x g for
10 minutes at room temperature. The aqueous layer was transferred to a
new eppendorf tube containing 40 pi 3 M sodium acetate (NaAc) pH 5.2 and
800 pi 100% ethanol (pre-chilled to -20°C). The tube was mixed by inversion
and then incubated overnight at -20°C to allow precipitation of nucleic acids.
Nucleic acid was precipitated by centrifugation at 12000 x g for 10 minutes at
0°C. The pellet was washed with 80% (v/v) ethanol and then centrifuged at
12000 x g for 10 minutes at 0°C. The supernatant was removed and the
pellet dried on a hot block at 37°C for 10 minutes. The pellet was
resuspended in 50 pi nuclease free water (Promega).
2.4.19 Extraction using Qiagen DNeasy® Tissue kit
If DNA was to be extracted from cells in suspension (i.e. After FACS sorting),
the cells were pelleted by centrifugation in a 1.5 ml eppendorf tube and the
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supernatant discarded. If a frozen piece of tissue was to be used for DNA
extraction, approximately 25 mg of tissue was excised and cut into small
pieces before being added to a 1.5 ml eppendorf tube.
180 pi of buffer ATL and 20 pi proteinase K were added. Contents of tube
were mixed thoroughly by vortexing before being placed in a hot block to
incubate at 55°C. Digestion was allowed to proceed for between 4 and 16
hours with occasional mixing by vortexing until all aggregates of tissue had
dispersed. Following incubation, tube was vortexed for at least 15 seconds to
ensure complete mixing of contents. 200 pi of buffer AL were added and the
contents of tube mixed thoroughly by vortexing. Tube was incubated at 70°C
for 10 minutes. 200 pi of 100% ethanol was added and the contents of the
tube mixed thoroughly by vortexing.
The mixture was pipetted into a DNeasy Mini Spin Column placed in a 2 ml
collection tube. The tube was centrifuged at 6000 x g for 1 minute allowing
the mixture to pass through the silica membrane of the column. DNA
becomes bound to the silica membrane in the presence of high salt
concentrations and is thus retained. The DNeasy Mini Spin Column was
transferred to a clean collection tube. Two wash steps are carried out to
remove any contaminants which may be present. First 500 pi of buffer AW1
was added and the tube centrifuged at 6000 x g for 1 minute. Secondly 500
pi of buffer AW2 was added to the column. In this case centrifugation at 6000
x g was carried out for 3 minutes in order to completely dry the silica
membrane. The column was once again transferred - to a clean 1.5 ml
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eppendorf tube.
200 (j.1 of nuclease free water (Promega) was added to the centre of the silica
membrane. The tube was incubated at room temperature for 1 minute before
being centrifuged at 6000 x g for 1 minute. DNA is released from the silica
membrane in the presence of low salt concentrations and thus is eluted in the
water.
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Chapter 3: Results I
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3.1 Introduction
HIV particles are encapsulated by a host-derived lipid membrane. Embedded
in this membrane are complexes of Env proteins (reviewed in Berger et al.,
1999; Dragic, 2001). Each complex consists of three transmembrane gp41
portions non-covalently attached to three surface gp120 portions. It is thought
that binding of gp120 to host cell CD4 causes a conformational change which
then allows it to bind its co-receptor. This causes a second conformational
change which allowing gp41 to fuse with the host cell membrane and release
the contents of the virion into the cell. As Env mediates both cell binding and
membrane fusion, it is the major determinant of the cellular tropism of a given
HIV particle. The env gene is the most variable in the HIV genome and this
contributes to the differing abilities of HIV variants to infect different cell types.
One important factor in the cellular tropism of HIV is that different variants
can use different co-receptors. Primary HIV-1 virions most commonly use the
chemokine receptors CCR5 and CXCR4 as a co-receptor. Virions can use
only CCR5 (R5 variants), only CXCR4 (X4 variants) or either (dual-tropic
variants). Some associations between co-receptor usage and genetic factors
have been noted. For example, there is an association between the number
of basic residues in the V3 loop of gp120 and the ability to use CXCR4
(Fouchier et al., 19992; Basmaciogullari et al., 2002). In particular, the
presence of positive charged amino acids at amino acid positions 324 and
335 of env is strongly associated with CXCR4 usage. Substitutions at a
number of amino acid sites in gp120 are correlated with a switch from
CXCR4 to CCR5 usage in vivo (Rizzuto et al., 1998). In some cases, the
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ability of HIV variants to infect certain cell types is associated solely with its
ability to utilize a certain co-receptor. However, there are also many subtle
differences in the cellular tropism of HIV variants which have not been linked
to receptor usage alone. For example it is not clear why T-tropic isolates
cannot use CXCR4 to infect primary macrophages (Yi et al., 1998). Thus
even where the receptor usage of a given Env can be predicted from its
sequence, this gives only a partial understanding of the cellular tropism which
it would confer to a virion. In order to study subtle variations in tropism it is
necessary to use in vitro assays to determine the phenotype of different Envs.
It is possible to assess viral tropism by culturing HIV from an infected
individual and then testing its ability to infect cells in vitro. This method was
used in some of the first studies of HIV tropism (McDougal et al., 1985;
Klatzmann et al., 1984). The main problem with this approach is that the virus
must first be amplified by passage in cell lines. Clearly the selective
pressures acting on the viral population in vitro are substantially different to
those encountered in the human body. The virus initially obtained from the
individual will contain an array of genetic variants but passage in cell culture
will quickly select those most suited to lab conditions (Vartanian et al., 1991).
Perhaps most importantly, the virus will no longer face the challenge of
evading the immune system and thus variants which would be swiftly
neutralised in vivo may become dominant. Any findings regarding the tropism
of this virus may not reflect the true in vivo situation. A second drawback of
this method is that as a large number of genetically distinct HIV variants will
be present, it is difficult to note associations between observed phenotypes
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and genetic factors. Also, as there will be genetic variations across the whole
genome and not just the env gene, it is possible that observed differences
between variants may reflect differences in infectivity as apposed to true
differences in cellular tropism.
In order to circumvent these problems it is necessary to produce separate
populations of virus which are genetically identical except in the gene of
interest. There are two slightly different methods which are commonly used
to achieve this. In both cases recombinant DNA technology is used to amplify
HIV genetic material in prokaryotic cells. The DNA is used to transfect a
eukaryotic cell line. Once the HIV genome enters the eukaryotic nucleus, the
cell begins to act in the same manner as a HIV infected cell and produces
HIV particles. Providing the DNA used for transfection of a population of cells
is clonal, the virions produced should be almost identical. Only slight
variations due to one round of transcription error will exist.
The first of these methods is known as pseudotyping. In this technique, an
HIV genome with a defective env gene is transfected into the eukaryotic cell
line. A plasmid containing the functional env gene to be investigated along
with regulatory sequences required for expression are used to co-transfect
the same cells. Virions will be produced from cells with functional Envs on
their surface however the packaged RNA genomes will include the defective
env gene. These "pseudotyped" viruses can be used to infect cell lines to
assess tropism but these cells will not themselves produce infectious virus.
Pseudotyped retroviruses have been used in research for many years
(Hanafusa, 1965) and so this technique was quickly adapted for use with HIV
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after the discovery of the virus. A large amount of research work into tropism
continues to be carried out using pseudotyped HIV (Schmitz et al., 2004;
Canki et al., 2001).
An alternative method is to produce infectious chimeric virus. Recombinant
DNA technology is used to insert the env gene of interest into a plasmid
which contains the rest of the HIV genome. The env gene must be inserted in
the correct position in the correct frame. When this construct is transfected
into a cell line, infectious virus bearing the Env to be investigated will be
produced. In this case, the RNA genome will also possess the env gene of
interest and thus, providing the e/ivgene is functional, infectious virus will be
produced. This technique has been used in a number of recent studies
investigating tropism (Dittmar et al., 2001; Trouplin et al., 2001).
One obvious advantage of using the pseudotype method is that the virus can
only undergo one round of replication and therefore poses less of a threat to
human health than infectious virus. On the other hand, every time a
pseudotyped virus is required, a transfection must be carried out whereas
stocks of infectious chimeric virus can be grown up and stored for multiple
experiments.
These methods largely overcome the problem of selection of variants by
passage in eukaryotic cells. However, amplification of the DNA in prokaryotic
cells can also exert a selective pressure on the genome. Lentiviral genomes
often contain cryptic promoters which lead to translation of viral proteins in
the prokaryotic cells (Cunningham et al., 1993). Genomes amplified in E. coli
are often found to be non-functional or truncated presumably because
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functional proteins, when expressed, are toxic to the cells (Peden, 1992).
Indeed both Env and protease have been found to be toxic when expressed
in E. coli (Kusumi et al., 1992; Baum et al., 1990). In addition to selecting for
pre-existing defective genomes, growth in E. coli can result in new mutations
occurring within the genome. In particular, it is common for plasmids
containing the entire HIV genome to recombine at the viral LTRs thus
eliminating the genome (Yamada et al., 1995a). If the viral genome is
causing any inhibitory effect then cells containing these "looped-out"
plasmids will soon become the dominant variety.
One way to prevent selection of pre-existing defective genomes is to use
genetically identical copies of the gene of interest (i.e. derived from a single
proviral copy) for every transformation of E. coli. If this is carried out then
there will be no varieties of plasmid to compete for survival; any clones which
are obtained should contain the same gene (although mutation during growth
in the E. coli can still occur). In order to obtain copies of genes which are
derived from a single copy, it is necessary to dilute the template molecules to
a concentration such that most PCRs carried out on it will be negative
(Simmonds et al., 1990). This technique, known as limiting dilution PCR,
ensures that the few reactions which are positive are very likely to have
utilised a single copy of template. If a number of alleles of the same gene are
obtained, and each used for separate transformations then clones which
reflect the diversity in vivo can be obtained.
Using limiting dilution PCR to obtain env genes necessary for either a
pseudotyping or chimeric virus assay would limit the artefactual selection
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pressures on the gene outlined above. However, as mentioned, mutations
can also occur within E. coli and if these confer a selective advantage to cells
they may give rise to DNA sequences which are not reflective of those found
in vivo. In addition, if a given env sequence is particularly toxic it may not be
possible to amplify it using E. coli at all. For these reasons a method which
completely eliminates DNA amplification in prokaryotic cells would be highly
desirable.
3.2 Aims
The primary aim of this study was to produce a system that could be used to
assess the cellular tropism conferred to infectious virus by a given env gene.
A vector was produced which could be used to generate chimeric HIV
genomes containing env genes amplified at limiting dilution from patient-
derived DNA. The ability of cells transfected with the vector to produce
infectious virus was tested.
A secondary aim was to investigate methods of using the vector to produce
infectious virus without the need to amplify DNA in prokaryotic cells.
3.3 Results
3.3.1 Producing pNL4.3AenvEGFP
In order to produce chimeric virus containing PCR amplified env genes, a
vector was required which contained the entire HIV genome except the env
gene. The vector chosen as the basis of this new construct was pBluescript
NL4.3 2K (kindly donated by Matthias Dittmar). Two manipulations of the
vector were required. First the env gene was removed and secondly a
reporter gene was added in order that infection with the chimeric virus could
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be readily observed and quantified. The final construct also possessed
restriction sites allowing the ligation of new env genes.
The reporter gene chosen to be inserted into the vector was the enhanced
green fluorescence protein (EGFP) a mutant of the Aequorea victoria jelly
fish green fluorescence protein (GFP) (Cormack et al., 1996). EGFP
fluoresces up to 100 times more brightly than GFP when excited at 488nm.
This property means that it can be readily detected by fluorescence activated
cell sorting (FACS). Including this protein in the vector allows infection by the
resultant chimeric viruses to be easily monitored either by FACS analysis or
by observing infected cells under a UV microscope.
The strategy devised to carry out the required manipulations is outlined in
figure 3.1. The env gene was first removed by digesting the vector with Acc
65 I (an isoschizomer of Kpn I). The two Acc65 I sites which normally exist in
the pol gene of NL4.3 had been previously eliminated (Dittmar et al., 2001).
There are two further Acc65 I sites in NL4.3. One is 139 base-pairs
downstream from the start codon of env while the second lies 304 bases
after the end of env within the open reading frame of nef. Thus, digestion with
this enzyme results in the excision of the majority of the coding region of env.
Significantly, cryptic promoters which lead to expression of viral proteins in E.
coli have been identified in other lentiviruses at the extreme 5' end of the env
gene (Cunningham et al, 1993). It was hoped that retaining the first 139
bases of the lab adapted NL4.3 env sequence might enhance stability of
inserted env genes when grown in E. coli. After restriction digestion, the













Figure 3.1: Strategy used to produce pBluescript NL4.3AenvEGFP. EGFP
was amplified using primers which incorporate restriction sites as shown.
This fragment was then digested with the outer restriction enzymes Acc 65 I
and BstW I. The plasmid pBluescriptNL4.3 was digested with Acc 65 I. Both
the EGFP fragment and the cut vector were gel purified to remove fragments
which could interfere with the ligation. The EGFP fragment was ligated into
the vector. The overhang left by BstW I is compatible with that produced by
Acc 65 I. The resultant sequence is not cut by either enzyme.
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The EGFP gene was inserted into the vector in such a way that when a PCR
generated env fragment was also inserted, EGFP would be situated in frame
with the start of nef. To achieve this, for amplification of EGFP, primers that
encoded a short fragment of new genetic material to be incorporated at both
the 5' and 3' ends of the PCR product were designed. The 5' primer encoded
an Acc65 I restriction site. This meant that when the fragment was digested
with Acc65 I it could be ligated to the left-hand Acc65 I "sticky" end of the
linearised vector. The 5' primer next encoded a short linker sequence before
the restriction site for Xho I. Most subtype B HIV sequences have a Xho I site
towards the beginning of the Nef open reading frame (approximately 150 bps
after the end of env). This is the only Xho I site found in most subtype B envs.
The 5' end of the 3' primer encoded a BsiW I restriction site. When DNA is
digested with this enzyme a sticky end is generated that is compatible with
the sticky end generated by Acc65 I digestion. Thus, after digestion with
BsiW I the fragment could be ligated at its 3' end to the right-hand Acc65 I
sticky end in the vector left by the excision of env. Ligation of these two ends
thereby eliminated this Acc65 I site. The now unique Acc65 I site at the 5'
end of env along with the newly introduced Xho I site could be used to ligate
in PCR generated and Acc65 I and Xho I digested env genes. The primer
encoding the Xho I site was designed such that when the env fragment was
ligated into the vector, the beginning of nefwould be in frame with the EGFP
gene. Thus the EGFP gene would be expressed as a Nef fusion protein.
The ligation mixture containing the EGFP fragment and the linearised vector
was used to transform E. coli. The cells were cultured on ampicillin
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containing agar plates at 37°C for 16 hours and resultant colonies used to
inoculate 3 ml of LB broth which was incubated at 37°C for 16 hours. Initial
minipreps of these cultures revealed a plasmid of approximately 3kb. It is
likely that this plasmid had arisen due to homologous recombination of the
plasmid at the LTRs leading to the removal of the viral genome as previously
reported (Yamada et al., 1995b). Growth of the 3 ml cultures at 30°C
eliminated this problem. Figure 3.2 shows a restriction digest of extracted
plasmid DNA obtained from individual colonies. The EGFP fragment could
potentially ligate into the vector in either direction. Digestion with Sbf I and
Kpn I (both unique restriction sites within this vector) was used to identify a
plasmid where the fragment had inserted in the desired orientation.
3.3.2 Production and growth of virus
The first step towards producing virus with the new vector was to insert an
env gene. Initially the NL4.3 env gene was cloned back into the vector. PCR
amplification of env was carried out using pBluescript NL4.3 as a template.
The gene was gel purified and double digested with Acc65 I and Xho I. The
vector, pNL4.3AenvEGFP was also double digested with Acc65 I and Xho I
and gel purified. A ligation reaction was performed using approximately 3
times the molar concentration of insert compared to vector. Figure 3.3 shows
an outline of this strategy. This ligation reaction was used to transform E. coli
which were then cultured on ampicillin containing agar plates at 37°C for 16
hours. Individual colonies were selected to inoculate 3 ml aliquots of LB broth
which were incubated at 30°C for 16 hours. The plasmid DNA was extracted
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Figure 3.2: Double digests of plasmids with Sbf I and Kpn I. Lanes 1 to 8:
minipreps; Lane 9: pNL4.3; Lane 10 1kb DNA marker. Digestion of intact
pNL4.3 results in 3 bands: one at approximately 2.5 kb (env), one at
approximately 3.5 kb and one at approximately 7 kb as seen in lane 9. The
cloning strategy aims to eliminate env and incorporates EGFP (0.75 kb). If
the EGFP fragment has inserted in the correct orientation, the largest
fragment will be approximately 7.75 kb while the second fragment will remain
approximately 3.5 kb. This pattern is observed in lane 6. Note that in lane 3
the small fragment is approximately 4.25 kb indicating that in this case the
EGFP fragment has inserted in the wrong orientation.
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Figure 3.3: Schematic diagram outlining strategy used to insert env gene by
ligation. PCR is used to amplify env. Both env and the vector are digested
with Acc 65 I and Xho I. Ligation of env into the vector can be carried out. As
the overhanging ends of Acc 65 I and Xho I are not compatible, the fragment
can only insert in the correct orientation.
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check for the presence of the insert. Figure 3.4 shows that the majority of
clones tested did contain the insert. This is as expected because using two
restriction enzymes to cut the vector and then gel purifying the linearised
vector means that the vector cannot self-ligate; an insert must be present. In
addition, the use of different restriction sites at the ends of env means that
the gene could only insert in the correct orientation.
Vector produced in this manner could be used to transfect mammalian cells.
Before a transfection, 293T cells were grown to approximately 80%
confluence in a 25 ml tissue culture flask. Approximately 1 pg of plasmid
DNA was used to transfect the cells by lipid transfection using Transfast
media and the cells were incubated at 37°C in the presence of 5% C02. Note
that a log of this and all further transfection experiments can be found in
appendix 1.
After one day, a faint glow was apparent when cells were observed at 10
times magnification under UV light. By day two, a number of brightly
fluorescing cells were visible as shown in figure 3.5. It was estimated that
approximately 1 in 50 cells were brightly fluorescent although many more
were dimly fluorescent. At this stage, 5 ml of media was removed from the
flask and 5 ml of C8166 cell culture (at a concentration of approximately 2.5 x
105 cells/ml) was added. After two further days, when a few of the C8166
cells appeared to be infected, 5 ml of media and non-adherent cells were
transferred into a flask containing 5 ml of C8166 cell culture at a
concentration of approximately 2.5 x 105 cells/ml. Within a week many
brightly glowing cells could be observed and by week two almost every cell
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Figure 3.4: Plasmid DNA double digested with Sbf I and Kpn I. Lanes 1 to 6:
minipreps; Lane 7: 1kb marker DNA. If the vector has failed to digest or
digested and self-ligated the approximate size of fragments expected would
be 7.75 kb and 3.5 kb. This pattern is observed in lanes 3 and 5. If env has
been successfully inserted, the larger fragment should be approximately
10kb while the small fragment should remain 3.5kb. This pattern is observed
in lanes 5 and 6.
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Figure 3.5: 293T cells transfected with NL4.3EGFP viewed at 10X
magnification using (A) normal light and (B) UV light after 2 days incubation
C ■ D
Figure 3.6: Tissue culture cells infected with NL4.3envEGFP viewed at 10X
magnification. C8166 cells infected with NL4.3envEGFP viewed under (A)
normal and (B) UV light. PM1 cells infected with NL4.3ADAenvEGFP under
(C) normal and (D) UV light.
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appeared to be infected as seen in figure 3.6 (A/B). Numerous syncytia were
also observed.
The method outlined above was repeated to produce virus possessing
different env genes. Infectious virus possessing the env genes from three
common lab strains: HXB2, YU2 and ADA were produced. HXB2 is an X4
variant while ADA and YU2 are R5 variants. For each env gene, miniprepped
plasmid was transfected. Transfection of 293T cells with the plasmids
resulted in similar numbers of fluorescing cells as had been observed with
transfection of the NL4.3 env containing vector. As C8166 cells do not
possess the CCR5 chemokine receptor they could not be used for infection
with the ADA or YU2 env containing virus. Instead, PM1 cells which possess
both CCR5 and CXCR4 were used for amplification of all four viruses. Again
the PM1s were first co-cultured with the transfected 293T cells before being
transferred to new flasks containing fresh cells. The virus containing HXB2
env grew in a manner very similar to the virus containing NL4.3 env, after
one week many cells were infected and by week two most cells appeared
infected. Many syncytia were also observed. In contrast, the ADA and YU2
env containing viruses grew more slowly. Patches of infection were seen
within clumps of cells however even after a number of weeks, there were
many more uninfected cells than infected (figure 3.6C/D). This result is
consistent with the slow growing phenotype characteristic of R5 viruses. The
virus containing YU2 env had a particularly slow growing phenotype and thus
the ADA env containing virus may be more useful for future experiments.
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Attempts were also made to produce the viruses possessing the env gene
from the dual-tropic variants Sf162 and 89.6. Unfortunately, although
fluorescence was apparent in 293T cells transfected with clones possessing
these env genes, no infectious virus was detected. It is unclear why this
occurred. Possibly the clone used as a template for PCR amplification of the
env gene contained a defective copy of this gene. Initial attempts to produce
virus with a YU2 env gene were also unsuccessful. It later transpired that the
clone used as PCR template for the YU2 env gene was defective. When an
alternative YU2 clone was used as template for the env PCR, it was possible
to produce infectious virus possessing the YU2 env gene.
An alternative explanation is that growth of the plasmids containing the Sf162
and 89.6 env genes in E. coli could have led to the selection of defective
copies of env generated by PCR. There is some evidence that this process
was occurring with other env genes. For example, in the experiment started
on 3/02/03 (see Appendix 1 for details), only 2 of the 5 ADA env containing
clones were capable of producing infectious virus. Since all of these clones
used an env PCR fragment derived from the same cloned template, it seems
likely that selection of defective copies occurred in E. coli.
Inclusion of the EGFP gene in the chimeric virus allowed infection to be
monitored by FACS. PM1 cells which had been infected for 1 week with
NL4.3ADAenvEGFP were harvested by centrifugation and fixed in 4% (w/v)
paraformaldehyde. These cells were analysed using a FACscalibur flow
cytometer. The results are shown in figure 3.7. There was a marked increase
in fluorescence emitted by infected compared to uninfected cells.
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Figure 3.7: Flow cytometric analysis of uninfected and infected PM1 cells. In
the histogram plot of uninfected cells it can be seen that 1.10% of cells have
sufficient fluorescence to fall within the marker M1. In the histogram plot of
infected cells it can be seen that this number rises to 11.36%.
125
FACS analysis could be a valuable and objective method of monitoring
infection in future studies using the chimeric virus technique.
The four viruses (containing NL4.2, HXB2, ADA or YU2 env genes) were
tested for co-receptor usage. 5 ml of culture medium was removed from PM1
cells which had been infected for 2 weeks. The media was filtered through a
0.22 pm filter. The media was then added to a 25 ml flask containing
indicator cells grown to approximately 80% confluence. Table 3.1
summarises the abilities of the four viruses to infect indicator cell lines.
Initially ghost cells expressing CD4 in conjunction with either no co-receptor,
CCR5 only or CXCR4 only were used. Infection of these cells with the YU2
env containing virus is shown in figure 3.8. Surprisingly, syncytia were
observed in the CCR5 expressing ghost cells when infected with the YU2 env
containing virus. Syncytia formation is not usually associated with in vitro
growth of R5 viruses although this finding is consistent with the observation
of syncytia in HIV infected brains (where R5 variants predominate) (Sharer,
et al., 1985) and with some other in vitro studies (Gorry et al., 2002; Lai et al.,
2001). Unfortunately, it was discovered that all ghost cells express CXCR4 at
low levels and therefore the co-receptor usage of viruses could not be
accurately assessed using this cell line. This explains the finding that the
NL4.3 and HXB2 env-containing viruses were able to infect all types of ghost
cells. U87 cells which express either no co-receptor, CCR5 only or CXCR4
only, in conjunction with CD4, were used for further experiments. In this case,
the results obtained were as expected from the predicted phenotype of the
env genes. This confirmed that the virus possessed the correct env genes.
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NL4.3EGFP + + + - + -
NL4.3HXB2envEGFP + + + - + -
NL4.3ADAenvEGFP + - - + - -
NL4.3YU2envEGFP + - - + - -
Table 3.1: Infection of co-receptor expressing cells by harvested virus
incorporating the envgene from common lab strains of HIV. +: Infection was
observed; Virus did not infect the cell line. NL4.3 and HXB2 are CXCR4
using strains while ADA and YU2 are CCR5 using strains. Results are largely
as expected given these predicted phenotypes. One surprising result is that
both NL4.3EGFP and NL4.3HXB2er?vEGFP are able to infect all Ghost cell
lines. The explanation for this is that all varieties of this cell line express low
levels of CXCR4.
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Figure 3.8: Co-receptor expressing cells infected with NL4.3ADAenvEGFP
virus viewed at 10X magnification. CCR5 expressing ghost cells under (A)
normal and (B) UV light; Syncytia formation in CCR5 expressing ghost cells
under (C) normal and (D) UV light; CCR5 expressing U87 cells under (E)
normal and (F) UV light.
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The ability of the system to produce infectious viruses containing env genes
amplified from patient DNA was tested. DNA was extracted from tissue
samples obtained from the right occipital and the left temporal lobes of the
brain of a study subject who had died of AIDS. Limiting dilution PCR was
carried out to obtain ten env fragments for each brain region. These env
fragments were cloned into pNL4.3AenvEGFP as described previously. DNA
extraction, limiting dilution PCR and cloning were carried out by Mathew
Marsden, a post-doctoral fellow working in the group (Marsden et al., In
press). The resultant clones were used to transfect 293T cells. PM1 cells
were co-cultured with the 293T cells for two days before being transferred to
a flask containing fresh cells as described previously. Cells were monitored
daily for infection by observation at ten times magnification under UV light for
infection. The results are summarised in table 3.2. In some cases the 293T
cells fluoresced but co-cultured PM1 cells did not become infected. This
suggests that the ne/EGFP protein was expressed in the 293T cells however
the env gene was deficient in some way and thus the resultant virus was not
sufficiently fit to enter cells. From the table it can be seen that approximately
half of the viruses did not infect PM1 cells. This suggests that a high
proportion of the env genes investigated were defective in some way. This is
consistent with previous reports which have found high levels of defective
proviral genomes in vivo (Sanchez et al., 1997). It cannot be ruled out,
however, that the high proportion of non-infectious viruses obtained was due
to some flaw in this method of virus production. This will have to be fully

























Table 3.2: Production of infectious virus from clones incorporating patient-
derived env genes. ++: Fluorescence/infectious virus was present; +: Limited




3.3.3 Producing virus without amplifying DNA in E. coli
The method of chimeric virus production described above eliminates much of
the selective pressure placed on viral genomes by standard cloning methods.
This is due firstly to the use of limiting dilution PCR to generate env
sequences. This prevents preferential primer binding, recombination during
PCR and single nucleotide polymorphisms. In addition, retention of the first
part of env from the lab adapted strain NL4.3 rather than cloning in patient-
derived env genes should reduce the likelihood of cryptic promoter
sequences being present. Nevertheless, a method which eliminated the need
to use prokaryotic cells for amplification of the genome would be preferable.
Such a method would allow production of viruses with env genes that more
closely reflect the diversity present in vivo. Additionally, a method which did
not require cloning in E. coli would reduce both the time taken to produce
virus and the cost of the procedure. This could be particularly important for
applications such as drug resistance assays (see discussion).
Three methods were devised to produce infectious virus using
pNL4.3AenvEGFP without DNA amplification in E. coli. The simplest of these
involves carrying out a ligation reaction exactly as previously (figure 3.3), but
using it directly to transfect 293T cells. This method will be referred to as
non-cloning method 1. Ligation reactions were carried out using
approximately 4 pg of digested env fragment and 4 pg of digested vector. As
the env fragment is approximately 2.5 kb and the vector is approximately 7.5
kb this mixture represents a three fold molar excess of env. Two days after
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transfection with the ligation mixture some 293T cells were seen to be
fluorescent. The frequency of fluorescence was estimated to be 1 in 500 cells;
ten-fold lower than that observed when 1 pg of env containing vector was
used (data not shown). In addition, there was considerable evidence of cell
toxicity; many cells died while others appeared more rounded than usual and
became non-adherent. It was assumed that this was due to the large amount
of DNA used for the transfection. The large quantity was necessary because
during the ligation reaction many ligations would occur which would not
produce DNA encoding the complete HIV genome. This non-HIV coding DNA
would include cut vector fragments which had ligated to other cut vector
fragments or env fragments which had ligated to other env fragments. These
DNA fragments could not cause the cell to produce virus. It would be
advantageous to devise a method in which a larger proportion of the DNA to
be transfected would be capable of producing infectious virions. This would
allow smaller quantities of DNA to be used and would thus lead to lower
levels of toxicity. PM1 cells were co-cultured with the fluorescing 293T cells
and evidence of infection was observed.
A variation on the ligation mixture method was designed to maximise the
quantity of HIV-coding DNA used for transfection by amplifying fragments
which had ligated in the desired manner (non-cloning method 2). The ligation
mixture was used as template for two separate PCRs. The products of these
were two overlapping fragments which together encoded the HIV coding
sequence (figure 3.9). The larger fragment was amplified using a forward
primer which annealed in the plasmid sequence upstream of the 5' HIV LTR
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Overlap extension
Figure 3.9: Overlapping fragments method of virus production (non-cloning
method 2). Ligation was carried out as described previously and illustrated in
figure 3.3. PCR was carried out using the ligation mix as template to produce
two overlapping fragments which together encoded the entire HIV genome
including LTRs. Note that fragments which had ligated at one end only could
also serve as template. The two overlapping fragments were transfected into
293T cells.
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and a reverse primer which annealed in env downstream of the V3 region.
The smaller fragment was amplified using a forward primer which annealed
in env upstream of the V3 region and a reverse primer which annealed in the
plasmid sequence downstream of the 3' HIV LTR. Thus the two generated
fragments had an overlap consisting of the entire V3 region. These
fragments were subjected to an overlap extension reaction to generate full
length viral genomes. This method is a variation on standard PCRs. The
fragments were first mixed in PCR buffer and Taq and dNTPs added. The
fragments were heated to separate the strands. The temperature was then
lowered to allow annealing of single strands of DNA. In some cases, a strand
from each of the different fragments will anneal in the overlapping portion.
The temperature was then raised to an optimum temperature for Taq activity.
In cases where strands from different fragments have annealed, second
strand DNA synthesis will now proceed in a 5' to 3' direction producing a
fragment encoding the entire HIV genome. The optimal number of required
overlap extension cycles was investigated. Five cycles appeared to give the
optimum amount of overlap extension product while additional cycles
appeared to result in degradation of the DNA fragments (data not shown).
The resultant DNA was used to transfect 293T cells. The product of the
overlap extension reaction (approximately 8 pg), a mixture of fragments
which had not been subjected to overlap extension (approximately 8 pg) or
each of the fragments alone were used to transfect 293T cells. Either of the
fragments in isolation did not result in fluorescence of the 293T cells.
Surprisingly, after two days the overlap extension and the fragment mixture
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wells contained similar numbers of fluorescent cells (approximately 1 in 500)
(data not shown). This suggested that the major mechanism for the
production of full length viral genomes was recombination within the
transfected cells and not the overlap extension reaction. Levels of toxicity
could not be accurately assessed for this experiment due to a fault in the
incubator which led to a high level of cell death (see note in Appendix 1 for
details). Co-culture of PM1 cells confirmed that infectious virus was present.
A less time consuming method of virus production utilising recombination
within 293T cells was devised (figure 3.10) (non-cloning method 3). The use
of a ligation reaction was eliminated. Instead PCR based techniques alone
were used. The basis of the technique was to modify the PCR generated env
fragment so that it would overlap at both ends with the cut vector. Both
fragments could then be used to transfect 293T cells. The PCR generated
env fragment already had a region of overlap with the cut vector at its 5' end;
the portion which had removed by digestion with Acc65 I in previous methods
descrihed However the portion downstream of the Xho I restriction site was
homologous with a region in nef which lies downstream of EGFP in
pNL4.3AenvEGFP. Thus, if recombination was allowed to take place at this
end, the EGFP gene would be removed. It was decided to modify the env at
its 3' end so that it ended with a region which overlapped with EGFP. First a
fragment was produced which encompassed the start of nef and the entire
EGFP gene as present in pNL4.3envEGFP. To generate this fragment, PCR
was carried out using pNL4.3HXB2envEGFP as template and using a
forward primer which annealed at the beginning of nef and a reverse primer
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Figure 3.10: Second overlapping fragments method of virus production (non-
cloning method 3). A DNA fragment was generated which encorporated the
end of the env fragment (the first portion of the nef gene) and the EGFP
fragment. A PCR was carried out using both this fragment and PCR
generated env as template with primers positioned as shown.
NL4.3AenvEGFP was digested with Acc65 I and Xho I. The cut vector and
envEGFP fragment were transfected into 293 T cells.
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which annealed at the end of EGFP. This fragment was purified and then
mixed with an env fragment. PCR was carried out using this mixture as
template. The forward primer annealed at the beginning of env while the
reverse primer annealed at the end of EGFP. As the two templates had a
region of overlap (the nef gene), after denaturation, some strands from the
two different fragments would anneal. This would then provide a template for
completion of the em/EGFP fragment.
The purification method of the ne/EGFP fragment was crucial in this process.
When this fragment was spin column purified, the envEGFP fragment was
produced by PCR even without the addition of an env fragment. This is
because enough of the pNL4.3HXB2env plasmid remained to act as a
template for this reaction. However if the nefEGFP fragment was gel purified
then envEGFP was produced only when both the env and the nefEGFP
fragments were present (data not shown). This suggests that in this case
both fragments are being used as template. Transfection of the envEGFP
fragment alone did not cause 293T cells to fluoresce (data not shown). 4 pg
each of cut vector and envEGFP fragment were used to transfect 293T cells.
After two day, similar levels of fluorescence to those seen in the other "non-
cloning" methods were observed (data not shown). Again a high degree of
toxicity was observed. Co-culture of PM1 cells confirmed that infectious virus
was present.
The quantity of DNA it was possible to use without toxic effects was
investigated (figure 3.11). The main toxic effect seemed to be due to the cut
vector. Reducing the quantity from 1.2pg to 0.3 pg reduced the toxic effect
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Figure 3.11: 293T cells one day after transfection viewed at 10X
magnification under light microscope. Cell death is observed where a high
concentration of cut vector-1 2pg- is used (A and B). Reducing the quantity
of cut vector to 0.3pg results in far less cell death (C). Media alone (D),
Transfast reagent alone (E) or 1.3pg of envEGFP fragment (F) do not appear
to cause significant cell death.
'
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considerably. 1.2|jg of the envEGFP fragment did not appear to cause
significant toxic effect. Using these quantities of fragments reduced the
amount of cell death observed. However this did result in a relatively low
transfection efficiency as measured by the proportion of cells fluorescing after
2 days. Less than one cell in a 1000 appeared to be glowing. Next the
quantity of envEGFP fragment required for optimum virus production was
investigated. In addition to 0.3 pg of cut vector, either 0.9 or 1.5 pg of
envEGFP fragment was used to transfect 293T cells and the proportion of
fluorescing cells assessed after two days. Surprisingly, using the lower
quantity of em/EGFP resulted in a higher proportion of fluorescing cells. This
could be due to a slight toxic effect exerted by the higher quantity.
An overview of the three methods of virus production is given in figure 3.12.
Despite low efficiencies, all three methods of virus production described were
capable of producing a variety of infectious viruses (table 3.3).
3.4 Discussion
In this chapter methods were investigated for the production of virus which
could be used to characterise env phenotypes. A new vector,
pNL4.3Ae/ivEGFP, was developed which enabled the production of chimeric
viruses incorporating PCR amplified env genes. Recombinant DNA
technology was used to insert env genes. Two factors in the method of virus
production minimised artefactual selective pressure on the HIV genome.
Firstly, the env genes were amplified at limiting dilution. This ensured that all
the clones produced were essentially identical. If a mixed template is used for



















Figure 3.12: Overview of non-cloning methods used to produce infectious
virus.
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env Method 1 Method 2 Method 3
293T PM1 293T PM1 293T PM1
HXB2 + + + + + +
ADA + + + + + +
Patient derived + + + + + +
(ROI)
Subtype A N/D N/D
+ +
Subtype C + +
Table 3.3: Comparison of ability of different non-cloning methods to produce
fluorescence in transfected 293T cells and co-cultured PM1 cells. Presence
of fluorescence in PM1 cells indicates that infectious virus was present. Note
that the methods requiring ligation can not be used to produce virus with non-
b subtypes of HIV-1 as the required restriction sites are not present.
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This could lead to fitter variants becoming over-represented. To obtain a
number of clones which more accurately reflect the diversity of env present in
vivo, a number of limiting dilution env products can be cloned separately. A
second advantage this method has over some previously described methods
is that the initial 139 bases of env are cleaved off before cloning. In viruses
produced by this method, the fragment coding for the first part of env is
derived from the NL4.3 backbone. As NL4.3 is a lab adapted strain, it is
unlikely that this portion will contain cryptic promoters. Thus the chances of
env being expressed in E. coli are minimised. This reduces the chance of
growth in E. coli exerting any selective pressure on the viral genome.
This "cloning" method was used to produce infectious viruses incorporating
env genes from four common lab adapted strains of HIV: NL4.3, HXB2, YU2
and ADA. Infection of cells by chimeric viruses could be monitored by FACS.
When tested with co-receptor-expressing cell lines, these chimeric viruses
had tropism profiles identical to the expected phenotype of the lab strains
themselves. This confirms that the viruses have incorporated the exogenous
env genes as expected. The cloning method was also used to produce virus
incorporating env genes amplified from HIV-infected human DNA.
Approximately half of these viruses were not replication competent in PM1
cells. This may reflect a high incidence of defective env genes in vivo.
However, further work must be carried out to ensure that this result is not due
to a defect in the method of virus production.
The cloning method described aims to minimise the selective pressure
exerted on the viral genome by growth in E. coli. However, this selective
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pressure is not eliminated. In particular, mutations which arise during PCR
(i.e. due to Taq error) or during DNA replication in E. coli cells could confer a
selective advantage to certain variants which could become overrepresented.
A method which completely eliminated DNA amplification in E. coli would be
preferable.
To this end, three new methods of virus production were attempted. The
three methods are described fully previously. In brief the first method
involved performing a ligation reaction and using this to transfect cells. The
second method used the ligation reaction as template for a PCR which
produced two overlapping fragments. These fragments were used to
transfect cells. The third method involved modifying the env fragment so that
it overlapped at both end with the cut vector. The modified env and cut vector
were used to transfect cells.
All three methods were capable of producing infectious virus however none
were particularly efficient. In the case of the first method, a large portion of
the DNA used for transfection would not code for the HIV genome. In order to
obtain enough DNA encoding the HIV genome for efficient virus production a
large quantity of ligation reaction would have to be used to transfect the cells.
Unfortunately, using a large quantity of DNA is toxic to the cells. The second
and third methods rely on recombination within the cells to produce HIV
encoding DNA. It appears that while this does occur, it is not sufficiently
efficient to produce large quantities of virus. The virus produced by any of
these methods could be amplified by growth in PM1 cells. However, this
process will impose a selection pressure on the virus favouring any de novo
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mutations which enhance fitness.
Further work is required to find a method which can produce sufficient virus
but does not require amplification of DNA in E. coli. It is possible that slight
modifications of one of the methods described could achieve this. For
example, an overlap extension reaction could be carried out using the
fragments obtained by the third method. These could be used as the
template for a further PCR which amplified the entire HIV genome. A very
high proportion of the resultant DNA fragments would encode the HIV
genome. These could be used to transfect cells.
There are a number of potential research applications for a method which
accurately assays the phenotype of env genes. For example, there has been
much recent debate about whether different subtypes of HIV have different
tropism profiles. Conflicting results have emerged regarding the relative
abilities of different subtypes to infect Langherhan's cells. Two studies found
that subtypes E and C were more able to infect these cells however two
subsequent studies found no such differences (SotoRamirez et al., 1996;
Essex et al., 1997; Pope et al., 1997; Dittmar et al., 1997). There have been
some suggestions that the frequency of syncytium-inducing (SI) variants
differs by subtype (Dewolf et al., 1994; Zhong et al., 1995). Subtype C in
particular seems to have a low frequency of SI variants (Peeters et al., 1999).
Some associations between co-receptor use and subtype have been
reported. In one study CXCR4 viruses were underrepresented in subtype C
viruses echoing the findings of less SI variants in this subtype. Additionally,
dual-tropic viruses were absent from all subtype D viruses investigated
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(Tscherning et al., 1998). One study has investigated the neurotropism of
subtypes A and D (Zhang et al., 2001). Brain derived subtype A and D
viruses were found to be more divergent than subtype B viruses when
compared to spleen derived samples. A method able to produce viruses,
contained env genes which reflected the diversity found in vivo, could be vital
in clarifying these issues.
In addition to its value in tropism research, a method of chimeric virus
production could have important clinical applications. Recently a number of
potential therapeutic agents which inhibit HIV entry have been described.
Currently, the most promising of these is a synthetic peptide known as T20.
T20 binds to the gp41 portion of env and thereby inhibits its fusion with host
membranes (Kilby et al., 1998). Phase three clinical trials of this agent are
underway. Variants resistant to T20 have emerged in study subjects
receiving T20 monotherapy (Wei et al., 2002). If T20 or other entry inhibitors
becomes widely available as a treatment for HIV it will be important to
monitor patients for the development of drug resistance. The chimeric virus
technique described here could be used to achieve this. Chimeric viruses
containing env amplified from patients could be grown in cells in the
presence of the entry inhibitor. The presence of the EGFP gene in the
viruses would provide a quick and easy way to identify resistant mutants.
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Chapter 4: Results II
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4.1 Introduction
In recent years the development and administration of clinically effective
antiretroviral agents in the form of highly active antiretroviral therapy (HAART)
have provided a valuable means of suppressing HIV replication in the
peripheral blood and lymphoid systems of treated patients. These therapies
have been successfully employed to extend the life of HIV infected
individuals yet do not comprise a cure for infection because replication
competent HIV persists in certain cellular and/or anatomical reservoirs from
which it can re-emerge upon cessation of therapy (Davey, Jr. et al., 1999).
One such potential viral reservoir or "sanctuary site" is within the central
nervous system (CNS), where partially immunoprivileged conditions in
conjunction with sub-optimal concentrations of antiretroviral agents could
allow continued virus replication in spite of effective suppression in the
periphery, circumstances that may also provide an ideal environment for the
development of antiviral drug resistant viral variants. Considerable interest
therefore exists in genetically characterising HIV-1 variants within the CNS of
patients who have been treated with HAART
Therapeutic agents used to treat HIV infection must target the virus while
having a limited effect on the host cell. Many processes in the HIV life cycle
rely upon catalysis by essential host cell enzymes. Clearly inhibition of these
enzymes cannot be used to reduce viral replication, as normal cell processes
would also be affected. The HIV encoded enzymes are however suitable
drug targets and indeed most currently licensed antiretrovirals inhibit either
viral reverse transcriptase (RT) or protease (PR). A detailed description of
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the function of these enzymes is given in section 1.5.2.
There are two main types of RT inhibitors; the nucleoside analogue RT
inhibitors (NRTIs) and the non-nucleoside RT inhibitors (NNRTIs). The NRTIs
include the drugs zidovudine (AZT), didanosine (ddl), stavudine (D4T) and
lamivudine (3TC) (reviewed in Rang et al., 2003; Menendez-Arias, 2002).
These exert their effect by acting as alternative substrates for RT. Once
inside the cell they must be triphosphorylated by the host cell machinery
before they are active. They can then compete with host cell deoxynucleotide
triphosphate molecules (dNTPs) for incorporation into a growing DNA
molecule. Once incorporated, the NRTIs act as chain terminators as they do
not possess the hydroxyl group at the 3' end of their ribose moiety necessary
for the attachment of another dNTP.
Resistance to this type of drug can occur due to mutations near the
nucleotide binding site of RT that result in host dNTPs being bound
preferentially to NRTIs. For example the M184V mutation results in a steric
barrier to lamivudine binding (Sarafianos et al., 1999). This is because the p-
branched amino acid valine is in opposition with the oxythioliane ring of the
inhibitor. Mutations which confer resistance to NRTIs can also be found in
areas of RT distal to the active site. Such mutations do not affect the ability of
RT to bind NRTIs but rather increase the removal of the chain terminating
nucleoside (Arion and Parniak, 1999; Meyer et al., 1999).
A group of agents closely related to the NRTIs, are the nucleotide RT
inhibitors such as tenofovir. These compounds are already
monophosphorylated and thus the conversion to a triphosphate form can
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occur more quickly. Their mode of action is the same as the NRTIs and thus
similar patterns of resistance mutations are likely.
The NNRTIs are a heterogeneous group of compounds which have a mode
of action quite distinct to the NRTIs. They do not bind to the active site of the
enzyme and thus are non-competitive inhibitors (reviewed in Rang et al, 2003;
Menendez-Arias, 2002). Instead they bind to a hydrophobic pocket close to
RT's active site and induce a conformational change in the protein structure
which abrogates its catalytic activity. This class of therapeutic agents
includes nevirapine, delavirdine, efavirenz and capravirine.
As the NNRTIs do not interact directly with the active site of the enzyme,
mutations to their binding site may have a relatively small effect on viral
fitness. Thus resistance to NNRTIs can appear quickly after the start of
treatment. Indeed single amino acid changes can sometimes be sufficient to
confer high-level resistance to certain NNRTIs (Balzarini, 1999). Some of the
newer NNRTIs such as efavirenz and capravirine are less affected by such
single amino acid changes. These agents attach to a number of conserved
amino acids and thus multiple mutations at sites constrained by strong
selective pressure are required to abrogate drug effectiveness (Ren et al.,
2001; Ren et al., 2000).
In the past decade, a number of drugs have been developed which inhibit
viral PR (reviewed in Rang et al, 2003; Menendez-Arias, 2002). These PR
inhibitors (Pis) act on a late stage of the HIV life cycle; the cleavage of the
viral proteins which allows viral maturation. Like the NRTIs, Pis are
analogous to the normal substrate of PR and thus act as competitive
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inhibitors. Examples of Pis are saquinavir, nelfinavir, indinavir, ritonavir and
amprenavir.
Mutations which confer resistance to Pis, can occur either in the PR gene
itself or sequences encoding the cleavage regions recognised by PR
(reviewed in Menendez-Arias, 2002). Mutations to the active site of PR often
reduce viral fitness significantly however further mutations elsewhere in PR
can compensate for this. In addition, mutations at the cleavage sites in the
GagPol polyprotein can result in an increased cleavage efficiency further
compensating for mutations to the PR active site. Thus in order for the virus
to become resistant to Pis and remain relatively fit, a number of mutations at
different locations are required. This delays the emergence of variants with
high-level resistance to these drugs (Molla et al., 1996; Zhang et al., 1997).
Drug resistance mutations can be classified according to their effect on
phenotype (Hirsch, et al., 2000). Some mutations cause high level resistance
to a given drug and are rapidly selected for. Such mutations have been
termed primary or major mutations. Secondary, or minor, resistance
mutations may contribute to resistance when primary mutations are present.
Alternatively in some cases they counteract a loss of viral fitness caused by
the acquisition of primary mutations.
Monotherapy with any other known anti-retroviral agent, is not effective for
extended periods of time because resistant variants quickly emerge and
predominate in treated individuals. This can be explained by the error prone
replication of HIV in combination with the very high levels of viral turnover in
infected individuals which allows extremely rapid viral evolution (see section
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1.9.1). Concurrent treatment with a number of different anti-retroviral agents
is far more effective at suppressing viral replication. The current treatment
regime of choice is highly active retroviral treatment (HAART). This involves
treatment with at least three drugs including either one or two NRTIs, a
NNRTI and/or a PI (reviewed in Menendez-Arias, 2002; Weller, 1999).
As mentioned above, a major problem with HAART is that although viral
replication is suppressed, the virus is never eliminated from certain cellular
and anatomical reservoirs termed sanctuary sites. Thus once treatment is
stopped, virus is still present to reseed infection of other sites. In addition a
major concern is that if virus is able to replicate in areas where there are
suboptimal levels of drugs, resistant variants could evolve.
One such sanctuary site is the CNS. Anti-retroviral agents are retarded from
entry into the CNS to varying degrees with most appearing to have poor CNS
penetration. Certain agents including zidovudine and indinovir have been
reported to be able to enter the brain more efficiently but this may have been
overestimated (reviewed in Groothuis and Levy, 1997). Some studies have
measured the amount of drug in post mortem brain tissue and compared the
levels with those found in plasma. Unfortunately, in most cases no account
has been taken of the significant quantity of blood present in any piece of
brain tissue. Thus much of the drug assumed to be present in the brain may
in fact have been present in capillary blood vessels.
Other studies have measured the concentration of a given drug in the CSF.
This however, will probably not represent the concentration of drug in the
extra-cellular fluid (ECF) of most of the brain. Drugs moving from the CSF
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into the ECF do so by diffusion and a gradient of concentration is created
according to distance from the brain surface. The penetration of drugs from
the CSF into the human brain ECF is thought to be between 1 and 1.5 cm
from the brain surface (Blasberg et al., 1977). Thus the drug concentrations
found in the CSF may only be found around cells very near to the brain
surface.
Detailed calculations which take into account the transcapillary uptake and
efflux of drugs reveal that the concentration of zidovudine likely to be found in
the CNS of treated individuals is far lower than the concentration required to
inhibit even the most zidovudine sensitive strains (Groothuis and Levy, 1997).
This is in contrast to the oft-cited statistic that zidovudine levels in the CNS
are approximately 60% of those found in the periphery. Studies of the uptake
of Pis into the CNS are currently sparce. One study did calculate the uptake
of indinavir across the blood brain barrier (Stuver et al., 1996). The authors
reported a low uptake of the drug into the CNS although the uptake rates
were higher than those reported for NRTIs.
In light of the poor CNS penetration of many drugs, a number of investigators
have expressed a fear that the brain might provide a sanctuary site where
drug-resistant variants can evolve. Various studies have addressed this by
comparing the occurrence of drug resistance mutations in sequences from
different sites.
Several studies have compared sequences of RT derived from the CSF and
blood of zidovudine treated individuals. An early study found that
concentrations of zidovudine in the CSF four hours after administration are
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50% of those found in plasma (Klecker, Jr. et al., 1987). As mentioned
previously, the concentration of zidovudine in the brain ECF is likely to be
considerably lower. Thus the CSF does not necessarily represent the most
likely sanctuary site for evolution of drug-resistance variants. Indeed most
studies have found no differences in the distribution of mutations conferring
resistance to zidovudine when sequences from the CSF and plasma are
compared (Sei et al., 1996; Wildemann et al., 1993; Distefano et al., 1995).
Relatively little research has been done on the distribution of zidovudine
resistance mutations in virus from the brain itself. One study obtained
sequences of RT from proviral DNA extracted from brain tissue, spleen or
lymph node (Wong et al., 1997). In three out of the four study subjects
examined, a difference in distribution of zidovudine-resistance conferring
mutations was observed between brain and spleen/lymph node. In these
study subjects the sequences derived from the brain were more likely to be
zidovudine sensitive compared to spleen/lymph-node sequences. A study
which obtained RT sequences from RNA extracted from brain tissue, spleen
and lymph node found the distribution of resistance mutations to be
concordant within most individuals (McClernon et al., 2001). In four out of ten
individuals who had taken zidovudine however, there was some degree of
discordance in the distribution of resistance mutations. Again, in all these
cases, the brain derived RT had fewer resistance-associated mutations.
Thus the extent to which the brain may act as a sanctuary site for viral
replication during zidovudine treatment remains unclear. From the limited
studies available it appears that in some cases the RT gene may contain
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fewer resistance mutations in the brain than in the periphery. This could
occur if levels of the drug were very low in the brain and thus exerted no
selective pressure on the virus. It is possible that in some regions of the brain
closer to the surface and therefore to the CSF, higher but still sub optimal
levels of zidovudine may drive the evolution of resistant variants.
The distribution of mutations which confer resistance to Pis between the
brain and the periphery is even less well characterised. Again, there is a
possibility that sub-optimal concentrations of the drug may drive the evolution
of drug resistant mutants. Alternatively, it is possible that if the drug is
present at very low concentrations, there will be no drug pressure on the PR
gene and therefore wild-type PR will be present in the brain.
Clearly further research is required to fully characterise the distribution of
drug resistant mutations in HIV found in the brain.
4.2 Aims
The aim of this project was to characterise the distribution of drug resistance
associated mutations in HIV proviral DNA isolated from post-mortem brain
and lymphoid tissue.
4.3 Results
4.3.1 Selection of study subjects
The integrity of the blood brain barrier and thus the ability of virus and drugs
to enter the CNS may differ depending on the stage of HIV-related illness.
For this study two subjects who had died from AIDS-related illness and two
who had died while still pre-symptomatic were chosen (tables 4.1 and 4.2).
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Study Age Sex Cause Risk No. of lymphocytes Time before death




320 30 M AIDS IVDU 8 103 2m
369 31 M AIDS IVDU 23 440 7d
311 29 F OD IVDU 260 1432 18d
234 34 M OD IVDU 229 294 4m22d
Table 4.1: Clinical background of study subjects. OD: Over-dose.
Study HIV related pathology Other Proviral load per 106
subject pathology ceils
Atrophy HIVE p24GM p24WM Lymphoid Brain
320 + + + + PML 2592 1150
369 - + - - CMV,
lymphoma
102 40
311 - - - - none 81 887
234 - - - - none 9 3
Table 4.2: Brain pathology of study subjects. HIVE: HIV encephalitis; p24GM:
p24 antigen detected in grey matter by immunohistochemistry; p24WM: p24
antigen detected in white matter by immunohistochemistry; PML: Progressive
multifocal leukoencephalopathy; CMV: Cytomegalovirus.
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The first criterion for selection of subjects was that they must have taken anti-
retroviral drugs for a minimum of one year (figure 4.1). Additionally, subjects
considered to have a relatively high chance of harbouring distinct viral
variants in the brain and lymphoid system were chosen. Thus this was not a
random sample of subjects but rather a case study of subjects who were
thought most likely to harbour distinct patterns of drug resistance between
compartments. The subjects who had died with AIDS-related illness were
selected on the grounds that pathological evidence of HIVE had been found.
This condition is associated with compartmentalisation of virus between brain
and the lymphoid system (Wang et al., 2001). A previous study (Marsden et
al, in press) had identified two pre-symptomatic study subjects (234 and 311)
in whom V3 sequences derived from the brain were phylogenetically distinct
from those present in the lymphoid system. Thus these subjects were also
chosen for inclusion.
4.3.2 Method of limiting dilution PCR
PCR amplification using a genetically heterogeneous template may result in
products which do not accurately reflect the in vivo situation. Certain variants
may be preferentially amplified due to higher affinity with the primers used for
PCR potentially leading to an over-representation of minor variants. Partially
synthesised product can dissociate from its template during the denaturation
step and then re-anneal to a different template molecule. This can lead to
artefactual recombinant products (Meyerhans et al., 1990). In order to obtain
unadulterated PCR products amplified from a single template molecule,
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Figure 4.1: Timelines showing antiretroviral drug regimes of study subjects.
Numbers indicate years since initiation of treatment. Coloured bars below
timelines indicate periods of time when antiretroviral drug was taken, t
Indicates death of patient.
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2.1.5). In this technique the template DNA is diluted to a point at which more
than half of the PCRs carried out will be negative. It is assumed that any
reactions which are positive have proceeded using a single molecule as
template. In practice, a large number of PCR reactions must be carried out
for every limiting dilution product obtained (table 4.3 and figure 4.2).
4.3.3 V3 sequencing
The most variable region of the HIV genome is the V3 region of gp120 and
this makes it useful in studies of viral evolution. Comparison of V3 sequences
from brain and lymphoid tissue can indicate if a separately replicating viral
population is present in the brain. Note that segregation of V3 sequences
between brain and the lymphoid system does not guarantee that pol
sequences will be similarly distinct as discordant phylogenies between
different proviral regions are common (Morris et al., 1999). However, the
presence of distinct sequences indicates a degree of genetic
compartmentalisation between HIV variants in the brain and lymphoid system
has occurred and thus it is more likely that distinct patterns of drug resistance
mutations will be found. If the V3 sequences group phylogenetically with
lymphoid derived sequences, it is likely that they have been amplified from
virus present in contaminating blood in the brain sample or that they
represent recent viral infiltration.
Between five and eight limiting dilution V3 PCR products were obtained from
brain and lymphoid tissue of study subjects 150 and 207. The V3 primers
used produced a 324 bp fragment (figure 4.3A). These products were











320 Lymph node V3 45 5
Brain V3 45 8
Lymph node P-B 100 8
Brain P-B 40 8
369 Lymph node V3 45 8
Brain V3 88 5
Lymph node P-B 40 8
Brain P-B 190 7
Lymph node PR 60 8
Brain PR 204 8
311 Lymph node P-B 63 8
Brain P-B 83 8
Lymph node PR 80 8
Brain PR 80 8
234 Lymph node P-B 45 7
Brain P-B 63 8
Total 1271 120
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Figure 4.2: Obtaining limiting dilution PCR products- representative gel
images. A: Nested PCRs were carried out on serial ten fold dilutions of the
extracted DNA (lane 1: undiluted; lane 2: 10"1; lane 3: 10"2; lane 4: 10 3). B:
Twenty replicate nested PCRs were carried out using template at
concentration estimated to yield less than 8 positive reactions out of twenty.
Typically, a dilution of 1/3 of the last positive ten fold dilution was used
initially. Thus in this case, template DNA at a concentration of 1/3 x 101 was
used. All PCR reactions carried out using template at this concentration were
positive and so further replicates were attempted at a lower concentration. C:
Twenty replicate nested PCRs were carried out using template at
concentration of 10~2. Six reactions were positive and these products were
thus assumed to be amplified from a single template molecule. Further
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Figure 4.3: Location of PCR fragments (shown here in red) within HIV
genome. A: V3 fragment (nucleotides 7009 to 7333) B: RT fragment
(nucleotides 2622 to 3252) Note that two overlapping fragments amplified
from a single primary product were used to obtain the full sequence. C: PR





A: Study subject 320
r£
B: Study subject 369
C: Study subject 311 D: S,ud* subiect 234
Figure 4.4: Phylogenetic trees constructed using V3 sequences amplified at
limiting dilution. Distances between sequences were calculated using the
Jukes-Cantor distance correction method (distances indicated on scales
below trees). The distance matrix was used to construct trees using the
neighbour-joining method. The robustness of observed groupings was tested
by bootstrap resampling and values over 70 are indicated on the trees. The
V3 sequence of the subtype B lab variant HXB2 was used as an outgroup to
root the trees. Red circles represent brain-derived sequences. Blue squares
represent lymphoid tissue-derived sequences. Trees for subjects 311 and
234 were obtained from Matt Marsden (Marsden et al., in press).
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amino acid sequences of the sequenced fragments are shown (figure 4.5).
V3 sequencing had been carried out previously by Matt Marsden for study
subject 234 and 311 and the amino acid alignments and phylogenetic trees
obtained are also included here for reference (Marsden et al., in press). Only
one sequence in the entire data set (311L-1, Fig 4.5) included a basic amino
acid at either position 11 or 25 within the V3 loop, a characteristic that is
indicative of X4 variants. Therefore consistent with a large number of
previous reports all brain derived sequences within this study had a predicted
CCR5 using, macrophage tropic viral phenotype.
In three of the four study subjects the V3 tree topologies provided strong
evidence for genetic compartmentalisation between brain and lymphoid
derived sequences. Study subjects 369, 311, and 234 each had brain derived
sequences that clustered together in monophyletic, bootstrap supported
lineages, which were distinct from all lymphoid sequences obtained from the
same individuals. Brain derived V3 sequences from subject 320 also
clustered together into a single lineage separate from the majority of
lymphoid sequences. However in this case the presence of a lymph node
derived sequence within the brain lineage reduced the level of sequence
segregation according to tissue as compared with the other study subjects.
A clear divergence between lymphoid and brain derived V3 sequences
formed part of the criteria for the inclusion of study subjects 234 and 311.
4.3.4 RT sequencing
The region of RT used for sequencing was 630 bps and was encoded by two
overlapping PCR fragments amplified from a single primary PCR product
163
jf jg
YU2 EIVIRSENFT NNAKT1IVQL NESWINCTR PNNNTRKSIN I..GPGRALY TTGEIIGDIR QAHCMTLSKTQ WENTLEQIA
HXB2 DV A D T—E R -QR FV -I-K-.-NM- X-RAK -NA—K
320L-1 -V A—S D K E-K PG-G-P S-F- A I-G-D —N K
320L-2 -V A—S D N K E-K-S G-P S-F- A RAM -T
320L-3 -V A—S D Ml K E-K-S G-P S-F- A RAM -T
320L-4 -V A—S D MI K E-K-S G-P S-F- A RAM -T
320L-5 -V A D M K E-K-S G-H F- A-A RAM -T
320B-1 -V AI— D N K E-K-S G-H . F- A-A RAN -T
320B-2 -V A D N K E-K-S- G-H . F- A-A RAM -T
320B-3 -V A D M K E-K-S G-H F- A-A RAM -T
320B-4 GV FA D M K E-K-S- G-H F- A-A RAM -T
320B-5 -V A D N K E-K-S- G-H F- A-A RAM -T
320B-6 -V-N—A D-L-M K E-R-S H G-H 1- A-A E Y—RAK JLT
320B-7 -V A D N K E-K-S G-H F- A-A RAM -T
320B-8 -V A D M K E-K-S G-H . F- A-A RAN -T
369L-1 -V A—S D S -Q- S RG-H -. -X—S-F- VT I-RAE -ND KKK
369L-2 -V A—S D S K S RG-H -. .X—S-F- VT I-RAK -ND K-I
369T.-3 GV A—S D S A S RG-H -. .X—S-F- VT I-RAK -ND—QK-V
369L-4 -V A—S D S K -S RG-H -..X—S-F- VT I-RAK -ND—KE-V
369L-5 -V A—S D S A S RG-H -..X—S-F VT I-RAK -ND—KE-V
369L-6 -V A—S D M S RG-H -..X—S-F VT 1—RAK -ND K-V
369L-7 -V A—S D S -Q S RG-H -..X—S-F- VT I-RAE -ND K-V
369B-1 -V A—S D S K -S RG-H -. .X—S-F- VT I-RAK -ND—KE-V
369B-2 -V A—S D S K S RG-H --.X—S-F- VT I-RAK -ND—KE-V
369B-3 -V A—S D S K -S RG-H -..X—S-F- VT I-RAK -ND—KE-V
369B-4 -V A—S D S K -S RG-H -..X—S-F- VT I-RAK -ND—KE-V
369B-5 -V A—S D S K S RG-H -.-X—S-F- VT I-RAK -ND—KE-V
311L-1 -V Q V-M A-D-I- RG— F- —EKV—N— I-EAK -N K—V
311L-2 Q—S 1 A-D-I RG .. F V—N I-EAM -N K—V
311L-3 -V Q—S V A-D-I RG-S . F V—N— I-EAK -N K—V
311L-4 -V Q V-M A-DYI RG F V—N I-EAK -NS—K—V
311L-5 -V Q—S V A-D-I RG .. F- V—N— I-EAM -N K—V
311L-6 -V Q—S 1 A-D-I- RG— . F- V—N— I-EAS -N K—V
311L-7 -V Q—S 1 A-D-I RG .. F- V—N— I-EAK -N K—V
311L-8 -V—K-Q—S V-M K—A IK KRG .. F V—N— I-EAN -S K—V
311B-1 -V S F- N— EAK -N K
311B-2 -V S .. F- N— EAK -N K
311B-3 -V S F- N— EAK -N K
311B-4 -V S F- N— EAK -N K
311B-5 -V S F- N— EAK -N K
311B-6 -V S F- N— EAK -N K
311B-7 -V S F- N— EAK -N K
311B-8 -V S F- N— EAK -N K
234L-1 -V M KQ F- A V R T—S-E -N-A-K-V-
234L-2 -V M 1 T F- A V R-F-T-NS-K -N-A-K-V-
234L-3 -V DLN M —T-I T . F- V—N— R-F-T-NS-K -N-A-K-V-
234T.-4 -V W 1 T F- A V R-F-T-MS-K -N-A-K-V-
234B-1 -V 1 KQY-E-K H F V R-D -N K—V
234B-2 -V V-M KQY-E-K .. F V R-D -N K—V
234B-3 D M KQY-E-K F- V R-D -N K—V
234B-4 D M KQY-E-K .. F- V R-D -N K—V
234B-5 D M KQY-E-K .. F V R-D -N K—V
234B-6 D M KQY-E-K .. F- V R-D -N K—V
234B-7 D N KQY-E-K .. F- V R-D -N K—V
Figure 4.5: Predicted V3 amino acid sequences of PCR products amplified at
limiting dilution from post-mortem tissue. L: Lymphoid tissue derived; B: Brain
tissue derived. Green asterisks indicate sites at which the occurrence of
positively charged amino acids is strongly correlated with CXCR4 usage.
Dashes indicate identical bases. Dots indicate an alignment gap.
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(figure 4.2B). Between seven and eight limiting dilution copies of each of the
two fragments were obtained from brain and lymphoid tissue for each subject.
The products were sequenced, aligned and phylogenetic trees produced
(figure 4.6).
The tree topology for subject 320 suggests a high degree of genetic
compartmentalisation between sequences amplified from brain or lymphoid
tissues. All brain-derived sequences cluster together in a monophyletic
lineage. Lymphoid-derived sequences form three lineages, all distinct from
the brain sequences. In contrast, the tree for subject 369 provides little
evidence of genetic compartmentalisation; brain and lymphoid derived
sequences appear to be completely intersperced. The tree topologies for
subjects 311 and 234 indicate an intermediate degree of genetic
compartmentalisation. In both cases the brain-derived sequences form a
polyphyletic group composed of three distinct lineages (two are boot-strap
supported for subject 311 while all three are boot-strap supported for subject
234). No lymphoid-derived sequences are found in any of these lineages
however lineages containing lymphoid-derived sequences are intersperced
with "brain lineages".
The Los Alamos HIV drug resistance database was used to identify putative
resistance-conferring mutations in the amino acid sequences (figure 4.7).
This information is summarised in table 4.4.
There were no examples of mutations conferring resistance to an NRTI which
had not been prescribed to the subject from which the sequence was
amplified. For example, no mutations conferring a high degree of resistance
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A: Study subject 320





C: Study subject 311 D: Study subject 234
Figure 4.6: Phylogenetic trees constructed using RT sequences amplified at
limiting dilution. Trees were produced as outlined in figure 4.4. Red circles
represent brain-derived sequences. Blue squares represent lymphoid tissue-
derived sequences.
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Figure 4.7: Predicted RT amino acid sequences of PCR products amplified at
limiting dilution from post-mortem tissue. L: Lymphoid tissue derived; B: Brain
tissue derived. Dashes indicate identical bases. Dots indicate an alignment gap.
Stars indicate a stop codon. Mutations conferring low to intermediate zidovudine
and stavudine resistance and minor lamivudine resistance, indicated by red
arrows, are M41L (Larder and Kemp, 1989); L210W (Gurusinghe et al., 1995)
and T215Y (Larder and Kemp, 1989). (Bazmi et a!., 2000; Taylor et al., 2000:
Garcia-Lerma et a!., 2003; Zhang et al., 1994) Mutation conferring minor
zidovudine, stavudine and lamivudine resistance, indicated by an orange arrow
is: V118I (Hertogs et al., 2000). Mutations which confer resistance to lamivudine
but cause hypersensitivity to zidovudine, indicated by green arrows are: K65R
(Tisdale et a!., 1997) and M184V (Tisdale ef al, 1997). Mutation data obtained
from the Stanford HIV Drug resistance Database (Rhee et al. 2003). Note that
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Figure 4.7: Continued
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Table 4.4: Summary of resistance mutations present in RT sequences. L:
lymphoid; B: Brain; AZT: zidovudine; 3TC: lamivudine; PFR: Predicted Fold
Resistance- values are the median susceptibility of all isolates from the
Stanford IIIV drug resistance database containing the mutations shown and
no other major drug-resistance mutations. Number of isolates tested to obtain
median susceptibility values shown in brackets. Drug resistance mutations
are colour coded as follows: Red: Low to intermediate AZT and D4T
resistance; minor 3TC resistance. Orange: Minor AZT, D4T and 3TC
resistance. Green: Confers hypersensitivity to AZT and D4T and
intermediate resistance to 3TC. Mutations data obtained from the Stanford
HIV Drug resistance Database (Rhee et al., 2003).
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to zidovudine were found in subject 369 who had not taken this drug. Thus,
the most likely explanation for the resistance mutations seen in the
sequences is that evolution of the virus took place within the host in response
to selective pressure from RT inhibitors. However, it cannot be ruled out that
some of the mutations could have been acquired through transmission of a
drug resistant variant; Indeed a study carried out in America revealed that
between 1996 and 2000, approximately 10% of newly acquired HIV
infections were with a virus possessing at least one NRTI-resistance
conferring mutation (Little et al., 2002).
There was no difference in the pattern of drug resistance-conferring
mutations between sequences derived from the brain and lymphoid tissue of
subject 320 despite the sequences forming separate lineages according to
tissue origin on the phylogenetic tree. Examination of the nucleotide
sequence revealed that the observed phylogenetic split between the groups
of sequences is largely due to segregating polymorphisms at two key
nucleotide positions; at both position 363 and 393 the lymphoid-derived
sequences have a guanine residue while the brain-derived sequences have
an adenine residue (data not shown). Interestingly, both nucleotide changes
are synonymous. Abrogation of these two discordant nucleotides results in
phylogenetically interspersed sequences. All the sequences amplified from
subject 320 possessed the R83K mutation. This mutation has been linked to
NRTI resistance in one study (Masquelier et al., 1999) however another
study found the mutation to be negatively related to RT inhibitor usage
(CeccheriniSilberstein et al., 4 A.D.). Thus the in vivo significance of this
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mutation is unclear. It is possible that the mutation is capable of conferring
either sensitivity or resistance depending on the other mutations present in
the sequence.
The brain and lymphoid tissue derived sequences from subject 369 also
show no differences in the distribution of resistance mutations. Only one
drug-resistance mutation is represented at all (M184V) and this appears in
two lymphoid tissue and two brain derived sequences. As mentioned
previously, this mutation confers resistance to lamivudine. The finding of no
difference in drug-resistance conferring mutations between brain and
lymphoid tissue is compatible with the interspersed nature of these
sequences on the phylogenetic tree.
The only subject for which there was a substantial difference in drug-
resistance mutation patterns between compartments was subject 311. One
mutation conferring resistance to zidovudine (M41L) was fairly evenly
distributed in sequences from both compartments. However two mutations
were over-represented in the lymphoid derived sequences. These mutations
were L210W and T215Y which confer resistance to zidovudine. Interestingly,
two other mutations which may be associated with RT inhibitor use were also
over-represented in the lymphoid-derived sequences. These are K122E
which is associated with RT inhibitor use but does not appear to contribute
significantly to resistance and R11K which confers resistance to zidovudine +
atevirdine (data not included in table 4.4).
At first glance, the drug-resistance/ mutation pattern of subject 234 appears
to differ between compartments however, this is largely due to the presence
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of one lymphoid tissue-derived variant (234L-7) which possesses multiple
drug resistance mutations. If this sequence is removed then the distribution
of drug resistance and drug associated mutations is fairly equal between
compartments. Further sequences would need to be obtained to determine if
sequence L7 represents a significant population of highly drug-resistant
variants in the lymphoid compartment.
PR sequencing
Of the four study subjects two (369 and 311) were believed to have taken Pis.
Thus the distribution of resistance mutations in the PR gene was examined in
sequences amplified from these subjects. The region of PR used for
sequencing was 325 bps long (figure 4.2C). Eight limiting dilution copies of
the fragment were obtained from brain and lymphoid tissue for each subject.
The products were sequenced, aligned and phylogenetic trees produced
(figure 4.8).
The tree topologies for both subjects suggest a degree of genetic
compartmentalisation. In both cases, all brain-derived sequences cluster in
single monophyletic lineages (boot-strap supported in the case of subject
311). However, the presence of lymphoid-derived sequences within these
lineages reduces the degree of genetic segregation according to tissue of
origin.
The Los Alamos HIV drug resistance database was used to identify putative
resistance-conferring mutations in the amino acid sequences (figure 4.9).
This information is summarised in table 4.5.
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A: Subject 369 B: Subject 311
Figure 4.8: Phylogenetic trees constructed using PR sequences amplified at
limiting dilution. Trees were produced as outlined in figure 4.4. Red circles
represent brain-derived sequences. Blue squares represent lymphoid tissue-
derived sequences.
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Figure 4.9: Predicted PR amino acid sequences of PCR products amplified at
limiting dilution from post-mortem tissue. L: Lymphoid tissue derived; B: Brain
tissue derived. Dashes indicate identical bases. Dots indicate an alignment
gap. Stars indicate a stop codon. Minor protease inhibitor resistance
mutations, indicated by blue arrows, are L10I (Kempf et al., 2001;
Watkins et al., 2003; Condra et al., 1996), G16E (Carrillo et al., 1998), K20R
(Kempf et al, 2001; Molla et al., 1996; Condra et al, 1996), L23l(Croteau et
al., 1997; Kempf et al, 2001; Watkins et al, 2003; Condra et al, 1996), E35D
(Rusconi et al., 2000), M36I (Molla et al, 1996), L63P (Kempf et al, 2001;
Watkins et al, 2003; Gong et al., 2000; Condra et al, 1996), A71T (Patick et
al., 1995; Kempf et al, 2001; Markowitz et al., 1998; Condra et al, 1996;
Rusconi et al, 2000) and A71V (Kempf et al, 2001; Markowitz et al., 1995;
Markowitz et al, 1998; Croteau et al, 1997; Gong et al, 2000; Gatanaga et al.,
2002; Partaledis et al., 1995; Watkins et al, 2003). The only major protease
inhibitor resistance mutation, shown in dark blue, is M46L, (Kaplan et al.,
1994; Kempf et al, 2001; Watkins et al, 2003; Molla et al, 1996; Croteau et al,
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Table 4.5: Summary of drug resistance mutations present in PR sequences
amplified at limiting dilution from brain and lymphoid tissue. Dark blue: major
mutation- confers intermediate resistance to some protease inhibitors,
bfu minor mutations- may contribute to resistance (Rhee et al, 2003).
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Unfortunately, after the sequencing work had been completed, it emerged
that there had been a clerical error at the time of the post-mortems on these
subjects. Further investigations of the clinical records and interviews with the
clinicians responsible for the care of the individuals revealed that Pis had not
in fact been prescribed to these subjects. The data has nevertheless been
included here as it will serve as a valuable control for further investigations
(now on-going) into the distribution of drug-resistance mutations in individuals
who have taken Pis.
Only one mutation which may contribute an intermediate degree of PI
resistance, M46L, was present in any of the sequences (B369-2 and B369-3).
It is possible that this mutation was acquired through dual-infection and
recombination with a drug-resistant variant from an individual taking a PI.
Alternatively the variant which originally infected this subject may have
harboured the M46L mutation. This has been described in a previous study
although it appears to occur rarely; only one of 38 acutely infected subjects
harboured virus possessing the M46L mutation (Re et al., 2004).
All other mutations detected in the PR sequences were minor resistance
mutations which may contribute to resistance in the presence of other
mutations but which are also present at a relatively high frequency in drug-
naive subjects (Re et al, 2004). Thus the presence of these drug resistance
mutations is consistent with the clinical data showing that these individuals
did not take a PI. In subject 311 these minor mutations appear to be
overrepresented in the lymphoid-derived sequences while in subject 369 they
are slightly overrepresented in the brain-derived sequences.
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4.4 Discussion
In this study the pattern of drug-resistance associated mutations found in HIV
proviral DNA isolated from post-mortem brain and lymphoid tissue were
compared. Examination of RT sequences revealed that for three out of four
study subjects, the drug-resistance associated mutation pattern was similar
in both compartments. In one subject, there were significantly more drug-
resistance associated mutations in lymphoid-tissue sequences than in those
amplified from the brain.
A surprising finding was that sequences amplified from the two subjects who
had died from AIDS-related illnesses had very few drug-resistance
associated mutations. In both cases there was a period of some months (15
months for subject 320 and 6 months for subject 369) between the cessation
of treatment and death. Studies have shown that almost all individuals taking
one or two NRTIs only for at least a year, harbour virus containing drug
resistance mutations (GomezCano, et al. 1998). Thus it is highly likely that at
the time of receiving treatment, these individuals harboured virus which
contained some degree of resistance to the NRTIs they were taking. It is
probable that the rapid viral replication which presumably took place during
the later stages of illness after treatment had been stopped, allowed drug-
sensitive variants to expand and predominate. It would be expected that
drug-resistant proviral copies would still be present in the DNA of long lived
cells. However, explosive replication of drug-sensitive variants after the
cessation of treatment may mean that the relatively small sample of
sequences carried out in this project was not sufficient to detect such
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"archived" copies.
It is interesting to note that there were also considerable intervals between
the end of treatment and the death of the subjects who had not progressed to
AIDS (11 months for subject 311 and 45 months for subject 234). Despite
this, a large number of drug-resistance conferring mutations are present in
the sequences derived from these subjects; particularly for subject 311.
There have been reports of maintenance of drug-resistance mutations in the
viral population despite no anti-retroviral drug for extended periods of time
after transmission of drug-resistant variants (Delaugerre et al., 2004). It is
thought that the maintenance of resistant variants in these circumstances is
because there is no "reserve" of wild-type virus to outgrow other variant on
cessation of therapy. Thus subject 311 may have been initially infected with
drug-resistant variant. Additionally, viral replication in pre-symptomatic
subjects may be more controlled by host immunity and thus evolution to wild-
type virus may take longer. Some sequences amplified from this subject have
few or no drug-resistance associated mutations suggesting that over time
these variants may have become dominant.
If an organism reproduces asexually and recombination does not occur, the
evolutionary relationships implied by phylogenetic analysis of sequences
amplified from different regions of the genome should be identical. In
contrast, comparison of the phylogenetic trees obtained in this study for
different regions of the HIV genome from single study subjects reveals that
there are discordant phylogenetic relationships. Most strikingly, the V3
sequences from subjects 369 and 234 segregate according to tissue of origin
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yet the RT sequences from the same anatomical sites are intersperced. This
suggests that in these cases a process of recombination has contributed to
the observed genetic diversity. This is consistent with previous reports of
frequent in vivo recombination events (Morris et al, 1999; Dykes et al., 2000).
The packaging of two homologous copies of the RNA genome in each virion
underlies this phenomenon. An alternative hypothesis is that the selective
pressures on RT sequence are identical in the CNS as they are in the
periphery while the selective pressure on V3 differs between the two sites. If
this were the case then a process of convergent evolution could lead to the
phylogenetic grouping of brain derived V3 sequences.
Recombination plays an important role in the global genetic diversity of HIV
as demonstrated by the high prevalence of circulating recombinant forms
(CRFs) in some areas (Gao et al., 1996; Gao et al., 1998). As yet there has
been no evidence that recombinant forms arise and become dominant in a
given region due to any selective advantage. Thus it has been assumed that
the differing geographical distribution of CRFs is merely due to stochastic
events. In contrast, the consistent findings of intra-patient recombinant forms
clustering according to anatomical sites, strongly suggests that
recombination is an important adaptive mechanism for HIV in response to
selective pressures. One such selective pressure is the constraint on viral
attachment and entry imposed by differential expression of host cell
receptors. It is noteworthy that in this and previous studies (Morris et al, 1999)
the genetic region which shows the greatest degree of segregation according
to anatomical location is V3. This region is the major determinant of HIV
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tropism and thus it appears that the presence of different cellular targets in
different locations is a crucial selective pressure. Once HIV enters a new
anatomical region, there will be selection of variants with mutations in V3
which are able to attach and infect cells more efficiently. Other genomic
regions which do not face such a strong selective pressure in the new
environment may maintain similar sequences to variants in other locations
through a process of recombination. Thus differential selective pressure
appears to play an important role in the compartmentalisation of V3
sequences observed between brain and lymphoid tissue.
Similar evidence of frequent recombination events between brain and
lymphoid tissue derived sequences has led some investigators to suggest
that genetic drift due to anatomical separation is not an important factor in the
segregation of sequences according to location. However, examination of the
sequences in this study reveals evidence of just such a process of genetic
drift. A puzzling finding was that the RT sequences derived from brain and
lymphoid tissue for study subject 320 are phylogenetically distinct despite no
evidence for differences in the pattern of drug resistance mutations between
these two compartments. Examination of the nucleotide sequences revealed
that the split was mainly due to two synonymous mutations. It is difficult to
envision how such mutations could provide any selective advantage to
variants and thus this strongly suggests that a process of genetic drift and/or
stochastic events have contributed to the divergence of brain and lymphoid
tissue derived RT sequences in this subject. The infection of the brain may
have been seeded by variants which were not representative of the entire
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viral population present in the lymphoid system. Some degree of anatomical
segregation may have then contributed to the separate evolution of the two
lineages.
Examination of the PR nucleotide sequences reveals that there is differential
distribution of some synonymous mutations between the lymphoid tissue and
brain derived sequences for both subject 369 and 311 (data not shown).
Thus it appears that genetic drift may also have played a role in the
segregation of these lineages. However, non-synonymous mutations are also
unevenly distributed resulting in different patterns of minor drug-resistance
associated mutations between the two compartments. The mechanism
underlying this phenomenon is unclear. It is possible that a combination of
genetic drift and stochastic events have contributed. Alternatively it is
possible that some selective pressure is directing differential evolution in the
two compartments. Neither of these individuals appears to have taken a PI
and thus differential drug-pressure is not likely to have played a role.
However, it is possible that some subtle differences in cellular biochemistry
between lymphoid and brain cells selects for certain mutations in the
protease gene.
A hypothesis which is often mentioned in the scientific literature is that sub-
optimal levels of anti-retroviral drugs may lead to evolution of drug-resistant
variants in the CNS. This study found no evidence of such a phenomenon. In
fact, investigation of one pre-symptomatic study subject revealed far more
drug-resistance mutations in lymphoid-derived sequences than in those
amplified from brain tissue. This results is in common with previous studies
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which have identified cases with more drug-resistance mutations in the
lymphoid system than in the brain but no cases where the opposite is true
(Wong et al, 1997; McClernon et al, 2001). One explanation for the failure to
support the hypothesis mentioned above is that the levels of drug found in
the CNS may be far lower than many have previously assumed (see section
4.1 for more details). Thus, rather than there being sub-optimal levels of
drugs allowing evolution of resistant variants, there may in fact be only
negligible levels of drugs. This would allow the continued growth of drug-
sensitive variants after the selective pressure of the drugs has removed them
from the periphery.
This does not mean that the evolution of drug resistance-associated
mutations does not occur in the brain. As mentioned previously, it is thought
that the concentration of zidovudine at a given location in the brain is
inversely correlated with the distance from the brain surface (Blasberg et al,
1977). Thus there may be a layer of the brain at which the drug concentration
is sufficient to inhibit growth but not high enough to eliminate viral replication
entirely. Such conditions would indeed promote the evolution of drug
resistant variants. The method used in this project may be too crude to detect
this process although it is possible that the lineage of brain-derived
sequences amplified from subject 369 which possessed a high number of
drug-resistance mutations could be due to such a process. The emergence
of new techniques could lead to exciting advances in this area. For example,
the use of in situ PCR or laser capture microdisection followed by PCR,
would allow the occurrence of drug-resistance associated mutations at a
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given location to be correlated with distance from the brain surface.
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Chapter 5: Results III
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5.1 Introduction
HIV associated dementia (HAD) affects approximately 30% of people with
untreated AIDS (Mcarthur et al., 1993). Thus, given the huge number of
individuals infected with HIV, HAD is likely to be the leading cause of
dementia worldwide. The neuropathological changes associated with HAD
are termed HIV encephalitis (HIVE). The pathognomic feature of HIVE is the
presence of multinucleated giant cells (Budka et al., 1991). Other
pathological features may include astrocytosis, myelin pallor, infiltration of
monocytic cells and neuronal loss (Bell, 1998). Current opinion is that the
observed pathology arises as a result of a cascade of damaging processes
initiated by infected microglia and macrophages (reviewed in Kaul et al.,
2001; Mollace et al., 2001). However, a vigorous debate continues as to the
extent of infection of other resident brain cells and their potential contribution
to neuropathology.
Conflicting results about the brain cells infected by HIV have emerged from
immunohistochemical studies (reviewed in Brack-Werner, 1999). Most
studies have stained cells with antibodies against HIV structural proteins
which appear late in the viral life cycle. The most common peptide stained for
is the capsid portion of the Gag polyprotein (p24 antigen). Such studies have
detected viral proteins mainly in macrophages, giant cells and microglia
(Vazeux et al., 1987; Nuovo et al., 1994) or occasionally also in astrocytes
(Saito et al., 1994; Pumarola Sune et al., 1987). In contrast, early viral
proteins such as Nef and Rev have been found frequently in astrocytes but
rather less commonly in microglia/macrophages (Saito et al, 1994; Ranki et
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al., 1995). This suggests that astrocytes are infected in vivo but have a very
limited capacity to produce structural proteins and therefore infectious virus.
In situ hybridisation studies have generally identified viral RNA mainly in
microglia/macrophages (Koenig et al., 1986). However, in keeping with the
immunohistochemistry studies, viral RNA coding for early proteins has been
detected in up to 20% of astrocytes (Saito et al, 1994; Ranki et al, 1995). The
main limitation of in situ hybridization is that a large amount of RNA must be
present to give a positive result. This means that results obtained using this
technique may underestimate the number of infected cells. In particular cells
in which low levels of viral RNA are produced, are unlikely to be detected as
positive.
To overcome this problem, a technique called PCR amplified in situ
hybridization (or simply in situ PCR) has been devised. In this technique,
PCR amplification is carried out with the cells themselves acting as the
vessels for the reaction (Bagasra et al., 1993). In common with other
techniques, in situ PCR has demonstrated abundant infection of microglia. A
number of studies have also reported low level infection of astrocytes or
neurons (Bagasra et al., 1996; Nottet et al., 1996). Interpretation of these
results is complicated by the frequent occurrence of false positives when
using in situ PCR. Numerous factors can influence the likelihood of false
positives arising including the number of PCR cycles, the length of incubation
with proteinase K and the size of the PCR product (Haase et al., 1990;
Strappe et al., 1998). False positives appear only on slides where some cells
are truly positive. This suggests that they occur due to diffusion of PCR
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product between cells. Thus the inclusion of HIV negative slides does not
provide an adequate control. That the results of some in situ PCR studies
might reflect a high degree of false positives is supported by the fact that the
calculated proviral loads are often far higher than those found using tube
based PCR systems (Bell et al., 1998).
Thus, despite the plethora of techniques available, the question of which
brain cells are infected and to what extent remains controversial. One
approach which could help resolve this would be to purify different brain cell
types and then test each population separately and directly for HIV infection
using PCR.
Separation of individual brain cell types has posed a major challenge to
scientists for many years (reviewed in Poduslo and Norton, 1975). The
cellular structure of neural tissue is immensely complex with most cell types
possessing some form of cellular processes which connect and intertwine
with other cells and cellular processes (reviewed in Berry et al., 2002).
Neurons have two types of process which allow the propagation of electrical
signals; dendrites receive afferent signals while axons deliver efferent signals
to adjacent neurons. Projections from oligodendrocyte cellular membranes
form myelin sheaths which wrap around neuronal axons forming concentric
lamellae. The multiple projections emerging from astrocytes give them their
characteristic "star-like" shape. These processes can connect with other
astrocyte processes to allow signal propagation. In addition they can
ensheath blood capillaries contributing to the blood brain barrier or connect
with the nodes between myelin sheaths and thus influence neuronal
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signalling. Microglia also possess processes and in this respect are unique
amongst known tissue macrophages. All these connections mean that brain
cells are tightly lashed together and thus separation is extremely difficult.
The first stage in any technique for bulk separation of brain cells is to form a
single cell suspension. This usually involves some type of enzymatic
digestion, followed by mechanical agitation to tease out cells followed by
forcing the cell mixture through some type of mesh to ensure that only single
cells are present. The exact method employed depends on the subsequent
application. For example if the morphology of cells is to be examined, very
gentle techniques of cellular disaggregation must be employed. If cell surface
antigens are to be examined (or used to aid cell separation as in FACS
sorting) then the enzyme used must be carefully chosen to avoid digestion of
the antigen of interest.
The most effective way to obtain large populations of "pure" brain cells is to
culture primary brain cells using conditions which selectively inhibit growth of
all cell types other than the one of interest. This approach has been
successfully used to isolate oligodendrocytes, astrocytes, microglia and
neurons (Shi et al., 1998; Budziszewska et al., 2002; Liuzzi et al., 2004). The
major disadvantage of this method is that the cells undergo change and
differentiation ex vivo. This means that the phenotype of cells obtained may
not accurately reflect that found in vivo.
For many years the only method available for separation of cells from a cell
suspension without culturing was isopycnic separation using solutions of
various densities. Various media can be used to form density gradients
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including sucrose, albumin, Ficoll and Percoll. There are two types of density
gradient: continuous or discontinuous (figure 5.1). A continuous gradient is
formed when a tube containing media of a given dilution is centrifuged at a
high g force. This results in a gradient of density being formed with the
highest density being at the base of the tube and the lowest at the top. Cells
to be separated can be layered on top of the gradient and the tube
centrifuged at a low g force. The cells or cellular components will move down
the gradient and settle where the density of the media equals their own
density. As cells of a given type will have a range of densities, bands of cells
in a continuous gradient will be wide and can be difficult to visualise.
To make a discontinuous gradient, various dilutions of media are prepared.
These are layered in a tube starting with the most dense and working up to
the least. Layering must be carried out very carefully so that the interfaces
between layers are distinct. The cells to be separated are layered on top of
the gradient. The tube is then centrifuged at a low g force. Cells descend
through the gradient and settle at an interface where the layer above is less
dense and the layer below is more dense than the cell itself. Cells with a
range of densities (i.e. the range between the densities of the two adjacent
layers) will form single narrow bands. Thus this method will produce more
discreet easily visible bands.
Methods based on tissue disaggregation followed by density gradient
separation have been used in many studies for separation of cell types with
various degrees of success (reviewed in Poduslo and Norton, 1975). The
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Figure 5.1: Schematic representation of separation of cells using Percoll
gradients. A: Separation using a continuous gradient results in diffuse poorly
visible bands of cells. Each band contains cells within a narrow range of
densities. B: Separation using a discontinuous gradient results in clearly
defined bands of cells. Each band contains cells with a wider range of
densities.
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type. The ranges of densities characteristic of given cell types overlap and
thus it is very difficult to obtain pure populations using this method. A method
which attempted to overcome this problem used an initial separation using
differential centrifugation in Ficoll media (Farooq and Norton, 1978). This
allowed enrichment of either astrocytes or neurons on account of their
differences in cell size and therefore sedimentation rates. These enriched
fractions were then separated using a discontinuous Ficoll gradient. Using
this method, neurons of 90% purity and astrocytes of 57% purity were
obtained.
While different cell types have quite similar and overlapping ranges of
densities, the broken processes and cell debris produced by tissue
homogenisation are distinctly less dense than whole cells. This is because
cell processes in general are composed mainly of lipid membrane with
relatively little cytoplasmic content. Thus density centrifugation can very
effectively separate whole cells from cellular debris.
Recently, various studies have attempted to purify brain cells using
fluorescence activated cell sorting (FACS). FACS sorting allows separation
of cells according to differences in size, density and antigen expression. This
technique has been largely used for analysis of blood cells which are found in
a preformed single cell suspension and are more or less devoid of cellular
processes (reviewed in Kantor and Roederer, 1997). Clearly, to separate
brain cells a single cell suspension must first be obtained. In addition, it is
necessary to remove the cellular debris and cellular processes which
constitute the bulk of the matter in a crude brain cell suspension prior to
194
FACS analysis in order to prevent clogging of the machine (personal
observation). Despite the inherent difficulties, studies have been published
recently which use FACS either for analysis of cell surface antigens or for cell
sorting of brain cells (Malatesta et al., 2000; Morelli et al., 1999; Sedgwick et
al., 1991).
It should be noted that most previous studies have used brains from mice or
rats which have been obtained under optimum conditions. The brains were
removed immediately following the death of the animal and in some cases
blood contamination was eliminated by prior infusion with saline solution.
Separation of human brain cells from post mortem tissue is complicated by a
number of factors. Firstly, the interval between death and refrigeration can be
many hours. The post mortem interval is often one to two days and can be
much longer. Finally, transport of the brain from the mortuary to the
laboratory can take up to a day. Thus the tissue has had ample time for
significant cell lysis and decay to occur compared with laboratory animal
studies where the brain can be removed and experimental work started
immediately following death.
5.2 Aims
The primary aim of this study was to develop a technique for bulk isolation of
pure cell fractions from post mortem human brains.
A secondary aim was to use this technique to separate brain cells from HIV




A log of all cell separation experiments carried out is provided in Appendix II.
The following text (sections 5.3.1 to 5.3.5) provides a more detailed
explanation of the optimisation of various aspects of the cell separation
procedure.
5.3.1 Tissue disaggregation
Initially, digestion was carried out using a previously published method
involving papain and collagenase (Wright et al., 1997) (section 2.4.3). This
method produced a single cell suspension although cellular morphology was
not preserved. Attempts to separate cells using ficoll enrichment followed by
a continuous Percoll gradient were preceded with a controlled trypsin
digestion (Chatterjee and Sarkar, 1984b) (section 2.4.4). This method
produced a cell suspension where cellular morphology was well preserved.
This allowed identification of cell types based on a combination of
immunostaining and cellular morphology. Unfortunately, cells prepared in this
manner did appear to be particularly "sticky". This could be due to the
preservation of cellular processes. Thus this method was replaced with a
standard method of trypsin digestion (section 2.4.5) for subsequent FACS
analysis. This technique produced a single cell suspension however there
was a concern that trypsin may be causing cell death and thus decreasing
cell yields. For this reason, a novel method of cell digestion was adopted
which involved purified collagenase and DNAse (Ford et al., 1995) (section
2.4.6). It was found using mouse brains that the cell yields obtained were




The first method of cell separation to be investigated was isopycnic
separation using a continuous Percoll density gradient. Prior to using a
continuous Percoil gradient, it is necessary to produce a calibration curve.
This allows the selection of the optimum concentration of Percoll for the
separation of the cells of interest. Due to variations in batches of Percoll,
centrifuges and local conditions, this may differ from lab to lab. To produce
the calibration curve, preformed Percoll gradients were produced using
various different concentrations of Percoll. Coloured beads of known
densities were separated using these gradients in the same manner as a cell
suspension. The distances travelled by beads of different densities in each of
the gradients were noted and a calibration curve created (figure 5.2).
The densities of different cell types as reported by previous studies are
shown in table 5.1. Using the calibration curve, it was decided that a gradient
using between 20 and 60% (v/v) percoll would give the optimum separation
of cells within the predicted range of densities. Separation of brain cells was
attempted using continuous Percoll gradients of a range of concentrations.
The results of these attempts were that a thick band of material formed near
the top of the gradient. This band had a predicted density of approximately
1,022g/ml. No other bands of cells were visible. The thick band of material
was examined microscopically and determined to be largely composed of
cellular debris and fragments of myelin. Some cells were also present in this
fraction. As brain cells are predicted to have a higher density than 1,022g/ml,
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Figure 5.2: Calibration curve showing distance migrated in preformed Percoll
gradients against density. Experiments were carried out using commercially
available density marker beads using different percentage compositions of
Percoll.
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Cell type Species Density
(g/ml)
Reference
Astrocytes Mouse 1-1.045 (Wechsler-Reya and Scott,
1999)
Rat 0.98-0.998 (Chatterjee and Sarkar, 1984)
Rat 1.03-1.072 (Sedgwick et al., 1991)
Neurons Mouse 1.045-1.085 (Wechsler-Reya and Scott,
1999)
Rat 1.026-1.150 Chatterjee and Sarkar 1984
Microglia Rat 1.03-1.072 (Sedgwick et al, 1991)
Leukocytes Rat 1.072-1.088 (Sedgwick et al, 1991)
Myelin Rhesus
macaque
1-1.039 (Westmoreland et al., 2002)
Rat <1.03 (Sedgwick et al, 1991)
All Glia Rhesus
macaque
>1.039 (Westmoreland et al, 2002)
Table 5.1: Observed densities of brain derived cells from various species
according to previous publications.
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it was assumed that the cells were being "caught" in this layer due to
clumping with lower density material. Attempts were made to reduce the
propensity of the material to clump. First 2 mM EDTA was added to all media
used in the preparation of a single cell suspension. This had little effect on
cell clumping. Next the media used for storage of the brain tissue prior to
separation was investigated. Brain material was stored in PBS, media A
(Poduslo and Norton, 1975) or without media for 1 hour or 24 hours.
Separation was carried out using a discontinuous Percoll gradient. Media A
appeared to reduce the amount of clumping slightly; material stored in this
media produced faint bands of cells following continuous Percoll separation
at an approximate density of 1.026g/ml.
Concurrently, a method of cell enrichment using Ficoll media was
investigated. This was an adaptation of a previously published method which
had been used to isolate neurons and astrocytes from rat brains (Farooq and
Norton, 1978). Ficoll enrichment was used prior to separation on a
continuous Percoll gradient. A gentle trypsin digestion which aimed to
maintain cellular morphology was used (Chatterjee and Sarkar, 1984a). This
means that the morphology of cells, along with immunocytochemistry, could
be used to identify cell types and thus calculate purities obtained. Ficoll
media was used to produce pellets enriched for either neurons or astrocytes.
Figure 5.3 shows that this method was able to enrich for these cell types and
that cellular morphology was strikingly well preserved. However, the
astrocyte enriched pellet contained a large amount of broken processes and
cellular debris.
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Figure 5.3: Immunocytochemical staining for GFAP (DAB with haemotoxylin
counterstain) in cell fractions enriched for A: Astrocytes and B:.Neurons
Visualised at 10 x magnification. Blue arrows indicate astrocytes. The red
arrow indicates a probable neuron.
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The next step in the published method was separation of cells from the Ficoll
enriched pellets on a continuous gradient. The Ficoll enriched pellets were
further separated using a preformed percoll gradient (40% (v/v) dilution). As
previously a thick band of material with a density of approximately 1.022g/ml
was apparent. A very faint band was visible lower down the tube. The
estimated density of this band was 1.026g/ml. Microscopic examination of the
top band revealed that it contained mainly cellular debris and broken
processes however there were also a large number of cells present (data not
shown). It appeared that the intact morphology of the cells caused them to be
"caught" in the large amount of low density debris. It was not possible to
obtain sufficient cells from the lower band to examine microscopically.
It was decided to use a more harsh digestion technique. This would result in
loss of cellular processes which should make the cells less "sticky". In
addition a discontinuous gradient was used so that bands of cells would be
more easily visible. Previous reports using discontinuous percoll gradients
had not been able to obtain pure cell fractions. However, removal of cellular
debris had been achieved. Thus the discontinuous percoll gradient was used
with the aim of separating cells from cellular debris. The cell suspension
obtained could be used for alternative separation techniques.
A discontinuous gradient with layers of 60% and 30% (v/v) was prepared.
Cells were suspended in PBS and carefully overlayed. Following
centrifugation, a thick band was visible between the PBS and 30% layer. A
thin band was visible between the 30% and 60% layers. Matter from both














Figure 5.4: Cells and cellular debris aspirated from the interfaces of layers of
a discontinuous percoll gradient viewed at 20 x magnification. A: Cellular
debris and myelin fragments aspirated from above the 30% percoll layer. B:
Cells aspirated from below the 30% percoll layer.
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This technique effectively removes a large amount of cellular debris and thus
was used prior to any FACS staining and analysis of brain cells.
5.3.3 Immunomagnetic separation
Immunomagnetic separation of glial cells has been successfully carried out
previously using the Dynabead (Dynal Biotech) system (Wright et al, 1997).
In our department immunomagnetic separation of blood cells has been
routinely carried out using MACS beads (Milteny Biotech) and thus it was
decided to attempt separation of brain cells with this system. MACS beads
are considerably smaller than Dynabeads. Additionally, Dynabead stained
cells are pulled to the side of an open test tube using a magnet whereas
MACS bead stained cells become attached to a magnetic matrix within a
column (figure 5.5).
Cells were incubated with anti-GAP43 or anti-CD45 antibodies and then Goat
anti-mouse IgG MACS beads were attached. The stained cell suspension
was passed through an automated MACS sorting machine.
Surprisingly, very little material emerged as a negative fraction and almost all
cells emerged as the positive fraction for each antibody. It appears that due
to the highly sticky nature of brain cells, all cells and cellular debris were
becoming stuck to the true positive cells which were attached via beads to
the magnetic matrix. Depletion of "sticky" cellular debris using a Ficoll
gradient prior to MACS separation was attempted. Unfortunately this had little
effect and most material continued to emerge as the positive fraction.
Significantly, even in negative control separations where no antibody or















Figure 5.5: Schematic representation of two different methods of
immunomagnetic separation using commercially available beads. The left-
hand diagram shows separation using MACS beads while the right-hand
diagram shows separation using Dynabeads. Note that MACS beads are
much smaller than Dynabeads and that MACS bead separation involves
passing the cells through a magnetic matrix while Dynabead separation is
carried out in an eppendorf tube. This diagram is not drawn to scale; while
the size of the Dyna beads relative to cells is similar to that shown, the MACS
beads are in fact not visible even under 20 X magnification.
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"positive" fraction. This suggests that cells were becoming lodged in the
matrix even in the absence of magnetic bead staining and emerged only after
repeated "flushing out". It was thus decided that MACS bead separation was
not a viable option for separation of brain cells.
It seems likely that the use of a magnetic matrix during MACS bead
separation explains why this technique was not successful while Dynabead
separation has been previously reported. Indeed, initial attempts at
separation using Dynabeads appeared to select a population of cells from the
cell suspension. Unfortunately, immunostaining of these cells was
inconclusive (data not shown) perhaps due to masking of antigens by other
antibodies.
This line of investigation was discontinued due to promising initial results
from FACS sorting of cells.
5.3.4 Cell fixation
HIV infected cells must be fixed prior to FACS analysis for biological safety
reasons. In addition, if antibodies to intra-cellular markers are used, cells
must be permeabilised. Standard fixation techniques make use of
paraformaldehyde. Thus for initial attempts at FACS analysis, fixation in
solutions of between 1 and 4% (w/v) paraformaldehyde was used. For the
staining of intra-cellular markers subsequent permeabilisation using Triton
solution was carried out. Unfortunately use of paraformaldehyde for fixation
can adversely affect the DNA and is therefore not suitable if DNA extraction
and PCR is to be carried out using the sorted cells. Ethanol fixation does not
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appear to damage nucleic acid (Gillespie et al., 2002; Ben Ezra et al., 1991).
Fixation in ethanol has the additional advantage of permeabilising cells so no
additional step is required. Initial attempts to fix cells in ethanol resulted in a
great deal of cell clumping. This problem was overcome by using a modified
"gentle" ethanol fixation technique (William Telford et al., 1997).
5.3.5 Flow cytometry
The antigen generally used to identify astrocytes is glial fibrillary acid protein
(GFAP). GFAP is the main intermediate filament component of the astrocytic
cytoskeleton (Eng et al., 2000). A monoclonal anti-GFAP antibody and a
secondary antibody conjugated to FITC were used (n.b. Details of all
antibodies are given in table 2.4). As GFAP is an intra-cellular antigen, all
cells were fixed and permeabilised before staining. As mentioned previously,
initial experiments used fixation with paraformaldehyde followed by Triton
permeabilisation but eventually a gentle ethanol fixation procedure was
adopted. The antibody was first tested on the human glioma cell lines U373
and A172. Expression of GFAP had been previously demonstrated in these
cell lines using Western Blot analysis (Tlhyama et al., 1993; Khalid et al.,
1999). The A172 were only weakly positive for GFAP (data not shown). The
reason for this is not known but it is possible that in vitro passage of the cell
line had altered its phenotype. As shown in figure 5.6, U373 cells were
strongly positive for the GFAP antigen by FACS analysis. 45% of anti-GFAP
stained cells fell within the marker M1 compared with only 1% of isotype
control stained cells. Flowever, the isotype control stained cells were far more
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Figure 5.6: Flow cytometric analysis of astrocyte cell line (U373MG) stained
with primary antibody and FITC conjugated secondary. Analysis of
fluorescence was carried out on events which lay within the R1 gate as
defined on the side versus forward scatter dot plot. Events lying out with this
gate were presumed to be dead cells or cellular debris. On the histogram
plots of or cells stained with the isotype control it can be seen that
approximately 1% of cells lie within the M1 marker. On the histogram plot of
cells stained with GFAP and a FITC conjugated secondary antibody
approximately 45% of events lie within the M1 marker. Note than staining
cells with either the isotype control plus a FITC conjugated secondary
antibody or with the secondary antibody alone results in a significant increase
in fluorescence compared to unstained cells.
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revealed a high degree of non-specific staining. This is probably due to the
permeabilisation of the brain cells. To circumvent this problem, an anti-GFAP
antibody directly conjugated to Cy3 was obtained. As shown in figure 5.7, this
antibody could be used successfully to stain the U373MG cells. In this case,
the isotype control stained cells were not significantly more fluorescent than
unstained cells. The antibody was next used to stain a single cell suspension
of murine brain cells. The results of this are shown in figure 5.8. Two distinct
populations were defined on the scatter profile. The proportions of anti-GFAP
stained cells lying within the M1 marker were 86% and 83% for gates 1 and 2
respectively. This is compared to less than 1% of isotype-control stained cells.
Thus it appears that astrocytes are present in both regions of the scatter plot.
The antibody was used to stain a single cell suspension of human brain cells
(figure 5.9). histogram plots did not reveal a significant shift in fluorescence
when anti-GFAP stained cells were compared to isotype control stained cells
(data not shown). However a dot plot of fluorescence against side scatter
revealed that a new population arises in the anti-GFAP stained cells. 58% of
anti-GFAP stained cells fall within gate R2 compared to 8% of isotype control
stained cells. Unfortunately, when this experiment was repeated using cells
which had been stained and stored for a day, no such change in
fluorescence was apparent (figure 5.10). This is probably due to the use of
the fluorochrome Cy3. This fluorochrome has an optimum excitation
wavelength of around 550 nm. This is higher than the wavelength used by
the FACS machine available and thus the fluorescence is probably sub-







































Figure 5.7: Flow cytometric analysis of astrocyte cell line (U373MG) stained
with directly conjugated antibody. The gate was defined as previously. On the
histogram plots of cells stained with the isotype control it can be seen that
approximately 1% of cells lie within the M1 marker. Note that there is not an
increase of fluorescence using the isotype control compared to unstained
cells. On the histogram plot of cells stained with the GFAP:Cy3 antibody
approximately 83% of events lie within the M1 marker.
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Figure 5.8: Flow cytometric analysis of mouse brain cells stained with directly
conjugated antibody. Two populations of cells could be seen on the scatter
plot of side versus forward scatter. These were selected as separate gates in
order to assess which contained GFAP positive cells. On the histogram plots
of cells stained with the isotype control it can be seen that less than 1% of
cells lie within the M1 marker. On the histogram plot of cells stained with the
GFAP:Cy3 antibody approximately 85% and 82% of events lie within the M1
marker when events from within Gates R1 or R2 respectively are analysed.
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Region Events % Gated % Total
R1 4860 100 00 24.30
R2 408 8.40 2.04
Region Events % Gated % Total
R1 4618 100.00 23.09
R2 2665 57.71 13.33
Figure 5.9: Flow cytometric analysis of human brain cells stained with directly
conjugated antibody GFAP:Cy3. No distinct populations of cells were
apparent from the dot plot of side versus forward scatter. Events chosen for
analysis were defined by gate R1. It was assumed that most events falling
outwith this gate were dead cells or cellular debris. Histogram plots
comparing events within R1 showed little increase in fluorescence when cells
stained with GFAP:Cy3 were compared with those stained with the isotype
control (data not shown). However, a dot plot of fluorescence against side
scatter, revealed that a new population arises in the GFAP:Cy3 stained cells.
This population was defined on the dot plot by gate R2. When cells stained
with the isotype control are analysed 8.4% of events fall with this gate. When
cells stained with GFAP:Cy3 are analysed this percentage rises to 57.7%
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Region Events % Gated % Total
R1 10696 100 00 53.48
R2 182 1.70 0.91
Region Events % Gated % Total
R1 10416 1 00.00 52.08
R2 113 1,08 0.57
Figure 5.10: Flow cytometric analysis of human brain cells stained with
directly conjugated antibody GFAP:Cy3 where stained cells have been stored
for a number of days. Gate R1 was defined as previously. Unlike the previous
experiment, there does not appear to be a significant new population when
cells stained with GFAP:Cy3 are compared with those stained with the
isotype control.
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periods, could eliminate this small amount of fluorescence. Due to the
unpredictability of availability of the FACS sorter, it is often necessary to store
cells after staining and before sorting. For this reason the anti-GFAP antibody
conjugated to Cy3 is not suitable. A new anti-GFAP antibody conjugated to
AlexaFluor 488 was obtained. This antibody was used to stain a single cell
suspension of human brain cells. The results are shown in figure 5.11. Again,
a dot plot revealed a new population better than a histogram plot. 40% of
anti-GFAP stained cells fall within gate R2 compared to just 1% of isotype
control stained cells. This antibody can therefore be used to FACS sort
human brain cells.
Microglia are thought to be the main brain cell infected by HIV in vivo. It
would therefore be very useful to purify microglia from a HIV infected brain
and assess levels of infection. An antibody which has previously been used
for identification of microglia is CD11b. CD11b (also known as complement
receptor 3 or CD18), is a member of the integrin family of adhesion receptors
which plays an important role in mediating the transmigration of leukocytes
(Ehlers, 2000). In addition, CD11b acts as a pattern recognition receptor for
various endogenous and exogenous molecules and mediates cellular
activation. An anti CD11b antibody conjugated to FITC was used. Initially the
antibody was tested on the cell line J774 which had previously been shown
to express CD11b (Zeger et al., 1990). As shown in figure 5.12,
approximately 95% of cells stained with the antibody fell within the M1
marker of fluorescence. This is compared to only 1% of cells stained with an
isotype control. The antibody was next used to stain a single cell suspension
214




Region Events % Gated % Total
R1 2770 100 00 16.91
R2 26 0.94 0 16
Region Events % Gated % Total
R1 2621 100 00 15.32
R2 1050 40 06 6.14
Figure 5.11: Flow cytometric analysis of human brain cells stained with
directly conjugated antibody GFAP:AlexaFlour 488. Gate R1 was defined as
previously. Histogram plots comparing events within R1 showed little
increase in fluorescence when cells stained with GFAP:AlexaFlour were
compared with those stained with the isotype control (data not shown).
However, a dot plot of fluorescence against forward scatter, revealed that a
new population arises in the GFAP:AlexaFlour stained cells. This population
was defined on the dot plot by gate R2. When cells stained with the isotype
control are analysed approximately 1% of events fall with this gate. When












Marker Events % Gated % Total
All 4893 100.00 77 04
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Figure 5.12: Flow cytometric analysis of macrophage cell line (J774).Analysis
of fluorescence was carried out on events which lay within the R1 gate as
defined on the side versus forward scatter dot plot. Events lying out with this
gate were presumed to be dead cells or cellular debris. On the histogram
plots of unstained cells or cells stained with the isotype control it can be seen
that approximately 1% of cells lie within the M1 marker. On the histogram plot
of cells stained with CD11b:FITC approximately 95% of events lie within the
M1 marker.
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of murine brain cells. As shown in figure 5.13, cells falling within gate 3 show
an increased fluorescence when anti-CD11b stained cells are compared with
those stained with an isotype control. 30% of anti-CD11b cells fall within the
M1 marker compared to only 1% of isotype control stained cells. The
antibody was next used to attempt to select human microglia cells. The
results of this experiment are shown in figure 5.14. Unfortunately, it appears
that this antibody was not able to stain human CD11b effectively and thus
could not be used for separation of these cells.
Another antigen which has been used for immunohistochemical identification
of human microglia cells is CD68. CD68 is a transmembrane protein found in
the endosomal membranes of monocytic cells (Gordon, 1999). It's functions
are not fully understood but may include enhancing phagocytic uptake of
oxidised low density lipoprotein (Ramprasad et al., 1995). An anti-CD68
antibody conjugated to FITC was obtained. As CD68 is intra-cellular, cells
were permeabilised with ethanol prior to staining. This antibody identified a
population of cells from a single cell suspension of human brain (figure 5.15).
Approximately 4% of anti-CD68 stained cells fall within gate R1 compared to
just 0.4% of cells stained with the isotype control. It was therefore decided to
use this antibody for subsequent cell sorting.
5.3.6 Analysis of sorted samples
Having optimised the protocol to be used, HIV infected brains were obtained
for cell sorting. Clinical details of the study subjects from which tissue was
used are given in table 5.2. Cells were stained using either the FITC
conjugated anti-CD68 antibody or the AlexaFluor 488 conjugated anti-GFAP
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Figure 5.13: Flow cytometric analysis of mouse brain cells. Analysis of
fluorescence was carried out on events which lay within the either the R1, R2 or
R3 gates as defined on the side versus forward scatter dot plot. These gates
were defined as they contain events which showed a significant increase in
fluorescence when cells stained with CD11b:FITC are compared to unstained
cells or cells stained with the isotype control. Gate R3 includes both the R! and
R2 gates as well as some additional events. It was selected in order to
investigate if using this larger gate allowed additional CD11b positive cells to be
detected. On the histogram plots of unstained cefls or cells stained wrth the
isotype comtrol it can be seen that less than 1% of cells lie within the M1 marker
for each of the gates. On the histogram plot of cells stained with CD11b:FITC
approximately 12%, 62% and 30% of events lie within the M1 marker for cells
within gates R1, R2 and R3 respectively. The total number of cells identified as
CD11b positive was 74, 869 and 1079 for gates R1, R2 and R3 respectively.
Thus, gate R2 contains the greatest percentage purity of CD11b positive ceils
























































































Marker Events % Gated % Total
All 1400 100.00 1.40
M1 869 62.07 0 87
102
CDIIbFITC
Marker Events % Gated % Total
All 3600 100.00 3.60
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Figure 5.14: Flow cytometric analysis of human brain cells. Analysis of
fluorescence was carried out on events which lay within the R1 gate as
defined on the side versus forward scatter dot plot. On the histogram plots of
unstained cells or cells stained with the isotype control it can be seen that
approximately 1% of cells lie within the M1 marker. On the histogram plot of
cells stained with CD11b:FITC approximately 7.75% of events lie within the
M1 marker.
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Isotype FITC CD68 FITC
kt3 io4
Region Events % Gated % Total
R1 77 0.39 0.39
Region Events % Gated % Total
R1 1745 4.43 4.43
Figure 5.15: Flow cytometric analysis of human cells. No gate was on the
side versus forward scatter plot in order to allow the maximum number of
positive cells to be identified. A histogram plots of cells stained with
CD68:FITC did not show significantly higher fluorescence compared to
unstained cells or cells stained with the isotype comtrol (data not shown).
However, a dot plot of fluorescence against side scatter reveals a new
population of events (gate R1) in cells stained with CD68:FITC compared
with those stained with isotype control. When cells stained with CD68:FITC
are examined, 4.43% of cells fall within gate R1 compared to only 0.39%
when cells stained with the isotype control are used.
221
Study Age Sex Cause Risk No. of lymphocytes Time before death
subject of group per pi blood of last lymphocyte
death CD4 CD8 count
150 32 M AIDS MSM nk nk nk
207 43 M OD IVDU 335 649 1m18d
Table 5.2: Clinical background of study subjects. OD: Over-dose; MSM: Men
who have sex with men; IVDU: Intra-venous drug user; nk: not known
Study subject Tissue/Cell Purity Proviral load
150 Brain n/a 7.2 per 1 x 10B cells
Spleen 9540 per 1x10^ cells
Astrocytes 98% <1 per 1 x 104 cells
Microglia 99% <1 per 1 x lO1* cells
207 Brain n/a 0.16 per 1 x 106 cells
Spleen 5250 per 1 x 10b cells
Astrocytes 98% <1 per 3 x 10b cells
Microglia 93% <1 per 1 x 104 cells
Table 5.3: Calculated proviral loads and cell purity. As no provirus was
detected in any of the sorted cells the proviral load must be less than 1 copy
per the number of cells tested. The percentage purity values indicate the
proportion of cells positive for the relevant antigen (GFAP for astrocytes and
CD68 for microglia) during FACS.
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antibody as these antibodies had given the optimum staining as described
above. Both antibodies have almost identical absorption and emission
spectra (figure 5.16) and thus single staining was necessary. 10% of cells
were left unstained, 10% were stained with the isotype control and of the
remainder of the cells, 50% were stained with the anti-CD68 antibody and
50% were stained with the anti-GFAP antibody. The population of astrocytes
to be collected was defined on fluorescence against forward scatter dot plot.
The population of microglia to be collected was defined on a fluorescence
against side scatter dot plot. These plots enabled population with maximum
purities to be collected. A suspension of single cells was obtained as shown
in figure 5.17. The proportion of contaminating events of the population
obtained was calculated by dividing the proportion of isotype control stained
cells which fell within the defined gate by the proportion of cells stained with
the antibody of interest which fell within the defined gate. This data was used
to calculate the purity of the populations as shown in table 5.3.
Purified cells were pelleted and their DNA extracted. The DNA concentration
was assessed using a spectrophotometer. Nested (3-actin PCRs were
positive at dilutions of DNA which represented an average of one cell per
PCR tube (data not shown). However, despite carrying out many hundreds of
reactions, no nested V3 PCRs were positive.
As the brains used were derived from study subjects who had died without
AIDS defining illnesses, it was possible that any HIV present in the brain was
simply due to contaminating blood and that a separate brain cell tropic
variant had not emerged. To test this hypothesis DNA was extracted from
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Wavelength (nm)
Figure 5.16: Absorption and emission spectra of Alexa Fluor 488 (dashed
line) and FITC (continuous line) (Flaughland, 1999). Please note that the
intensity of fluorescence has not been shown to scale in order to allow
comparison of spectral characteristics. Alexa Fluor 488 emits a higher
intensity of fluorescence than FITC.
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Figure 5.17: Single cell suspensions obtained from FACS sorting of human
brain cells visualised at 20X magnification using normal (A, C and E) or UV
(B, D and F) illumination. A and B: Cell suspension used for FACS sorting; C
and D: GFAP positive cells stained with anti-GFAP antibody conjugated to
AlexaFluor 488 ; E and F: CD68 positive cells stained with anti-CD68
antibody conjugated to FITC. Note the large size and irregular morphology of
the GFAP positive cells. This is as expected for astrocytes.
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portions of frozen brain and spleen samples from the same study subjects.
Limiting dilution V3 PCR was carried out and V3 products amplified from
single templates were sequenced. Proviral loads were calculated for each
tissue and the sequences were compared phylogenetically.
As shown in table 5.3, the proviral loads in the brains of both study subjects
were extremely low. In addition the phylogenetic tree obtained using
sequences from study subject 150 shows that the sequences obtained from
brain and spleen are completely interspersed (figure 5.18). This supports the
hypothesis that the sequences amplified from the brain were derived from
blood contaminants. Despite carrying out many hundreds of PCRs, only one
sequence was obtained from the brain of study subject 207. As shown in
figure 5.19, this sequence appeared "spleen-like" when compared
phylogenetically with sequences obtained from the spleen. These results
suggest that there was almost no HIV provirus in the brain of this individual
and that any virus present was likely to be contained in resident blood
vessels.
5.4 Discussion
In this study a method was devised to isolate pure populations of astrocytes
and microglia from fresh human brain material obtained at post mortem. This
procedure could be adapted to also purify other cell types including
oligodendrocytes and neurons. The procedure involved first homogenising
the tissue to produce a single cell suspension. Broken cell processes and
cellular debris were removed using a two step Percoll gradient. The purified




















Figure 5.18: Phylogenetic tree showing the genetic relationships between V3
sequences obtained from brain and spleen tissue from study subject 150.
Spleen sequences are represented by blue squares while brain sequences

















Figure 5.19: Phylogenetic tree showing the genetic relationships between V3
sequences obtained from brain and spleen tissue from study subject 207.
Spleen sequences are represented by blue squares while brain sequences
are represented by red circles.
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cell surface markers. A number of antibodies were tested for their ability to
stain brain cells. Testing was carried out first on cell lines, then on murine
brain cells and finally using post mortem human brain material. A gentle
method of ethanol fixation was used. This allowed the staining of intra¬
cellular antigens while maintaining the integrity of cellular DNA. The use of
primary antibodies followed by fluorochrome conjugated secondary
antibodies resulted in an high level of non-specific staining. For this reason
directly conjugated antibodies were chosen. The antibodies which were best
able to select microglia and astrocytes were anti-CD68 and anti-GFAP
respectively.
Cells from HIV positive brain samples were separated and the extracted DNA
tested for HIV sequences using PCR. None of the DNA from the separated
cells was positive for HIV proviral DNA. Limiting dilution PCR carried out on
DNA extracted from whole brain tissue revealed that the material used had a
very low proviral load and that sequences found in the brain grouped
phylogenetically with those found in the spleen. Taken together, these results
suggest that in the study subjects investigated, there was no separately
replicating population of HIV in the brain. It is likely that the presence of V3
template within the brain tissue was due to contamination of the tissue with
blood.
It would be very interesting to carry out this work on brain material from a
study subject who had died of AIDS particularly where there was pathological
evidence of HIVE. However, obtaining such material in current times is
extremely difficult. For example, in Edinburgh there has only been one post
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mortem on a subject with HIVE, where consent has been obtained for
research on organs, since the advent of treatment with HAART in 1996 (Bell,
J personal communication).
One possible option would be to carry out similar studies using an animal
model of HIVE. A number of lentiviral infections have been studied as
potential models of HIVE (reviewed in Burudi and Fox, 2001). These include
feline immunodeficiency virus (FIV) infection of cats, Visna-Maedi virus
infection of sheep and caprine arthritis encephalitis virus infection of goats.
Strains of SIV are found in various African monkey species and do not
appear to cause pathology in their natural host. However, infecting a
previously unexposed host species with SIV can result in an
immunodeficiency disease similar to AIDS. For example, the model which
has been used most frequently is infection of macaques with a sooty
mangabey strain of SIV. Different strains of SIV differ in their ability to cause
neurological disease in macaques. Passage of virus through microglial cell
lines along with the use of recombinant DNA technology has allowed
neurotropic variants to be produced. In one particularly effective model of
neurovirulence a neurotropic clone, SIVMAc17E-Fr, is inoculated along with a
potent immunosuppressive virus, SIVMAcB670/Delta, into pig-tailed
macaques (Mankowski et al., 2002). This results in a consistent accelerated
model of HIVE with over 90% of animals developing encephalitis within 6
months of infection. Such models produce a disease which closely mirrors
HIVE in many ways. However, there are some differences in pathology. In
particular there have been no reports of infection of cell types other than
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microglia/monocytes in macaque models. Thus using this model to
investigate the extent of infection of different brain cells could be misleading if
previous reports of infection of astrocytes and neuron in humans are correct.
To circumvent this problem, some studies have used SIV/HIV (SHIV)
chimeras to infect macaques (Joag et al., 1997; Liu et al., 1999). It is thought
that this might lead to a disease which more closely mimics that found in
humans.
If infected brain material was obtained either from macaque or human study
subjects, a number of aspects of neuropathogenesis could be investigated.
As attempted in this study, HIV proviral loads could be determined for
different cell types. This would help solve the question of which cell types are
infected and to what extent. In addition, env genes could be amplified from
different cell types and used to produce chimeric viruses as described in
chapter 3. These could be investigated to identify the specific factors (both
viral and host) which determine cell tropism.
Another possibility would be to extract RNA from populations of sorted cells.
This would require the tissue to be processed and fixed soon after death of
the subject in order to prevent RNA degradation. Thus, logistically, this may
only be possible when using an animal model. Extracted RNA could be
assessed using a microarray to investigate regulation of specific genes. For
example, it would be informative to monitor levels of mRNA for peptides
involved in regulating oxidative stress; a process thought to be implicated in
HIVE associated pathology (reviewed in Mollace et al, 2001; Kaul et al, 2001).
Expression of genes such as nitric oxide synthase and superoxide dismutase
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(which acts to reduce superoxide anion) could be assessed in different brain
cells. The two compounds which are regulated by these enzymes, nitric oxide
and superoxide anion, react together to form the highly damaging product
peroxynitrite which may contribute to the development of HIVE. The release
of these and other oxidative compounds is promoted by the proinflammatory
cytokines such as IL-1(3 and TNFa. Also, certain chemokines such as MCP-1
may play a role in recruiting monocytes/microglia to areas of inflammation.
Assessing the mRNA levels for these and other immune molecules in specific
brain cell types could dramatically further our understanding of the
pathogenesis of HIVE.
Two recent studies have used laser capture microdissection to capture cells
from HIVE brain material and assessed them for HIV infection (Torres-Munoz
et al., 2001; Trillo-Pazos et al., 2003). Both studies report infection of
neurons while the more recent paper also describes frequent infection of
microglia and astrocytes. Further studies using this exciting new technique
will be required to confirm these findings. As techniques capable of
investigating at such a "micro" level are developed, new details about the
cellular pathogenesis of HIV should emerge. Hopefully, within a few years the
controversy of which cells are infected and to what extent will be solved. In
addition, and perhaps more importantly, far more detailed investigations of




Despite an unprecedented amount of research, there are still many aspects
of HIV pathogenesis which remain incompletely characterised. One such
area is cellular tropism. In its broadest sense, this topic encompasses a
variety of research foci including characterisation of cells infected in vivo,
characterisation of the genotypic/phenotypic nature of variants infecting
different cell types/ anatomical sanctuaries and investigation of the host and
viral factors which determine differential tropism. In this project a variety of
techniques were employed in an attempt to further address these issues.
The aim of the first part of the project was to produce an in vitro system
which would allow more accurate characterisation of viral and host factors
involved in cellular tropism. HIV requires a co-receptor in order to infect a cell
(Feng et al., 1996). In vivo, the main co-receptors used are CCR5 and
CXCR4. Variants can thus be defined as CCR5 using (R5), CXCR4 using X4
or dual tropic (X4R5). These differences account for some of the differences
in cellular tropism between viral variants however, it appears that other
factors may also play a role (Yi et al., 1998). In order to fully address the
factors determining cellular tropism, various in vitro approaches have been
used. The principle of all these methods is to amplify the virus and then
assess its ability to infect different cell types. The simplest method of viral
amplification is to culture the virus directly from infected blood/tissue. The
problem with this method is that culturing in vitro exerts a selective pressure
on the population. Due to HIV's inherently rapid rate of evolution and the
presence of a heterogenous starting population, the virus obtained may not
accurately represent the virus present in vivo. In addition, it is difficult to
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correlate differences in tropism to genetic factors when a mixed population of
virus is used. Methods which employ amplification of viral sequences in
prokaryotic cells have been used. The env gene, (the major viral determinant
of tropism) can be amplified either alone and used to produce pseudotyped
virions or the gene can be inserted into and amplified in the context of the
entire HIV backbone which can then be used to produce infectious virus.
Such methods have the advantage that the population of virus produced will
be homogenous and differential growth of variants should not influence the
results. However, amplification of viral sequences in prokaryotic cells can
also exert a selective pressure of the sequence. In particular various HIV
genes have been demonstrated to be toxic to E. coli (Kusumi et al., 1992;
Baum et al., 1990). This phenomenon can lead to preferential growth of
bacteria containing defective genomes (Peden, 1992). Thus a method for
production of viruses which does not involve amplification of env in
prokaryotic cells would be valuable. A novel vector was produced which
allowed the production of chimeric viruses containing exogenous env genes
and the EGFP gene. Three methods using this vector to produce infectious
virus without amplification of env in prokaryotic cells were investigated. All
methods were able to generate infectious virus. The quantity of virus
produced was low and thus further optimisation will be required in order to
generate sufficient virus for effective studies of viral tropism.
The second part of this project sought to further characterise the drug
resistance genotype of variants infecting two compartments- the brain and
the lymphoid system. Anti-retroviral drugs have poor penetration into the
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CNS. For this reason, there has been much discussion within the scientific
community regarding the distribution of drug resistance mutations within the
brain. Two alternative hypotheses have been proposed. One theory is that
poor penetration may lead to sub-optimal drug levels which could hasten the
evolution of drug-resistant variants in the brain. Alternatively, drugs may be
retarded from entry to such a degree that only negligible amounts will be
present in the brain. This could lead to the brain becoming a sanctuary site
for drug-sensitive variants which could not survive in the lymphoid system. To
address this issue post-mortem brain and lymphoid tissue was obtained from
four HIV positive individuals. A fragment of RT was amplified by PCR from
the proviral templates present in the tissue. Approximately eight limiting
dilution fragments were amplified and sequenced for each tissue.
Examination of the aligned sequences revealed that in three out of four
subjects there were no differences in the pattern of drug resistance mutations
between the two compartments. However, in one subject there were
significantly more drug resistance mutations in the lymphoid-derived
sequences than in those amplified from the brain. These results are
consistent with two previous studies which found either no difference in
distribution of drug resistance mutations between brain and lymphoid derived
sequences or an overrepresentation of drug resistance muations in lymphoid
derived sequences (Wong et al., 1997); (McClernon et al., 2001). A portion of
the PR gene was amplified and sequenced from the tissue of two subjects
who had not taken Pis. These results will be used as a control for a future
study investigating the distribution of PI resistance mutations in tissues of
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subjects who have taken Pis.
The final part of this project sought to characterise the cellular location of HIV
in the brain. Conflicting results have emerged regarding which CNS cells are
infected with HIV. It is generally accepted that the major cell types infected by
HIV within the brain are microglia and macrophages (Vazeux et al., 1987;
Koenig et al., 1986). However various investigators have reported infection of
astrocytes or even neurons (Saito et al., 1994; Bagasra et al., 1996; Trillo-
Pazos et al., 2003). Methods which could be used for the bulk isolation of
highly pure cell populations from post-mortem HIV positive brains were
investigated. An important consideration was the preservation of cellular DNA
so that subsequent PCRs could be carried out. Thus the separated cell
populations can be tested for the presence of HIV provirus. A number of
techniques for cell separation were attempted. Optimal results were obtained
by a process involving removal of cellular debris by density centrifugation;
permeabilisation using ethanol; staining for intra-cellular antigens and finally
FACS sorting. This method was used to obtain highly pure populations of
microglia and astrocytes from post-mortem brains. Extracted DNA from these
populations was negative by PCR for HIV provirus. It is assumed that this
result was due to the low proviral loads in the brain material used.
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Appendix I: Log of Transfection experiments
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Start date Genetic material transfected Fluorescence Fluorescence



































































30/10/02 1. pNL4.3(YU2env)EGFP (C) x x
2. pNL4.3(YU2env)EGFP (M1) x x
14/11/02 1. pNL4.3aEGFP (C)
2. pNL4.3(YU2env)EGFP (C)
3. pNL4.3(HXB2e/w)EGFP (C)
18/01/03 1. pNL4.3(YU2env)EGFPa (C)
2. pNL4.3(YU2env)EGFPb (C)
3/02/03 1. pNL4.3(ADAenv)EGFPa (C) " "
2. pNL4.3(ADAenv)EGFPb (C) * x
3. pNL4.3(ADAenv)EGFPc (C) " "
4. pNL4.3(ADAenv)EGFPd (C) * x
5. pNL4.3(ADAenv)EGFPe (C) " x
6. pNL4.3(R01env)EGFP (C) " x



































































12/02/03 1. pNL4.3(ADAenv)EGFP (M1)
19/02/03 1. pNL4.3(R04env)EGFP (C)
2. pNL4.3(R05env)EGFP (C)


















be due to faulty
C02 regulator on
incubator.
6/03/03 1. pNL4.3(R01 env)EGFP (C) N/D All cells died as
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2. pNL4.3(R02em/)EGFP (C) "
3. pNL4.3(R03env)EGFP (C) "
4. pNL4.3(R04env)EGFP (C) x
5. pNL4.3(R05eni/)EGFP (C) '
6. pNL4.3(R06env)EGFP (C) "
7. pNL4.3(RO70e/w)EGFP (C) "
8. pNL4.3(R08env)EGFP (C) "
9. pNL4.3(R09env)EGFP (C) "
10. pNL4.3(RO10env)EGFP (C) *
11. pNL4.3(LT1ew)EGFP (C) x
12. pNL4.3(LT2env)EGFP (C) "
13. pNL4.3(LT3env)EGFP (C) "
14. pNL4.3(LT40eni/)EGFP (C) "
15. pNL4.3(LT5env)EGFP (C) x
16. pNL4.3(LT6e/iy)EGFP (C) "
17. pNL4.3(LT7env/)EGFP (C) "
18. pNL4.3(LT8eny)EGFP (C) "
19. pNL4.3(LT9enu)EGFP (C) "
20. pNL4.3(LT10env)EGFP (C) "
21. pNL4.3(HXB2en>/)EGFP (C) "
22. pNL4.3(ADAew)EGFP (C) "
23. pNL4.3(HXB2e/7v)EGFP (M2) "
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24. pNL4.3(ADAenv)EGFP (M2)





































21. frag S/307 (ADA env)
22. frag AS/306 (ADA env)
23. pNL4.3(ADAenv)EGFP (M2)
24. pNL4.3(ADAenv)EGFP (M2)
25/03/03 1. pYFP N/D
2. pNL4.3(FIXB2env)YFP (M2)
3. pNL4.3(ADAenv)YFP (M2)





using L or OE











All cells died as
previous#

















3. 1.2 pg envEGFP fragment
4. 0.3 pg ADAem/EGFP fragment
5. 1.2 pg pNL4.3(Aenv)EGFP













6. 0.3 pg pNL4.3(Aer?v)EGFP
linearised + 0.3 pg envEGFP fragment
7. 0.4 pg NL4.3(ADAenv)EGFP
8. 0.1 pg pNL4.3(ADAenv)EGFP
9. Transfast reagent only
10. Media only
8/06/03 1. 0.3 pg pNL4.3(Aenv)EGFP
linearised
2. 0.3 pg pNL4.3(Aenv)EGFP
linearised + 0.9 pg ADAenvEGFP
fragment
3. 0.3 pg pNL4.3(Aer?v)EGFP
linearised- + 1.5 pg ADAewEGFP
fragment
4. 0.3 pg pNL4.3(Aenv)EGFP
















5. 0.3 pg pNL4.3(Aenv)EGFP














+ 0.9 pg PlenvEGFP
pg pNL4.3(Aenv)EGFP
+ 0.9 pg P2envEGFP
pg pNL4.3(Aenv)EGFP
















4. 0.3 pg pNL4.3(Aenv)EGFP * *
linearised + 0.9 pg subtypeAenvEGFP
fragment
5. 0.3 pg pNL4.3(Aenv)EGFP " *
linearised + 0.9 pg subtypeCenvEGFP
fragment
6. 0.3 pg pNL4.3(Aenv)EGFP " ✓
linearised + 0.9 pg HXB2envEGFP
fragment
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Abbreviations: (C): Cloned plasmid DNA; (M1): Non-cloning method 1
(Ligation mixture); (M2): Non-cloning method 2 (Overlap extension product);
(M3): Non-cloning method 3 (mixture of the products needed to produce virus
by the recombination method- i.e. linearised vector and an envEGFP
fragment); S/N: Supernatant from transfected 293T cells; N/D: Not done;
RO1-10 and LT1-10 are limiting dilution env products produced using
template DNA from the right occipital and left temporal brain lobes of a single
study subject respectively.
*ln these initial experiments C8166 cells were used as the susceptible cell
line. In all other experiments PM1 cells (which are susceptible to infection by
both X4 and R5 variants) were used.
#ln these experiments, after a number of day's incubation, the cells appeared
rounded and non-adherent. Large patches of the monolayer were decimated
and only cell debris was apparent. Transfection efficiencies when calculated
were extremely low. Initially it was presumed that the cells were becoming
infected by some contaminating organism (i.e. a virus or bacteria). Thus
much effort was put into cleaning and thoroughly decontaminating the
incubator and other equipment used. Additionally, a number of methods were
investigated to ensure that the DNA to be transfected was sterile. Eventually
it was determined that the incubator had a major fault in its C02 regulation. It
is likely that this underlay the continued problems with cell death as 293T
cells are particularly sensitive to low (i.e. less than 5%) C02 levels.
Unfortunately, the C02 monitor attached to the incubator continued to give
readings of 5% C02 when the levels were in fact far lower and thus the
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problem remained unrecognised for an extended period of time.
* Shortly after this date a, due to extenuating circumstances, I was assigned
a new panel of supervisors and moved to new lab facilities. As a result my
work on this project (which requires the use of a containment level three
laboratory) was discontinued.
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Appendix II: Log of cell separation experiments
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at 30,000 and 60,
000 x g
See figure 5.2
30,000 x g gave adequate
separation and so all further
continuous gradient
experiments were carried out









Bands of cells visible
30/10/01 Calf brain Attempt
separation of
brain cells
Digestion with 1 %
collagenase and
784 units/ml papain
in 1.5 M NaCI
solution at 37°C for
2 hours
Thick band of white material
(cell debris) visible



































Difficult to visualise bands of
cells using continuous Percoll
gradient
MACS separation invalid as










trypsin in PBS at
37°C for 10 minutes
and gentle trituration
Ficoll enrichment successful
(see figure 5.3) but large










Bands of cells poorly visible
in continuous gradient-







As on 18/12/01 but
with addition of 2



















carried out as on
18/12/01
All storage methods resulted
in large quantity of matter
(cellular debris) at top of
gradient

























All cells emerged as positive
































Cells emerged in "positive"
fraction even when no
antibody and/or beads
included
Cells are becoming lodged in
matrix probably due to size
and/or "stickiness"
MACS cannot be used
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6/08/02 Human To attempt Digestion as above Cell population selected by
brain immunomagn beads



















FACS separation Data difficult to analyse-
repeat experiment with prior












(layers of 30%, 37%
and 70%)
Material aspirated from
interface between 30% and
37% is a single cell
suspension
Most myelin and cellular

































fixation using 1 %
paraformaldehyde
Antibody able to select
population of brain cells-


















fixation using 1 %


















To Digestion with Anti-GFAP antibody stained
investigate trypsin population of cells after each
methods of of the cell treatments
permeabilisat Removal of cell
ion for debris using Optimal staining observed
staining of discontinuous following Triton
intra-cellular Percoll gradient permeabilisation
antigens
Treatment of cells Methanol fixation caused
using either clumping of cells
paraformaldehyde













To Removal of brain Staining successful and
investigate and storage at room comparable to using fresh
effect of temperature for 1 tissue
storage on hour and then at


















































































Cell yield was approximately
twice as high following
liberase/DNAse treatment
compared to Trypsin.
Little staining of A172 cells
U373 cells stained (figure
5.6)




antibody would be preferable
























To Gentle ethanol Cells remained in single cell
investigate fixation suspension- very little
"gentle clumping apparent
ethanol Staining with anti-





















When cells fixed prior to
CD11 b staining, there is a
large amount of non-specific
staining- isotype control
staining equal to anti-CD11b
staining
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Concluded that the anti-
CD11 b antibody was not
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and cell population sorted
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